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ABSTRACT 
Dongmei Lu 
 
Aerosol Delivery of Recombinant Antigen 85B in  
Microparticle Vaccine Systems for Protection Against Tuberculosis 
(Under the direction of Dr Anthony J. Hickey, PhD, D.Sc) 
 
The only available tuberculosis vaccine, bacille Calmette Guérin (BCG) has highly 
variable efficacy. Antigen 85B (Ag85B) is a protein secreted by Mycobacterium tuberculosis 
(MTB) in the early culture and a promising subunit antigen. Pulmonary vaccination is an 
attractive immunization route. It was proposed that Ag85B/adjuvants in microparticle 
formulations intended for pulmonary delivery would target macrophages, elicit related cell-
mediated immune response sufficient to protect guinea pigs from tuberculosis. Three specific 
aims were adopted to test the hypotheses. (1) To express recombinant Ag85 (rAg85B) from 
E. coli suitable for inclusion in polymeric microparticles for (2) in vitro screening of particle 
formulations with respect to related cell-mediated immunity and for (3) assessment of 
protection from infection in a guinea pig model of tuberculosis. 
rAg85B was expressed from two E. coli strains and encapsulated by spray-drying in 
poly(lactide-co-glycolide) (PLGA) microparticles with adjuvants muramyl dipeptide (MDP) 
or trehalose dibehenate (TDB) to be delivered as dry powder aerosols. The antigenicity of the 
recombinant forms was evaluated by monitoring IL-2 secretion from T hybridoma cells DB-1 
after recognition of Ag85B97-112 epitope presented by THP-1, antigen presenting cells. The 
-iv- 
powders were administered as single or multiple doses to guinea pigs to evaluate protection 
from a low dose aerosol infection with MTB strain H37Rv.  
Spray-dried microparticles exhibited mass median aerodynamic diameters (MMAD) 
of 2.5-3.0µm, suitable for inhalation aerosols. The amount of IL-2, an indicator of 
antigenicity, released from T hybridoma cells following PLGA-Ag85B microparticle 
administration to THP-1 phagocytic cells, was 92-360 fold that of rAg85B solutions. 
Surface-associated rAg85B played a significant role in the observed IL-2 release. This 
formulation extended epitope presentation as demonstrated by duration and extent of IL-2 
production.  
BCG prime: PLGA-Ag85B aerosol boosts (x2) appeared to enhance protection from 
infection with virulent MTB strain H37Rv compared to BCG alone. However, further work is 
required to demonstrate this effect conclusively. This is a clinically meaningful observation 
since many susceptible individuals in the developing world have been immunized with BCG.  
The results indicate that microparticles encapsulating rAg85B were immunologically 
effective, with preliminary evidence for protection and, potential for pulmonary vaccination 
to prevent MTB infection.  
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1.  Introduction 
1.1 Tuberculosis and its current vaccination status 
Tuberculosis (TB) has emerged as a global public health epidemic. The most recent 
data from the World Health Organization (WHO) indicated that there were approximately 9 
million individuals who developed active TB disease and more than 2 million died due to TB 
in 2003 (Denrell, 2003). The global epidemic of TB has affected the United States where 
there were 14,511 cases reported in 2004 (4.9 cases per 100000 individuals) (Xia and Lee, 
2004). Despite decreasing numbers of cases since 1992 in the United States, TB remains a 
serious public health problem among certain patient populations and is highly prevalent in 
many urban areas (Blumberg, Leonard and Jasmer, 2005). The incidence of TB has increased 
dramatically in areas where resources are inadequate to identify and treat all cases. Roughly 
one third of the world’s population is infected with TB. It remains latent in all but 5-10% of 
those infected as long as the immune system is healthy (Friedrich, 2005). 
Rising rates of multidrug-resistant tuberculosis (MDR-TB) have contributed to 
worsening treatment outcomes in some regions. This is a major public health problem 
because treatment is complicated, cure rates are well below those for drug-susceptible TB, 
and patients may remain infectious for months or years, despite receiving the best available 
therapy (Goble, Iseman, Madsen et al., 1993). Chronic MDR-TB is caused by a single strain 
of Mycobacterium tuberculosis (MTB): W-Beijing family. Acquisition of drug resistance by 
MTB results from mutations (caused by nucleotide substitutions, insertions or deletions) in 
specific resistance-determining regions of the genetic targets or activating enzymes of anti-
-2- 
TB chemotherapeutic agents (Post, Willcox, Mathema et al., Ramaswarmy and Musser, 
1998).  
The worldwide emergence of extensively drug-resistant tuberculosis (XDR TB) and a 
provisional definition for this form of TB were first reported in November 2005. The U.S. 
data indicated that 74 TB cases reported during 1993-2004 met the case definition for XDR 
TB. In October 2006, the World Health Organization convened an Emergency Global Task 
Force on XDR TB, which revised the case definition to specify resistance to at least isoniazid 
and rifampin among first-line anti-TB drugs, resistance to any fluoroquinolone, and 
resistance to at least one second-line injectable drug (amikacin, capreomycin, or kanamycin). 
National TB Surveillance System data were analyzed for reported XDR-TB cases during 
1993-2006; a total of 49 cases (3% of multidrug-resistant (MDR) TB cases) met the revised 
case definition for XDR TB. Of these, 17 (35%) were reported during 2000-2006. XDR TB 
presents a global threat and a challenge to TB-control activities in the world (Migliori, 
Besozzi, Girardi et al., 2007). 
In addition, tuberculosis is associated with increased mortality in HIV infection and is 
considered to be the leading cause of death among HIV-infected persons worldwide (Reyn 
and Vuola, 2002). Approximately one-third of the 40 million HIV-infected persons are co-
infected with TB, which is implicated in up to one-half of all AIDS death (Worley, 2006). In 
2006, TB still remains a major opportunistic infection in HIV-infected patients, often the first 
indication of immunodeficiency (Johnon and Decker, 2006). TB may be readily transmitted 
to individuals via the respiratory route at any stage of HIV infection. Currently, the incidence 
of TB in HIV-infected persons is 100 times greater than that of the general population. HIV-
infected persons have increased risk for MDR-TB (Gordin, Nelson, Matts et al., 1996).  
-3- 
1.1.1 Tuberculosis pathogen: Mycobacterium tuberculosis (MTB) 
Mycobacterium tuberculosis (MTB) is transmitted by aerosol infecting the lungs. It is 
the etiological agent of TB in humans. Humans are a reservoir for this bacterium. MTB is a 
nonmotile, rod-shaped bacterium that is 2-5 µm in length and 0.2-0.3 µm in width (Grosset, 
1993). In the classic case of tuberculosis, the MTB complexes appear in the well-aerated 
upper lobes of the lungs because MTB is an obligate aerobe. The bacterium is a facultative 
intracellular parasite, usually occupying the compartment vesicles of macrophages.  
The envelope of MTB consists of two distinct parts: the plasma membrane and the 
cell wall. The cell wall structure of MTB is unique among prokaryotes and is a major 
determinant of virulence for the bacterium. The cell wall complex contains peptidoglycan 
attached to lipids. Over 60% of the mycobacterial cell wall is lipid. The lipid fraction of MTB 
cell wall consists of three major components (Fig 1.1): (1) Mycolic acids are 1-alkyl 
branched 2-hydroxy fatty acids, typically with 70-90 carbon atoms. Mycolic acids make up 
50% of the dry weight of the cell envelope. Mycolic acids are strong hydrophobic molecules 
that form a lipid shell around the organism and affect permeability properties at the cell 
surface. They are thought to be a significant determinant of virulence in MTB. (2) Cord 
Factor (trehalose dimycolate) is responsible for the serpentine cording appearing in culture. 
Cord factor is toxic to mammalian cells and is also an inhibitor of polymonocyte migration. 
Cord factor is most abundantly produced by virulent strains of MTB. (3) Wax-D (autolytic 
product of cell wall mycolyl-arabinogalactan-peptidoglycan complex (mAGP)) in the cell 
envelope is the major component of Freund's complete adjuvant (FCA) (Besra and 
Chatterjee, 1994). Generally, high concentration of lipids in the cell wall has been associated 
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with MTB resistance to antibiotics, to killing by acid and alkaline compound, to lethal 
oxidation and its survival inside macrophages. 
Pulmonary TB begins when droplet nuclei containing the microorganism reach the 
alveoli. The development of pulmonary tuberculosis from its onset to its various clinical 
manifestations may be pictured as a series of interactions and confrontations between host 
and invader. (1) The inhaled bacillus may multiply, or may be eliminated by alveolar 
macrophages before any lesion is produced. (2) Small caseous lesions may progress, or may 
heal or stabilize before they are detectable. (3) Larger caseous lesions may grow locally and 
shed bacilli into the blood and lymph to infect the lungs again to form the secondary lesions, 
or they may heal or stabilize. (4) Alternatively, caseous lesions may liquefy and introduce 
bacilli and their products into the bronchial tree, making arrest of the disease more difficult 
(Dannenberg and Rook, 1994). In general, each successive stage of the disease meets with 
weaker host responses. Furthermore, in a given lung, each tuberculous lesion is independent, 
i.e., each lesion may be at a different stage, independent of other lesions. 
1.1.2 Macrophage activation and immune responses 
Once the first small caseous tuberculous lesion is established, all subsequent stages 
of disease are capable of causing both tissue-damage and macrophage-activation. The 
tissue-damaging response is often produced during delayed-type hypersensitivity (DTH) 
reactions to high concentration of bacillary products inhibiting the numbers of bacilli 
appearing extracellularly. This damage results in granuloma formation. Macrophage-
activation causes an accumulation of activated microbicidal macrophages around the 
caseous center of the lesions. The activated macrophages can kill and digest the bacilli they 
ingest intracellularly.  
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The mechanism of macrophage activation and initial immune response may be more 
important for vaccination (Fig 1.2). MTB is phagocytosed by resident alveolar macrophages 
after deposition in the lungs. The receptors involved in the specific uptake of pathogens are 
the macrophage mannose receptor (MMR) and complement receptor types 1 (CR1), 3 (CR3), 
and 4 (CR4) (Zimmerli, Edwards and Ernst, 1996). Toll-like receptors can stimulate 
pathogen uptake when interact with ligands (Thoma-Uszynski, Stenger and Takeuchi, 2001). 
IL-12 is induced following phagocytosis of MTB by macrophages, driving development of 
cell-mediated immunity (CMI), which is important in protection from MTB infection (Ladel, 
Szalay, Reidel et al., 1997). CD4 Th1 cells are of primary importance in this protection from 
initial infection. MTB resides primarily in a vacuole within the macrophage, resulting in 
MHC class II presentation of mycobacterial antigen to CD4 T cells. The primary effector 
function of CD4 T cells is believed to be the production of IFN-γ, and possibly other 
cytokines, sufficient to activate macrophages. The MTB bacilli within the vacuoles may have 
access to the cytoplasm (Teitelbaum, Cammer and Maitland, 1999). The antigen epitope –
MHC class I complex can be recognized by CD8 T cells, which then produce cytokines IFN-
γ and TNF-α and act as cytotoxic cells. IFN-γ is the key activating agent that triggers 
antimycobacterial effects of macrophages (Flesch and Kaufmann, 1987). It improves or 
augments the antigen presentation in macrophages, leading to a recruitment of more CD4+ T-
lymphocytes and cytotoxic T-lymphocytes (CTL) (Flesch, 1993)]. TNF-α, which can be 
secreted by macrophages, dendritic cells and T cells, induces chemokine production from 
macrophages and endothelial cells and also up-regulates adhesion molecules on vascular 
endothelial cells, resulting in cellular influx of further inflammatory cells (Hartmann and 
Plum, 1999). TNF-α, in synergy with IFN-γ, induces the production of nitric oxide and 
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related nitrogen intermediates (RNIs) by macrophages via the action of the inducible form of 
nitric oxide synthase (NOS). 
MTB can persist inside host phagocytic cells, the macrophages. These pathogens can 
survive the antimicrobial mechanisms of macrophages which are designed to destroy any 
incoming microbe. Pathogenic mycobacteria have evolved strategies to survive within 
macrophages by preventing phagosome–lysosome fusion, thereby creating a niche that 
allows them to persist within an otherwise hostile environment (Muellera and Pieters, 2006). 
Firstly, MTB arrests the normal maturation process of phagosomes to phago-lysosome 
(Gatfield, Albrecht, Zanolari et al., 2005) by changing the endosomal pH and inhibit the 
acidification of the early phagosome. Secondly, MTB produces chemicals such as superoxide, 
by the action of the enzyme superoxide dismutase (SOD), which might inhibit host defenses 
by interfering with host apoptosis (Skeiky and Sadoff, 2006). MTB avoids the development 
of a localized, productive immune response that could activate the macrophages leading to 
the destruction of the intracellular pathogens (Van Heyningen, Collins and Russell, 1997).  
1.1.3 Recent status in TB vaccine development 
There are treatment strategies available for drug-susceptible TB, MDR-TB and HIV-
co-infected TB. However, the most desirable approach is to prevent TB through vaccination.  
The currently available TB vaccine is attenuated strain of Mycobacterium bovis 
bacillus Calmette-Guerin (BCG). BCG is unable to stimulate an adequate cell-mediated 
immunity. It only protects against disseminated and meningeal TB in young children but is 
not effective against pulmonary TB, the most prevalent form of the disease in adults 
(Friedrich, 2005). The protective effect of BCG varies from 0%, overall efficacy of two 
different BCG vaccines compared with placebo in India (Tuberculosis Research Center 
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(ICMR), 1999), to as high as 80% effective in children, adolescents and young adults, with 
effects lasting up to 60 years in a study of native Americans (Aronson, Santosham, Comstock 
et al., 2004; Comstock, 1994; Fine, 1989). The potential reasons for variable efficacy of 
BCG include: 1) interference with the immune response to BCG caused by previous 
exposure to environmental mycobacteria; 2) differences among BCG vaccine sub-strains; and 
phenotypic changes in the vaccine during passage from the original cultures and during the 
manufacturing process; 3) the deletion of protective antigens from BCG; 4) variability in 
dose, route of administration, age of administration and genetic differences among vaccinees; 
and lyophilization of the vaccine (Brewer and Colditz, 1995; Fine, Carneiro, Milstien et al., 
1999)..  
The concerns of safety, loss of sensitivity to tuberculin skin test, and particularly the 
variable efficacy of BCG increase the need for new and effective vaccines for TB. Several 
strategies have been adopted to address this need. They are listed as followed.  
A.  Improved efficacy of BCG (Table 1.1) 
1) BCG overexpressing antigens. Horwitz’s group had produced a TB vaccine candidate, 
rBCG30, which overexpresses Ag85B and induces increased protection compared with BCG 
strain in animal challenge studies (Horwitz and Harth, 2003); 
2) BCG with the ability to escape endosome. Listeria monocytogenes Hly (listeriolysin) is a 
sulphydryl-activated cytolysin that forms pores in the membrane of the early phagosome. 
Kaufmann’s group had produced rBCG vaccine that excretes Hly to punch holes in the 
endosome and allows leakage of BCG to cytosol. Therefore CD8+ T cells responses are 
enhanced (Hess, Miko, Catic et al., 1998). 
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3) Reducing BCG interference with immunity. Host superoxides produced by macrophages 
kill MTB and can amplify host T-cell recruiting signals. Kernodle’s group has shown that 
secretion of superoxide dismutase (SOD), by MTB, to inactivate superoxides promotes 
granuloma formation and, therefore, contributes to inhibition of host defenses and persistence 
of the organism. rBCG with reduced secretion of functional SOD  (Kernodle, 2004) is more 
potent than the parent strain. It has also been proposed, by Jacob et al., that the deletion of 
genes of nlaA, which inhibit apoptosis of infected cells, might lead to a superior vaccine 
(Jacobs, 2005). 
4) Reintroduction of deleted genes. This strategy reintroduces regional domain (RD) 1 locus 
which encodes the immunodominant and protective ESAT-6 and CFP-10 proteins (Pym, 
Brodin, Majlessi et al., 2003) which were deleted during BCG attenuation.  
B. New attenuated live TB vaccines (Table 1.2) 
1) Inactivation of Phop, which regulates expression of many MTB proteins, attenuated MTB 
virulence while maintaining the pattern of immune responses associated with the parental 
MTB strain (Perez, Samper, Bordas et al., 2001). 
2) Auxotrophic mutant vaccine candidates (requiring the addition of a nutrient(s) for survival) 
have been produced. These mutants maintain their infective capability and have a limited 
duration of replication in the host (Guleria, Teitelbaum, McAdam et al., 1996; Jackson, 
Phalen, Lagranderie et al., 1999). The deletion of proteins involved in MTB lipid metabolism 
by disrupting both the panC, panD genes and lysA gene produced vaccine mc2 6020 (panC 
panD lysA), which does not replicate in vivo. Deletion of the RD1 region from the panC, 
panD mutant produced vaccine mc26030 (panC panD RD1) (Sambandamurthy, Derrick, 
Jalapathy et al., 2005; Sambandamurthy and Jacobs, 2005; Sambandamurthy, Wang, Chen et 
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al., 2002). Both of these highly attenuated mutants were safer than BCG in 
immunocompromised animals and provided similar levels of protection in mouse challenge 
studies. 
C. Subunit vaccines (Table 1.2) 
1) Biochemical approaches initially identified several of the most abundant proteins secreted 
by MTB, including Ag85 complex, MPT32, PhoS, DnaK, GroES, MPT46, MPT53, MPT63 
and the 19kDa lipoprotein (Andersen and Hansen, 1989; Nagai, Wiker, Harboe et al., 1991; 
Young and Garbe, 1991). There are also antigens in low molecular weight range, ESAT-6 (6-
10kDa) and Ag85B, MPT59 (26-34kDa) (Skjot, Oettinger, Rosenkrands et al., 2000). 
MTB32 (a secreted serine protease)(Skeiky, Lodes, Guderian et al., 1999) and MTB39 (a 
member proline-proline-glumatic acid family of protein on the cell wall)(Dillon, Alderson, 
Day et al., 1999) have also been identified. Antigen vaccine candidates, which have 
advanced towards clinical development using animal protection models, include Ag85A, 
Ag85B, ESAT-6, TB10.4, MTB9.9, MTB39 and MTB41. 
2) Recombinant fusion proteins are genetically generated. An example employs Ag85B and 
ESAT-6 (Hybrid-1)(Olsen, van Pinxtern, Rasmussen et al., 2001), MTB39 and MTB32 
(MTB72F)(Skeiky, Alderson, Ovendale et al., 2004). These fusion proteins can be more 
immunogenic than the individual components.  
3) Prime-boost vaccine strategies. The attraction of the heterologous prime-boost approach is 
that it preferentially expands TB-specific pre-existing memory cells against antigenic 
epitopes shared by both the prime and booster vaccines. This approach also minimizes the 
potential for generating antibody and T-cell neutralizing effects. An early study with a BCG 
prime-boost approach with adjuvanted proteins of Ag85A (Brooks, Frank, Keen et al., 2001) 
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resulted in enhanced protection compared to non-BCG-primed in animals. This suggested 
that subunit antigens as boosters to BCG-primed animals might generally induce superior 
protection.  
4) DNA vaccines (Table 1.2) 
Poxviruses and adenoviruses are potent DNA vaccine delivery vehicles. Intranasal 
mucosal delivery of a recombinant adenoviral (Ad5 based) construct expressing MTB antigen 
Ag85A (AdAg85A) conferred protection that was superior to that seen with BCG vaccination 
against a pulmonary MTB challenge (Wang, Thorson, Stokes et al., 2004). DNA vaccines 
showed great potential for use in heterologous prime-boost immunization strategies. Priming 
with BCG and boosting with a recombinant Modified Vaccinia Ankara virus (MVA) that 
expresses Ag85A induced increased levels of CD4 and CD8 T cells and enhanced protection 
in animals compared with a vaccination regimen using either BCG or MVA85A alone 
(Goonetilleke, McShane, Hannan et al., 2003). 
1.1.4 MTB secreted protein Antigen 85B (Ag85B) as the vaccination subunit antigen  
Many current vaccine candidates have been selected from extensive screening of 
MTB antigens in animal models. Because secreted and surface-exposed antigens seem to be 
the first antigen encountered by the immune system, these antigens have been widely 
screened for immunogenicity and protection. MTB proteins ESAT-6, Ag85 complex, Hsp60 
and hybrid protein: a fusion protein of ESAT-6 and Ag85B, a 72kDa fusion protein based 
upon the MTB32 and MTB39 antigens of MTB have shown protective capacity (Haile and 
Kallenius, 2005).  
The increasing number of proteins and enzymes recently identified as being involved 
in cell envelope biogenesis includes the three predominant secreted proteins of MTB: 
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antigens 85A, 85B and 85C. The three antigens form Ag85 complex, which is up to 41% of 
the total culture filtrate protein. All three purified enzymes (68-80% identical at the amino 
acid level) have recently been shown to catalyze the transfer of a mycoloyl residue from one 
molecule of α,α’ trehalose monomycolate (TMM) to another, leading to the formation of 
α,α’ trehalose dimycolate (TDM or cord factor). Ag85 complex is involved in the final stage 
of mycobacterial cell wall assembly (Belisle, Vissa, Sievert et al., 1997). The fibronectin-
binding activity exhibited by all three components suggests that they might also be involved 
in pathogenicity (Abou-Zeid, Ratliff and Wiker, 1988). By conferring on mycobacteria the 
ability to bind fibronectin, these antigens could facilitate their entry into host cells and 
promote their adherence to mucosal surfaces (Ehlers and Daffe, 1998). Ag85 complex 
interacts with the immune system at an early stage of the infectious process and induces both 
humoral and cell-mediated immune responses in MTB-infected patients (Daffe, 2000; Wiker 
and Harboe, 1992) and animal models. The early-stage antigens would be most useful in a 
preventive vaccine. In addition, successful naked DNA vaccines against TB, employing the 
Ag85A (Baldwin, D'Souza and Orme, 1999) (Denis, Tanghe and Palfliet, 1998) and Ag85B 
genes (Lozes, Huygen, Content et al., 1997; Ulmer, Liu and Montgomery, 1997), have been 
reported to elicit protection against MTB. DNA-Ag85B provided better protection than DNA-
ESAT6 and DNA-MPT64 (Kamath, Feng, Macdonald et al., 1999). Moreover, co-
immunization with DNA-Ag85B, DNA-ESAT6 and DNA-MPT65 provided better protection 
than that induced by any single DNA vaccine (Kamath, Groat, Bean et al., 2000). A 
recombinant BCG strain overexpressing MTB Ag85B elicited a higher level of protection 
than traditional BCG (Dhar, Rao and Tyagi, 2004). Recently, the fusion protein of antigen 
85B with Listeria monocytogenes (Miki, Nagata, Tanaka et al., 2004) or ESAT-6 (Olsen, van 
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Pinxtern, Rasmussen et al., 2001) was reported to elicit strong immune responses and 
protective effects against MTB. The immune response to low molecular weight secretory 
proteins of MTB in bronchoalveolar lavage (BAL) from minimal pulmonary TB and non-TB 
patients has been reported. Among polypeptides predominantly recognized by BAL 
lymphocytes, only Ag85A and Ag85B induced both NO and interleukin-12 in alveolar 
macrophages (Sable, Goyal, Verma et al., 2007). According to these reports, Ag85 complex 
or Ag85A and Ag85B molecules seem to be the ones of the most promising candidates for 
future subunit TB vaccines. Since antigen 85B elicits the strongest immune responses and 
also the most abundant subunit among 85A, B and C, antigen 85B will be the focus protein 
subunit for vaccination delivery in this research.   
1.1.5 Antigen 85B protein expression 
Usually investigators have separated the MTB Ag85B and multiple sub-unit protein 
complex from cell culture filtrate. MTB is exceptionally slow growing and biohazardous. 
Therefore, the growing, separation and purification procedures make it difficult to obtain 
large quantities of Ag85B from the culture filtrate. For example, growth of MTB for 2-3 
weeks in 150 liters of broth culture was required to produce 100mg of Ag85B (Horwitz, 
1995). The evaluation of Ag85 proteins for vaccine development and clinical trials imposes a 
practical requirement that they are produced in recombinant form in a rapidly growing, 
nonpathogenic host.  
Several reports on expression of Ag85A and Ag85B indicated that intracellular 
proteins or secreted antigens have been achieved (Harth, Lee, Wang et al., 1996; Kremer, 
Baulard, Estaquier et al., 1995), but the high-level expression and secretion of these proteins 
in native form has proven difficult. Horwitz et al. reported sufficiently high-levels of 
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expression and secretion of the native form of recombinant Ag85A and B proteins using 
Mycobacterium smegmatis and Mycobacterium vaccae, two rapidly growing nonpathogenic 
mycobacteria, as hosts (Harth, Lee and Horwitz, 1997). Other investigators indicated that the 
recombinant Ag85 subunits can be successfully expressed in Corynebacterium glutamicum 
(Salim, Haedens, Content et al., 1997), E. coli (Lakey, Voladri, Edwards et al., 2000) and 
plant leaves (Dorokhov, Sheveleva, Frolova et al., 2007). Lakey et al. employed Escherichia 
coli systems and concluded that the poor expression of some mycobacterial genes was due, in 
part, to the presence of low-usage E. coli codons. They used site-directed mutagenesis to 
convert low-usage codons to high-usage codons for the same amino acid in MTB genes for 
Ag85A and Ag85B. Replacement of five codons in the wild-type gene for Ag85B increased 
recombinant protein production in E. coli 54-fold, yielded 27mg/litre of Ag85B (Lakey, 
Voladri, Edwards et al., 2000). The recombinant Ag85B (rAg85) elicited proliferation and 
interferon-gamma (IFN-γ) production by lymphocytes from healthy tuberculin reactors and 
was recognized by monoclonal antibodies to native Ag85B, indicating that the recombinant 
antigen contained T cell and B cell epitopes (Lakey, Voladri, Edwards et al., 2000). The 
Ag85B used in this project was obtained by overexpression in same E. coli systems as 
Lakey’s.  
E. coli is a frequently used host since it facilitates protein expression by its relative 
simplicity, its inexpensive and fast high-density cultivation, the well-known genetics and the 
availability of a large number of compatible molecular tools. However, expression of 
recombinant proteins with E. coli as the host often results in insoluble and/or nonfunctional 
proteins. In Lakey’s Ag85B E. coli expression system, inclusion bodies and aggregates were 
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found in the proteins produced (Lakey, Voladri, Edwards et al., 2000). There are several 
strategies to increase ratio of soluble Ag85B in the E. coli cytoplasm.  
• Protein expression at reduced temperatures 
The aggregation reaction is, in general, favored at higher temperatures due to strong 
temperature dependence of hydrophobic interactions that determine the aggregation reaction 
(Kiefhaber, Rudolph, Kohler et al., 1991). A direct consequence of temperature reduction is 
the partial elimination of heat shock proteins that are induced under overexpression 
conditions (Chesshyre and Hipkiss, 1989). Furthermore, the activity and expression of a 
number of E. coli chaperones are increased at lower temperature (Ferrer, Chernikova, 
Yakimov et al., 2003; Mogk, Mayer and Deuerling, 2002). A sudden decrease in cultivation 
temperature inhibits replication, transcription and translation, which favor protein folding. 
However, bacterial growth is decreased resulting in a decreased amount of biomass 
(Sorensen and Mortensen, 2005). 
•  Special E. coli strains used to improve soluble expression 
Cysteines in the E. coli cytoplasm are actively maintained in a reduced state by 
pathways involving thioredoxin reductase (trxB) and glutaredoxin (gor). The disulfide bond- 
dependent folding of heterologous proteins is improved in the origami strains (Novagen) 
which have these two mutated reductases. Disruption of the trxB and gor genes encoding the 
two reductases, allow the formation of disulfide bonds in the E. coli cytoplasm (Bessette, 
Åslund, Beckwith et al., 1999). 
• Molecular chaperones drive folding of recombinant proteins 
A possible strategy for the prevention of inclusion body formation is the co-
overexpression of molecular chaperones. GroEL (Hsp60 chaperone family) operates the 
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protein transit between soluble and insoluble protein fractions and participates positively in 
deaggregation and reduction of inclusion bodies (Mogk, Mayer and Deuerling, 2002). 
Since the molecular chaperones in the cytosol can help to prevent protein misfolding 
and aggregation (Hartl and Hayer-Hartl, 2002) and site-mutated reductases are favorable for 
disulfide formation, E. coli, strain origami B, with chaperone vector was used in this project. 
One drawback in using an E. coli system to overexpress protein is endotoxin 
production. Lipopolysaccharide (LPS) is the major component of Gram-negative bacterial 
outer membranes (Reeves, Hoobs, Valvano et al., 1996). This endotoxin is continuously shed 
during bacterial growth. It activates the pattern recognition receptor Toll-like receptor 4 
(TLR 4), which is expressed on a subset of epithelial cells (Backhed, Soderha, Ekman et al., 
2001). Activation of the TLR 4 intracellular signaling pathway stimulates a proinflammatory 
response in epithelial cells, leading to epithelial production of various proinflammatory 
mediators that instructs cells in the underlying tissue and cells belonging to the immune 
system (Ba¨ckhed, So¨derha¨, Ekman et al., 2001). The injection of LPS, into experimental 
animals causes a wide spectrum of nonspecific pathophysiological reactions such as: fever, 
changes in white blood cell counts, disseminated intravascular coagulation, hypotension, 
shock and death (Bacteriology, 2002). Although LPS could be used as an adjuvant, the 
presence of large amounts as a contaminant in the antigens would interfere with the research 
into antigenicity and immunogenicity induced by the subunit antigen. It may also interfere 
with the normal functions of the host following immunization. Polymixin B can remove most 
of the endotoxin from solutions. Polymixins are a family of antibiotics that contain a cationic 
cyclopeptide with a fatty acid chain. Polymixin B neutralizes the biological activity of 
endotoxins by binding to the lipid A portion of LPS (Pierce Biotechnology). 
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1.2 Pulmonary aerosol vaccination is an alternative immunization approach  
Vaccination is one of the most powerful strategies to prevent infectious diseases in 
underserved region. The most common pathogens enter the body via mucous membranes in 
the nose, lungs and gastrointestinal tract. Respiratory viral and bacterial infections are a 
major cause of morbidity and mortality throughout the world (Woodland and Randall, 2004). 
Many pathogens involve or utilize the respiratory tract as a portal of entry into the body 
(Brandtzaeg, 1992; Breiman, Butler and McInnes, 1999). Therefore, pulmonary aerosol 
vaccination could be a potentially powerful way to rapidly immunize the population, 
inducing protection by exposing airways to vaccines. This route of vaccine administration, 
which follows the natural route of infection, may best mimic the induction of immunity in the 
respiratory tract by pathogens and may lead to more general systemic immunity. Aerosol 
vaccination is a noninvasive, nontraumatic method of antigen delivery that avoids the risk of 
transmitting hepatitis B, HIV and other blood borne agents through improper injection 
practices. Therefore, pulmonary immunization is a potential alternative to conventional 
parenteral delivery approaches. 
1.2.1 Pulmonary vaccination belongs to mucosal immunization  
Mucosal immunity is the first line of defense against pathogens entering the body via 
mucosal surfaces. Pulmonary, nasal and oral immune systems contribute almost 80% of all 
immunocytes. These cells are accumulated in, or transit between, various mucosal-associated 
lymphoid tissues (MALT), which together form the largest mammalian lymphoid organ 
system (Mestecky, 2005).  
Mucosal immunization can induce a systemic immunity: generation of secretory IgA 
antibodies, which are able to cross epithelial membranes and prevent future entry of 
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pathogens through the mucosal site. Furthermore, lymphocytes that were stimulated by 
antigens in the mucosal inductive site migrate via regional lymph nodes and thoracic duct to 
the blood stream and other mucosal effector sites. This migration leads to secretory IgA 
production at other mucosal sites of MALT (gut, nasal and genitourinary-associated 
lymphoid tissues) and has been termed the common mucosal immune system (CMIS) 
(Kiyono, Kweon, Hiroi et al., 2001; Lugton, 1999; MacDonald, 2003; van Ginkel, Nguyen 
and McGhee, 2000). Meanwhile, circumstantial evidence indicates the existence of cell-
mediated immunity (CMI) in CMIS (Gallichan and Rosenthal, 1996). The CMIS appears to 
have organ selectivity as enhanced memory is seen at the site of mucosal priming compared 
to that of distant mucosal sites (Mestecky, 1987). Maintenance of the memory T cells 
depends on the tissues in which exposure to antigen first occurred (Mackay, 1993). Mucosal 
vaccination, rather than systemic immunization, gave long-lived cytotoxic T memory 
lymphocytes (Gallichan and Rosenthal, 1996).  
Pulmonary immunization appears very promising since the lungs contain a highly 
responsive immune system. The pulmonary epithelium has a crucial role in host defense 
against inhaled pathogens as it presents physical barriers which include the mucociliary 
escalator, secretion of antimicrobial agents (Larrick, Hirata, Balint et al., 1995; McCray and 
Bentley, 1997; Wright, 1997), chemokines (Bivas-Benita, Ottenhoff, Junginger et al., 2005) 
and cytokines in the mucus layer covering the airway epithelium to prevent colonization of 
microorganisms. Pulmonary macrophages and dendritic cells play an important role in both 
innate and adapted immunity. Alveolar macrophages are abundant, numbering over a billion 
in the periphery and interstitium of the lungs (Bezdicek and Crystal, 1997). Dendritic cells 
are present in the epithelial linings of the conducting airways, submucosa below the airway 
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epithelium, within alveolar septal walls (Holt, Stumbles and McWilliam, 1999). These two 
cell populations are professional antigen presenting cells (APC). They are able to 
phagocytose, process and present antigens to stimulate T cells. Primary stimulation of T cell 
clones within the pulmonary lymphoid tissue is induced when macrophages and dendritic 
cells migrate to bronchial lymph nodes and home to T cell paracortical area (Banchereau, 
Briere, Caux et al., 2000; Poulter, 1997). Bronchus-associated lymphoid tissue (BALT), the 
respiratory part of MALT, is located mostly at bifurcations of the bronchus in animals and 
humans. Local T-cell responses have been noted. BALT can be thought of as a functional 
analogue to mucosal lymphoid aggregates in the intestine and, thus, deemed as a component 
of CMIS (Bienenstock and McDermott, 2005). There is evidence that mice genetically 
lacking spleen, lymph nodes and Peyer’s patches can generate strong primary B- and T-cell 
responses to inhaled influenza. These responses appear to be initiated at sites of the induced 
BALT (iBALT) which function as an inducible secondary lymphoid tissue for respiratory 
immune responses (Moyron-Quiroz, J., Kusser et al., 2004). Exposure of the lungs to various 
aerosol formulations designed to protect against influenza virus was more effective at 
inducing a local immune response than either intranasal administration or parenteral 
injections indicating that this route of administration is relevant for immunization (Smith, 
Bot, Dellamary et al., 2003). 
The physiological features of lymphoid tissues in the respiratory tract suggest there is 
potential for pulmonary immunization. Consequently, pulmonary vaccination is a reasonable 
strategy for protecting the population from infectious diseases where pathogens enter the 
body through the lungs via inhalation.  
-19- 
In tuberculosis pathology, MTB persists in macrophages in the lungs of the host. 
Therefore, pulmonary delivery of vaccines to the macrophages to initiate a cell mediated 
immune response is a mechanism of achieving pulmonary TB immunization. 
1.2.2. Current status of pulmonary vaccine delivery 
The potential for immunization of humans by aerogenic vaccination was recognized 
in the Soviet Union (Aleksandrov and Gefen, 1958) and the United States (Eigelsbach, 
Tigertt, Saslaw et al., 1962) forty years ago. The Russian investigators employed dry vaccine 
preparations containing living vegetative cells or spores of attenuated strains for vaccination 
to humans and indicated that aerogenic vaccination was as effective as subcutaneous 
vaccination against plague, tularemia, brucellosis and anthrax (Aleksandrov, Gefen, Garin et 
al., 1959; Aleksandrov and Gefen, 1958). Airborne BCG vaccination was conducted at 
University of Illinois in 1968. BCGs were nebulized to different age groups of people 
(Rosenthal, McEnery and Raisys, 1968). Rosenthal et al. indicated that tuberculosis 
pathology in human beings was similar to that in guinea pigs rather than mice or rabbits, 
providing important information on BCG aerosol immunization as well as animal models for 
tuberculosis. Rubella immunizations via the pulmonary, nasal and subcutaneous 
administrations were compared in 46 volunteers early in 1973. The humoral immunity via 
pulmonary delivery was comparable to that of subcutaneous vaccination (Ganguly, Ogra, 
Regas et al., 1973).  
Pulmonary immunization is an appealing means of protecting populations in 
biodefense strategies. Bacillus anthracis infection in humans occurs as cutaneous, 
gastrointestinal, or inhalational anthrax depending upon the route of exposure. Inhalational 
anthrax, the form most likely to occur during a bioterrorist attack, is difficult to diagnose 
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early, and despite antibiotic therapy, has a high fatality rate. In 1957, 32 volunteers were 
exposed to an aerosolized dry spore of live anthrax vaccine, composed of a mixture of strains 
STI-1 and No. 3, for 15 min in the Soviet Union. Few general adverse reactions were 
recorded (Aleksandrov, Gefen, Garin et al., 1959). Later a skin test indicated that the aerosol 
method induced higher immunity than subcutaneous and scarification methods previously 
used for immunization in the Soviet Union (Shlyakhov, 1968) (Shlyakhov and Rubinstein, 
1994). The pattern of CMI after aerosol anthrax immunization was investigated in human 
subjects. There were five phases in the kinetic pattern. In phase II (starting at 7 days post-
vaccination) an exponential rise to a maximum at day 15 occurred. In later phases, up to a 
year of reduction in skin reaction occurred. The loss of the skin reaction on day 30 is a 
characteristic feature of post-vaccination anthrax CMI. This may be explained by a blockade 
of macrophages by lethal anthrax toxin released by the multiplying vaccine strain (Shlyakhov, 
Rubinstein and Novikov, 1997).  
Francisella tularensis is a facultative intracellular bacterial pathogen. Infection may 
be caused by inhalation of contaminated air. Therefore, Francisella tularensis is considered a 
serious biohazard (Tarnvik, 1989). A live attenuated vaccine strain Francisella tularensis 
strain LVS was nebulized and administered to humans (Hornick and Eigelsbach, 1966). 
Immunity to aerogenic virulent LVS challenge appeared to be greater than the conventional 
parenteral vaccine administration.  
The only successful clinical case of pulmonary vaccination on a large scale, with 
characterization of aerosol device technology, is a pulmonary measles immunization study. 
Measles vaccination by pulmonary aerosol delivery has considerable appeal. Approximately 
4 million children in Mexico were exposed to measles vaccine aerosols and a high level of 
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successful prevention was achieved (Cutts, Clements and Bennett, 1997). The custom made 
system, Classical Mexican Device, used an International Product Inc. (IPI) jet nebulizer 
driven by an Evans industrial air compressor to deliver aerosols of the reconstituted 
Edmonston Zagreb strain of attenuated measles vaccine virus. The pulmonary delivery 
system produced 52-64% seroconversion, which compared favorably with the expected 
seroresponse to subcutaneous administration (4-23% seroconversion) in school children 
(Bennett, Fernadez de Castro, Valdespino-Gomez et al., 2002). IFN-γ production in cellular 
immunity was more robust in infants who received aerosol vaccines (Wong-Chew, Islas-
Romero, Garcia-Garcia et al., 2005). Many children received a much larger dose than that 
necessary for immunization without any side effects. The necessary immunization dose for 
different age groups of children has been estimated (Coates, Tipples, Leung et al., 2006). The 
WHO has identified three nebulization devices manufactured by Omron, Trudell and 
Aerogen that meet the desired performance criteria to replace the classical Mexican device 
(Laube, 2005). In order to overcome the cold-chain requirement and maintain the biological 
stability of measles vaccine, a pulmonary dry powder aerosol formulation is under 
development. The attenuated EZ strain of measles has been micronized by jet-milling after 
lyophilization. The measles vaccine was dispersible after blending with carrier lactose 
(LiCalsi, Maniaci, Christensen et al., 2001). The shift from liquid to powder formulation 
coupled with appropriate dry powder inhalation technology potentially strengthens the 
measles vaccine. The current Measles Aerosol Project by WHO aims at licensing, by 2007, at 
least one method for respiratory delivery of current measles vaccines (Henao-Restrepo and 
Auguado, 2006). 
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Clinical trials have demonstrated equivalence, or superiority in immune responses for 
measles and rubella delivered as inhaled aerosols with respect to alternative routes of 
administration (Sepulveda-Amor, Valdespino-Gomez, Garcia-Garcia et al., 2002).  
Pulmonary DNA immunization is a new and promising vaccination approach. DNA 
vaccines have the advantage of inducing a strong cellular immunity with a preference to 
cytotoxic T lymphocyte (CTL) and T helper type 1 (Th1) responses. The use of pulmonary 
delivery of DNA vaccines was recently described where plasmids encoding ovalbumin, 
hepatitis B surface antigen (Lombry, Marteleur, Arras et al., 2004) and HLA-A*0201-
restricted T cell epitopes of Mycobacterium tuberculosis (Bivas-Benita, Ottenhoff, Junginger 
et al., 2005) were delivered to a mouse model. Increased immunity as measured by antibody 
and cytokine production was achieved.  
1.2.3. Aerosol technology available for pulmonary delivery of vaccine 
Many aerosol exposure methods have been used to vaccinate animal models. 
Intratracheal instillation and insufflation allow direct delivery of liquids and powders, 
respectively, to the lungs. Animal exposure to aerosols has been achieved through a range of 
exposure chambers (whole body and nose-only chambers). For clinical trials, aerosol vaccine 
delivery requires delivery devices and formulations in which the antigens are incorporated.   
The site and efficiency of deposition of aerosolized particles in the respiratory tract is 
critically influenced by their particle size (defined as aerodynamic diameter), size distribution, 
particle shape and density (Gupta and Hickey, 1991). If the aerodynamic particle size is > 5 
µm, inertial impaction is the primary mechanism for deposition of the particles in the upper 
and central airways. The particles ≤ 3 µm, which have not deposited by impaction, deposit in 
the lower airways by sedimentation. Relatively low velocities, along with longer residence 
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times, in the lower airways favor the deposition of submicron size particles (< 1µm) by the 
diffusion process. Diffusion and sedimentation are the major mechanism of deposition in the 
lower airways of the lungs. Since particles that are subject to diffusion have little mass, this 
mechanism is not considered important for therapeutic or vaccine aerosol purpose. Aerosol 
vaccination usually depends on the target pathogen and the sites of the inductive immunity. 
Larger particles (> 5µm) are needed for the vaccination to prevent upper respiratory 
infections by respiratory viruses or bacteria (for example, Bordetella pertussis and 
Chlamydia pneumoniae (Reynolds, 2002)) and smaller particles (≤ 3 µm) for lower 
respiratory tract infections (Streptococcus pneumoniae, Bacillus anthracis as the examples 
(Reynolds, 2002)). 
Inhalers can be classified into three major categories: nebulizer, pressurized metered-
dose inhaler (pMDI) and dry powder inhaler (DPI).  
1.2.3.1 Nebulizers 
Two types of nebulizers are commercially available: air jet and ultrasonic nebulizers. 
Generally air jet nebulizers can generate smaller particle sizes (mass median aerodynamic 
diameter 2-5 µm), which more easily penetrate to the small airways. Nebulizers have some 
advantages: constant output can deliver aerosols of most solutions and provide large doses 
with very little patient co-ordination or skill; larger total doses can be delivered than with 
MDI and DPI devices; disposable nebulizers are inexpensive. However, treatments using 
these nebulizers are time-consuming and inefficient, resulting in the waste of active 
ingredient. 
Advances in technology have led to novel nebulizers that reduce waste and improve 
delivery efficiency. An enhanced delivery design, Pari LC Star (Pari, Germany), increases 
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aerosol output by directing auxiliary air and causing more generated aerosol to be swept out 
of the nebulizer for inhalation (Leung, Louca and Coates, 2004). Breath-actuated nebulizers, 
e.g. AeroEclipse (Trudell Medical International, London, ON, Canada) and Halolite (Medic-
Aid Limited, West Sussex, UK) have recently been developed. The AeroEclipse controls an 
actuator piston to produce aerosol in inspiration and at rest position in patient’s expiration 
(Leung, Louca and Coates, 2004). The Halolite monitors a patient's breathing pattern in the 
first three breaths and then targets the aerosol delivery into the first 50% of each inhalation. 
This ensures the aerosols are delivered to the patient during inspiration only, thereby 
eliminating drug loss during expiration (Denyer, Dyche, Nikander et al., 1997). A number of 
metered-dose liquid inhalers, including AERx (Aradigm, Hayward, CA, USA), AeroDose 
(Nektar-AeroGen, San Carlos, CA, USA) and Respimat (Boehringer Ingelheim, Ingelheim, 
Germany), have been developed to produce fine aerosols in the respirable range by forcing 
the drug solution through an array of nozzles with 30–75% of the emitted dose being 
deposited in the lungs (Dolovich, 1999; Ganderton, 1999).  
Pulmonary vaccination studies have been performed by nebulization of live attenuated 
pathogens, such as Francisella tularensis (Colan, Shen, Kuolee et al., 2005; Hornick and 
Eigelsbach, 1966), measles morbillivirus (Wong-Chew, Islas-Romero, Garcia-Garcia et al., 
2005), BCG (Cohn and Davis, 1958; Lefford, 1977), and Rubella rubivirus (Ganguly, Ogra, 
Regas et al., 1973). Nebulization delivers vaccine aerosols to the lower respiratory tract. 
However, there is a potency loss problem. Complex-molecules have been reported to 
frequently degrade in response to the shear force of jet nebulization (Schwarz, Johnson, 
Black et al., 1996). The stability of measles vaccine was determined during nebulization by 
the “Classical Mexican Device”. There was a 71% loss of vaccine potency after the nebulizer 
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was run continuously for 20min. The loss in viral potency was of the order of one third when 
the nebulizer was run in cycles of 30s on, 10s off (Coates, Tipples, Leung et al., 2006). 
Immunity may be elicited in response to small numbers of viable pathogens in the lungs. 
However, the issue of vaccine dose reproducibility in the mass vaccine campaign should not 
be neglected. 
1.2.3.2 Pressurized metered-dose inhalers (pMDI) 
pMDIs represent the majority of pharmaceutical aerosol products. They are 
comprised of drug formulation filled or packaged under pressure along with the energy 
source, a liquefied propellant, in a canister equipped with a valve, to meter accurate and 
precise doses, and an actuator. A pre-determined volume of non-aqueous liquid is discharged 
per actuation to offer the precise dose delivery on demand. pMDIs deliver only a small 
fraction of the drug dose to the lungs (10-20% of emitted dose). There is a cold propellant 
effect due to the evaporation of propellant when the aerosols impact on the back of the throat, 
which can be ameliorated by the use of a spacer. Poor hand–mouth coordination is another 
obstacle in the optimal use of a pMDI. Recently, the breath-actuated pMDIs have been 
developed to eliminate co-ordination difficulties by firing in response to the patient's 
inspiratory flow. The Autohaler (3M Pharmaceuticals, Minnesota, USA), increased lung 
deposition from 7.2% with a conventional MDI to 20.8% of the dose using the breath-
activated pMDI (Newman, Weisz, Talaee et al., 1991). Lately (May 2006) Accentia 
Biopharmaceuticals (Tampa, Florida) launched a new breath-activated, dose-counting inhaler 
(MD Turbo) (http://www.mdturbo.com/h_whatismdt.html). This device helps to coordinate 
the press-and-breathe action needed for proper use of an inhaler apart from counting the 
remaining doses in the inhaler.  
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Few vaccines have been delivered by propellant-driven metered dose aerosols. The 
hydrophobic propellant is not a “friendly” environment for most of the vaccine strains or 
aqueous soluble antigen proteins. Surfactants or cosolvents may be needed for pMDI vaccine 
formulation. Brown et al. delivered Streptococcus suis bacteria into the respiratory tract of 
swine in the presence of surfactants using liquefied dimethylether as propellant (Brown, 
George and Matteson, 1997). About 6-12% of bacteria were delivered to the deep lungs. 
After aerosolization, only 17-38% of the cell-wall proteins were associated with the bacteria 
and 30-50% of antigenicity in the respirable bacteria was retained after actuation. This report 
demonstrated that small particle aerosols of the bacteria vaccine from pMDI can be generated, 
but with significant loss of antigenicity (Brown, George and Matteson, 1997). 
1.2.3.3 Dry powder inhalers (DPI) 
The emergence of novel dry powder inhalers (DPIs) was driven largely by the 
Montreal protocol which addressed, in part, eliminating chlorofluorocarbons (CFCs) from 
traditional pMDIs. There are a wide range of commercially available DPI devices, from 
single-dose devices (Aerolizer (Novartis, Basel, Switzerland) and Handihaler (Boehringer 
Ingelheim, Ingelheim, Germany)) to multiunit dose devices provided in a blister pack 
(Diskhaler and Diskus (GlaxoSmithKine, Middlesex, UK)) or reservoir-type system 
(Turbuhaler (AstraZeneca, London, UK)) (Hickey, 2004b). Generally, inert carriers, most 
commonly lactose, are needed for dispersion of small particles of the active ingredients. 
Aerosols are created by directing the air through loosely-packed powders. Lung deposition 
varies from 12-40% of the emitted dose among the different DPIs (Hickey, 2004b). 
Insufficient deaggregation of the active ingredient from coarse carrier particles contributes to 
the low active ingredient deposition. Active DPIs are being investigated to reduce patients’ 
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inspiratory effort to disperse the fine particles. Aspirair (Vectura, Wiltshire, UK) is triggered 
by the patient’s inhalation. This inhaler generates an aerosol plume significantly slower than 
most inhalers currently available. Therefore, the use of Aspirair reduces the amount of drug 
that is unintentionally deposited in the mouth and throat, and subsequently swallowed rather 
than reaching the lungs (Tobyn, Staniforth, Morton et al., 2004). Spiros (Dura 
pharmaceuticals, San Diego, CA) uses a battery-driven propeller to aid the dispersion of 
powders. Inhance Pulmonary Delivery System (Nektar, San Carlos, CA) uses compressed air 
to aerosolize the powder and then converts it into a standing cloud in a holding chamber. 
This makes the generation of aerosol independent of patients’ inspiratory effort.  
In addition to the general advantages of dry powder vaccination, a unique feature of 
the route of administration is that, the alveolar APCs (especially macrophages and/or 
dendritic cells) are phagocytic and respond to small-size particulates by eliciting cell-
mediated and humoral immunity. These particulates could be whole vaccine strains, subunit 
proteins or DNAs formulated in particulates.  
Dry powder aerosol vaccination has been employed to immunize humans and animals. 
In the early 1960s, Russian investigators used dry vaccines of attenuated bacterial strains to 
immunize experimental animals against a number of diseases including, plague, tularemia, 
brucellosis and anthrax (Middlebrook, 1961). Large particle aerosols of a live, temperature-
sensitive recombinant influenza virus, were generated by spinning-top aerosol generator to 
immunize the mice (Jemski and Walker, 1976). These dry powder particles of influenza virus 
provided 89% survival after challenge.  
A dry powder measles formulation was suggested for delivery from Spiros inhalers 
(LiCalsi, Christensen, Bennett et al., 1999). These are durable, handheld and could be either 
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single or multidose devices. The delivery efficiency of Spiros technology was demonstrated 
by pulmonary imaging with radiolabelled albuterol sulfate. Scintigraphy results showed 
uniform deposition of radiolabelled drug throughout the tracheobronchial region and 
significant and uniform deposition in the alveolar region (Hill, Vaughan and Dolovich, 1996). 
The studies performed with nebulized measles vaccine provide evidence that the aerosol 
vaccine to the lungs need not be greater than the currently accepted minimum subcutaneous 
dose of 1000TCID50 (tissue culture ID50). The estimated measles vaccine concentrations 
could vary from 3 to 40% in lactose depending on TCID50 from different manufacturers. This 
blend is suitable for dispersion from inert lactose (LiCalsi, Christensen, Bennett et al., 1999). 
1.2.4. Components of pulmonary vaccine formulations 
Formulation is an important factor that affects the stability of subunit antigens or live 
attenuated/inactivated vaccine strains. The formulations also dictate the aerosol delivery 
device for vaccine administration. Delivery devices need various formulation strategies to 
meet the physico-chemical and aerodynamic criteria to generate the respirable aerosols.  
1.2.4.1. Adjuvants 
Adjuvants help to elicit early, high and long-lasting immune responses with limited 
quantities of antigen. They are the focus of vaccine research because the purified, synthetic 
subunits and DNA vaccines are frequently poor immunogens and require adjuvants to evoke 
immune responses (Degen, Jansen and Schijns, 2003; Seong and Matzinger, 2004). With the 
use of adjuvants an immune response can be selectively modulated to Th1 or Th2 type 
(Marciani, 2003), which is important for protection against diseases caused by intracellular 
viruses, parasites and bacteria.  
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There are several mechanisms of action for adjuvants: depot generation (aluminum 
compounds, immunostimulant complexes (ISCOM), emulsions, oil adjuvants (Freund’s 
complete/incomplete adjuvant)); immunomodulation (modification of cytokine networks, 
includes lipopolysaccharide (LPS), monophosphoryl lipid A (MPL), lipopeptides, CpG motif, 
muramyl dipeptide (MDP), cholera toxoid (CT)); and delivery vehicles (liposomes, 
biodegradable polymer microparticles) for antigens in targeting to APCs. The delivery 
vehicle function of adjuvants will be discussed in detail in the section describing particulate 
delivery systems. 
The only approved adjuvant for humans is alum (potassium aluminum sulfate). 
Alhydrogel (aluminum hydroxide) and adju-phos (aluminum phosphate) are also used in 
research and preclinical trials. Aluminum compounds have a good safety record in vaccines. 
Usually they elicit a strong humoral response but poor Th1 immunity. MF59 and MPL have 
also been used in human trials (Giannini, Hanon, Moris et al., 2006; Kahn, Sinangil, 
Baenziger et al., 1994; Martin, De Donato, Minutello et al., 1995) but there are no 
experimental reports on pulmonary vaccine delivery.  
In TB vaccine development, MTB cell wall components exhibit adjuvancy (Fidler, 
1992) and may readily be incorporated into particles due to their balance of hydrophobic and 
hydrophilic moieties. They may be useful in promoting the antigenicity of MTB derived 
molecules, such as Ag85, in a similar manner to the behavior of an intact microorganism 
(Lindblad, Elhay and Silva, 1997).  
In TB vaccination investigations, several adjuvants have been suggested for 
coincorporation with the subunit antigens. Muramyl peptides are the smallest components in 
MTB cell wall. They can induce production of a cascade of cytokines, including IL-1α, 1β 
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and IL-6. Lymphocytes recruited in response to cytokines and chemokines release IL-2 and 
IFN-γ. The use of the cell wall components to stimulate immune response is well suited to 
the restrictions on dose that can be delivered by aerosol. They can be delivered to 
macrophages by incorporation in liposomes applied to cancer therapies (Philipis, Chedid and 
Bernard, 1987; Phillips, Moras and Chedid, 1985) and TB vaccination (Pettis, Hall, Costa et 
al., 2000). Trehalose dimycolate (TDM) is a component in MTB cell wall. Due to TDM’s 
toxicity profile, synthetic analogue trehalose dibehenate (TDB) has been made to maintain its 
adjuvancy while reducing side effects. Anderson et al. reported that TDB could enhance CMI 
and antibody responses of TB subunit antigens Ag85B-ESAT6 when they were encapsulated 
in cationic liposomes. Immunization of mice with this formulation induced a strong, specific 
Th1 type immune response characterized by substantial production of the interferon-gamma 
and high levels of IgG2a isotype antibodies. The lymphocyte subset releasing the interferon-
gamma was identified as CD4 T cells (Davidsen, Rosenkrands, Christensen et al., 2005; 
Holten-Andersen, Doherty, Korsholm et al., 2004). Lipopolysaccharide (LPS) is composed 
of a hydrophilic polysaccharide and a lipophilic phospholipid (lipid A). LPS-induced cell 
activation requires a tripartite receptor complex in which one protein bind tightly to Toll-like 
receptor TLR 4 and TLR2. Binding of LPS by TLRs stimulates innate immunity, which in 
turn, activates adaptive immunity to activate NF-κB (Shizuo, 2003), induce nitric oxide-
independent killing of intracellular tubercle bacilli in human alveolar macrophages (Thoma-
Uszynski, Stenger and Takeuchi, 2001). Analogue monophosphoryl lipid A (MPL) retains 
adjuvancy at a lower toxicity (Ismaili, 2002). Anderson et al. have demonstrated that MPL 
could be used as one of the adjuvants in TB vaccine (Olsen, van Pinxtern, Rasmussen et al., 
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2001) (Brandt, 2000). Other adjuvants have been validated in animal studies, such as saponin. 
MDP and TDB are the major adjuvants used in this project. 
1.2.4.2 Microparticle systems 
Microparticle systems have been a common theme in the vaccine delivery field. They 
enhance the immune response greatly in comparison to soluble antigens. They have adjuvant 
functions and stimulate the immune response to help Th1 induction (Raychaudhuri and Rock, 
1998). Microparticle systems include liposomes, lipid-based and biodegradable polymer-
based microparticles. Some subunit antigens and DNA vaccines use viral vectors for 
pulmonary delivery. Recently, the biodegradable microparticles have drawn a lot of attention 
in the vaccine delivery. 
Biodegradable polymeric microparticles showed good adjuvant activity. Antigen 
uptake by APCs was enhanced by the association of antigen with polymeric microparticles. 
The biodegradable and biocompatible polyesters, poly(lactide-co-glycolides) (PLGA) are the 
primary candidates for the development of microparticles because they have been used in 
humans for many years as suture material and controlled-release delivery systems.  
Microparticle particle size (1-10µm) can be manipulated to target macrophages.  
Macrophages can present the antigens 100- to 1000- fold more efficiently to MHC class I and 
II pathways than soluble antigens alone when antigens are attached to small particles 
(Raychaudhuri and Rock, 1998). There is a greater potential for the microparticles residing in 
the lungs for extended period of time to be taken up by APCs. These microparticles can 
protect live vaccine strains or subunit antigens against rapid degradation by extracellular 
enzymes. They may also offer controlled-release dissolution profiles for antigen, which 
allows the development of single-dose vaccines. In contrast to alum, PLGA microparticles 
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have been shown to be effective for induction of CTL response (Raychaudhuri and Rock, 
1998). Yersinia pestis subunit and anthrax rPA have been delivered intranasally or 
intratracheally in PLGA formulations leading to an improved immune response with respect 
to other formulations (Eyles, Sharp, Williamson et al., 1998; Eyles, Williamson, Spiers et al., 
2000; Flick-Smith, Eyles, Hebdon et al., 2002) (Table 2).  
1.2.4.3 Dispersion of vaccines and microparticles 
Dry powder aerosol delivery is an attractive delivery method for pulmonary 
immunization since it has many advantages over nebulizer and MDI delivery of aqueous and 
nonaqueous droplets. However, dry powder vaccines are not currently commercially 
available. Dispersion of these particles must be demonstrated for dry powder vaccine 
delivery to become a reality. The interaction energy between micron-sized particles needs to 
be overcome to efficiently generate an aerosol. 
Sugar carriers (Steckel and Bolzen, 2004), sodium chloride salt (Chan, Clark, Gondal 
et al., 1997) and redistribution of drug particles from coarse particles to the fine particle 
component can improve drug aerosol dispersion (Lucas, Anderson and Staniforth, 1998). It 
has been reported that some fine particle addition to the carrier can improve the dispersion of 
the active pharmaceutical ingredient (Shah and Misra, 2004). 
Self-dispersion is another approach for aerosol particles. Large porous particles have 
mean geometric diameter up to 30µm, with good flow and dispersion properties (Edwards, 
Hanes, Caponetti et al., 1997). However, large porous particles evade phagocytosis by 
macrophages. Recently van der Walle et al. reported that PLGA microparticles could be 
manufactured with novel dimpled surfaces for pulmonary delivery of DNA (Mohamed and 
van der Walle, 2006). The hollow microparticles, with a low density (0.24g/cm3) and dimples, 
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were produced by addition of high molecular weight hydrophobic blocks of pluronic. The 
calculated aerodynamic diameter of microparticles was 3.8µm and the dimpled 
microparticles showed good aerosol dispersion properties. Porous particles larger than 10 µm 
are not suitable formulations for vaccine delivery in which the targeting APC is alveolar 
macrophages. There is an exception to this observation, which is a nanoparticle aggregate 
which disassembles upon deposition into its smaller component particles. 
1.2.5. PLGA microparticles as the pulmonary aerosol delivery carriers 
Microparticles of poly (lactic-co-glycolic acid) (PLGA) copolymers have been a 
major focus as antigen carriers (Alpar, Somavarapu, Atuah et al., 2005; Eldridge, Staas, 
Meulbroek et al., 1991; Jiang, Gupta, Deshpande et al., 2005; Tamber, Johansen, Merkle et 
al., 2005). PLGA microparticles have been used to deliver vaccines against TB in parenteral 
formulations. Ag85A DNA vaccine was adsorbed onto cationic PLGA microparticles (i.m) 
and similar protection levels against aerosol challenge was observed in mice using doses of 
PLGA-DNA two orders of magnitude lower than with naked DNA itself (Mollenkopf, 
Dietrich, Fensterle et al., 2004). A single-shot prime-boost vaccine formulation based on a 
mixture of two different PLGA microparticles containing DNAhsp65 and the recombinant 
hsp65 protein was developed. This formulation clearly presented good efficacy and 
diminished lung pathology in both mice and guinea pigs (de Paula, Silva, Carlos et al., 2007).  
Mice immunized with 71-kDa cell wall associated protein of MTB H37Rv in PLGAs 
exhibited significantly higher T-cell stimulation and cytokine release in comparison to the 
same protein emulsified in Freund's incomplete adjuvant (FIA) as well as a BCG vaccinated 
group throughout the post-immunization (p.im.) period.  The protective effect of 71-kDa-
PLGA was sustained (85%) while that of 71-kDa-FIA began to wane (70%) when increasing 
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the interval of challenge to 16 weeks post immunization. Further, the 71-kDa-PLGA 
immunized group exhibited a significantly higher (p < 0.001) clearance of bacterial load from 
the lungs and livers in comparison to the 71-kDa-FIA immunized group (Dhiman and 
Khuller, 1998). The early secreted antigenic target 6-kDa protein ESAT-6 was encapsulated 
in poly(lactide) (PLA) microparticles and intranasally instilled into mice. Microencapsulated 
ESAT-6 induced greatest numbers of ESAT-6 specific IFN-γ and IL-4 secreting cells in the 
lung and mediastinal lymph nodes (MLN). Similarly, ESAT-6 specific recall responses were 
strongest following intranasal immunization of mice with microparticle-encapsulated antigen 
(Carpenter, Williamson and Eyles, 2005). The research reports indicated that, PLGA carrier 
systems have great potential as adjuvant to enhance immunity. Their depot effect, sustained 
release manipulation and long-term protective properties of PLGAs brought them attention in 
antigen delivery for tuberculosis. 
There are no reports on vaccines delivered in PLGA carriers as aerosol into the lungs, 
the primary site of MTB infection in the host, to elicit an immune response. PLGA 
microparticles have been employed to deliver therapeutic drugs into the lungs. These 
microparticles encapsulating rifampicin (Garcia-Contreras, Sethuraman, Kazantseva et al., 
2006) (Suarez, 2001) were delivered as aerosol to tuberculosis-sensitive guinea pig model. 
Aerosolized particles reduced most measures of tuberculosis (TB) infection. PLGA 
nanoparticle-based inhalable sustained drug delivery system containing antitubercular drugs 
enhanced relative bioavailability (compared to oral administration) for encapsulated drugs 
(12.7-, 32.8- and 14.7-fold for rifampicin, isoniazid and pyrazinamide, respectively) (Pandey, 
Sharma, Zahoor et al., 2003). These studies are evidence for the potential of inhaled aerosol 
therapy for the treatment of TB. Respirable and sustained-released PLA particles containing 
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ipratropium bromide, a drug used to treat asthma and chronic obstructive pulmonary disease 
(COPD) (Taylor, Hickey and VanOort, 2006), provided an increased duration of effect in a 
guinea pig model of bronchoconstriction. Surface-modified PLGA nanospheres with chitosan 
improved pulmonary delivery of calcitonin due to the retention of nanospheres adhered to the 
bronchial mucus and lung tissue and the consequential sustained release at the adherence site 
(Yamamoto, Kuno, Sugimoto et al., 2005). Some peptide drugs were also administered in 
respirable PLGA carriers (Niwa, Takeuchi, Hino et al., 1995). These therapeutic aerosols 
while intended mechanistically to achieve different objectives, indicated potential for 
vaccines to be administered to the lungs. A number of new technologies are available to 
prepare respirable PLGA microparticles (Dailey, Kleemann, Wittmar et al., 2003; Mohamed 
and van der Walle, 2006; Ozeki, Beppu, Mizoe et al., 2006) that would facilitate pulmonary 
delivery of vaccines. 
1.2.6 Particle size characterization and physico-chemical characterization of dry 
powders 
1.2.6.1 Particle size characterization 
Quantitative descriptors of particle size are one of the specific properties of powders. 
The projected area diameter (dp) is obtained from two-dimensional images, generated by 
microscopy, of a particle. It represents the diameter of a circular disc with the same projected 
area as the particle being examined (Martin and Bustamante, 1993). The equivalent volume 
diameter (dv) is the diameter of a sphere of the same volume to the particle. These two 
particle size characterizations have limited application to particles deposited in the 
respiratory tract. The aerodynamic diameter (da) is the dimension used to represent airborne 
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particle size. The da is the diameter of a unit density sphere that has the same terminal setting 
velocity in air as the actual particle (Hinds, 1999). 
 
VTS = ρ0da2g/18η = ρpde2g/18ηχ 
 
VTS: terminal settling velocity of the unit density sphere 
ρ0: unit density;  
ρp: particle density;  
g: the acceleration of gravity 
η: air viscosity:  
χ: shape factor  
This equation states that the diameter of particles having uniform density, increases 
proportionately to the terminal settling velocity. A large particle is more likely to deposit by 
inertial impaction than a small one. However, if density varies, a larger, low-density particle 
can have the same terminal settling velocity as a smaller high-density particle. This is 
important since some manufacturing methods produce low-density particles, which may 
result in a significant difference between the directly observable, geometric diameter and the 
aerodynamic diameter. 
Powders consisting of particles of similar size (monodisperse) can be described by a 
single diameter. However, most powders consist of a range of particle sizes (polydisperse) 
that affect their flow and dispersion. The entire distribution of particle sizes must be 
characterized. The median diameter is used to represent the 50th percentile of the distribution 
and geometric standard deviation is used to represent the breadth of the particle sizes for log-
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normal distributions. The median diameter of a size distribution can be based on the count, 
mass, or volume and would be termed count median diameter (CMD), mass median diameter 
(MMD) and volume median diameter (VMD). The geometric standard deviation (GSD) for a 
normal distribution can be calculated from the following equation (Hinds, 1999). 
 
GSD = D84% / D50% = D50% / D16%   = [D84% / D16%] 1/2 
 
where D84% and D16% represent the diameters at the cumulative percentile of 84% and 16%. For 
an aerodynamic size distribution, the median is identified as the mass median aerodynamic 
diameter (MMAD). 
The span is an alternative measure of the breath and uniformity of a distribution, 
which is commonly used to describe formulations where laser diffraction technique has been 
used to collect equivalent volume diameter data. 
 
Span = (D90%-D10%) / D50% 
 
Where, D90% and D10% represent the diameters at the cumulative percentiles of 90 and 10%. 
The cascade impactor is used to separate airborne particles into aerodynamic size 
classes (Lodge and Chan, 1986). A cascade impactor operates on the basis of inertial 
impaction (Hinds, 1999). These devices consist of a series of stages with orifices that 
decrease in size with each succeeding stage. Particles are drawn into the impactor on the 
conveying air stream produced by a vacuum pump. Collection surfaces serve to obstruct the 
path of the airflow. Since the orifice size decreases with succeeding stages, the linear velocity 
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of air increases at each successive stage. Therefore, the inertia and stopping distance of 
specific size fractions of particles increase at each stage increasing their probability of 
deposition (Baron and Willeke, 2001). This allows particles with a range of aerodynamic 
diameters to be deposited on each collection surface with particles having a higher 
aerodynamic diameter depositing on the upper stages. Additionally, the amount of powder 
dispersed from the delivery device can be quantified and an emitted dose can be calculated. 
1.2.6.2 Physico-chemical property characterization  
The surface area of the particle influences particle interactions in a powder due to the 
number of contact points. Surface area for a single spherical particle is equivalent to πd2 and, 
therefore, increases proportionally to the square of the diameter, d. However, in a defined 
mass of powder there are many more small particles than large ones. On a population basis, 
the sum of the surface area of small particles is greater than that of large particles in any 
specific powder. The surface area is most commonly measured by gas adsorption at the 
surface of a known mass of powder (Crowder, 2003). 
Particles consist of organized structures of molecules the dimensions of which dictate 
the crystal system. Pharmaceutically the underlying molecular structure contributes to the 
stability of the powder system. Thermal analysis is one means of studying the structure. The 
principle underlying thermal analysis is to apply energy, in the form of heat that can be 
absorbed by the solid and may contribute to a re-ordering of the system into another form or 
result in dissociation of important elements of the structure. Differential scanning calorimetry 
(DSC) is the method most frequently employed to study these phenomena. DSC measures 
differences in the amount of heat required to increase the temperature of a sample with 
respect to a reference. DSC can sense the phase transition, denaturation and unfolding events 
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in peptides and proteins. DSC may also be used to measure kinetic phase transitions, such as 
glass transitions. 
The hygroscopicity, capacity to take on moisture, of a dry powder formulation can 
influence flow and dispersion properties. Powders with higher moisture contents are more 
likely to aggregate due to surface tension effects and capillary forces, and hygroscopicity can 
increase the probability of these effects occurring (Hickey and Ganderton, 2001). Moisture 
content can be determined by difference, measuring the changes in weight of a powder 
before and after heating assuming there is no degradation in the measured contents. 
The zeta potential is defined as the difference in potential between the surface of the 
tightly bound layer and the electroneutral region of the solution. The zeta potential has 
practical application in the stability of systems containing dispersed particles because this 
potential governs the degree of repulsion between adjacent, similarly charged, dispersed 
particles. Tabata et al. pointed out that the size and surface charge can affect their 
phagocytosis by macrophages (Tabata and Ikada, 1988). Phagocytosis is enhanced as the 
absolute value of zeta potential increases for both the negatively and positively charged 
surface. Therefore, measurement of zeta potential of particles may provide certain prediction 
on their phagocytosis by macrophages. 
Aerosol particles can acquire charge by flame charging, static electrification, 
diffusion charging, and field charging (Hinds, 1999). Of these mechanisms, static 
electrification plays the predominant role during DPI actuation. Static electrification occurs 
when particles interact with surfaces or detached from the bulk phase resulting in a 
separation of charges. In DPIs, this takes the form of surface charging, or triboelectrification. 
When particles are separated from each other or the surfaces of the dosage form or surfaces 
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of the inhalers, charge can be transferred resulting in a net charge on the particles. Particles 
experience significant friction during DPI discharge which tends to amplify this effect. The 
Electrical Low Pressure Impactor (ELPI) enables real time particle size distribution and 
concentration measurement. The ELPI is composed of a unipolar corona aerosol charger and 
a low-pressure cascade impactor (Fig 1.3). Deposition inside the impactor is dependent on 
particle aerodynamic diameter. Unlike conventional cascade impactors which are 
disassembled and the stages assayed chemically or gravimetrically after operation, ELPIs 
detect deposited particles by measuring the current resulting from dissipation of the particles’ 
electrical charge. The collected particle fractions can be measured simultaneously on all 
stages using a multichannel electrometer. Thus, when the ELPI is operated with charger 
turned on, it functions as a near real-time particle sizer. However, when operated with the 
charger off, the native particle charge is measured. The ELPI is a low-pressure impactor; 
operation at reduced absolute pressures allows collection of particles down to a size of 30 nm  
The static and kinetic surface charge properties, of PLGA microparticles, will be 
evaluated by zeta potential and real-time particle sizing, respectively. 
1.3 Statement of problem 
Currently, the only marketed TB vaccine is BCG. However, BCG has variable 
efficacy ranging from 0 to 80% in the worldwide clinical trials. Due to BCG’s variable 
protection as a vaccine in the prevention of MTB infection, a major scientific effort over the 
past several years has produced hundreds of potential TB vaccine candidates. Vaccine 
candidates are usually delivered via parenteral routes. There has been much less research into 
alternative delivery systems and administration routes for vaccination to elicit effective 
immunity to MTB. The site of antigen exposure will determine the immune response and 
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circulating antigen-specific T cells. The pulmonary route of exposure, by which most TB 
patients acquire their primary infection, might be a promising route for TB vaccination. 
Different delivery systems, especially particulate systems, are easily recognized by antigen 
presenting cells, may help to target macrophages in the lungs to elicit improved immunity. 
Aerosol immunization with a promising vaccine candidate mycobacterial subunit antigen 
85B (Ag85B), a subunit of antigen 85 complex, with immunostimulatory adjuvants as 
components in microparticle systems is proposed. 
1.4 Hypothesis and Specific aims 
1.4.1 Hypothesis 
Ag85B/adjuvants in microparticle formulations intended for pulmonary delivery  
• target macrophages. 
• elicit related cell-mediated immune response in vitro.  
• protect guinea pigs against challenge with virulent MTB (H37Rv). 
1.4.2 Specific aims: 
I. To evaluate the ability of Ag85B subunit together with different adjuvants loaded 
into microparticles.  
(a) Ag85B were obtained as recombinant protein expressed in E. coli. The antigenicity of 
rAg85B will be evaluated by T hybridoma cell recognition assay. 
(b) Poly (lactide-co-glycolide) (PLGA) microparticles were loaded with rAg85B 
with/without adjuvants by spray-drying method. The formulation parameters were optimized 
using factorial experimental design with multivariate statistical analysis. Different batches of 
formulations were manufactured with various loadings of rAg85B and adjuvants.  
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II. To elucidate the T hybridoma cells responses to different formulations; characterize 
the physico-chemical properties of microparticle systems as aerosols.  
(a) The phagocytosis of microparticle systems by macrophage-like cells was evaluated.  
(b) The proliferative nature of effector T cells after recognition of macrophage activation was 
determined. IL-2, which is released from hybridoma T cells and stimulates proliferation of T 
cells, was measured by T hybridoma cell recognition assay. The ability of different 
microparticle formulations to affect epitope presentation was measured by this bioassay upon 
macrophage inoculated by microparticle formulations.  
(c) Microparticle formulations were characterized to establish their suitability as aerosols. 
III. To evaluate the effect of vaccination with selected aerosol microparticle adjuvant/ 
antigen combinations. Protection will be measured using the guinea pig model of 
tuberculosis involving a low-dose virulent challenge. 
(a) Optimized adjuvant/antigen microparticle combinations were selected based on results 
obtained in specific aims 1-2 and delivered as aerosols to guinea pigs prior to challenge with 
low-dose virulent MTB H37Rv. The bacterial burden in lungs and spleens, weight changes 
after challenge of infected guinea pigs was compared with appropriate positive (BCG) and 
negative controls. 
1.5 Significance 
The MTB secreted subunit protein, Ag85B, is a promising antigen for inclusion in a 
vaccine against tuberculosis. Microparticle formulation systems for pulmonary delivery, a 
new route of delivery of TB vaccine, may protect the protein antigens from extracellular 
degradation. Furthermore, local delivery may result in reduced potential side effects and 
dosage amounts. Guinea pig protection studies with optimized formulations illustrated the 
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protective effects of this recombinant protein in the microparticle systems delivered as 
aerosols. These studies may offer the first evidence for the effect of a protein subunit vaccine 
delivered to the lungs for protection against tuberculosis, which has significant implication 
for worldwide disease control. 
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Fig 1.1 Cell wall structure of Mycobacterium tuberculosis.  
(Picture was modified from that obtained from 
http://student.ccbcmd.edu/courses/bio141/lecguide/unit1/prostruct/u1fig11.html with 
permission of Dr. Gary Kaiser in Community College of Baltimore County, Catonsville 
Campus). 
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Fig 1.2 Alveolar macrophage activation and immune responses. 
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Fig 1.3. Electrical Low Pressure Impactor (ELPI) operating principle.  
(http://www.dekati.com/cms/elpi/operating_principle) 
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Table 1.1 Summary of new-generation tuberculosis vaccine to improve BCG 
 
Vaccine Description Development stage Researchers/sponsors 
Live mycobacterial vaccines: modified BCG 
rBCG30 BCG Tice engineered to overexpress Ag85B 
Phase I trial in US, completed in 
2004; no serious adverse events 
M. Horwitz, UCLA; D. Hoft, St 
Louis University, US; T. 
Littlejohn, Winston, Salem, 
North Carolina, US  
Sponsor: Sequella, Aeras* 
rBCG-
Aeras 403 
BCG Danish with 
endosome escape and 
overexpression of several 
proteins including Ag85A, 
Ag85B and TB10.4 
Ongoing pre-clinical studies and 
GMP production; Phase I clinical 
trial planned for 2006 
 R. Sun, D. Hone, M. Stone, J. 
Sadoff, Aeras* 
rBCG
Ure:CHly+ 
BCG Pasteur with 
endosome escape 
Ongoing pre-clinical studies and 
GMP production; Phase I clinical 
trial planned for 2006 
S. Kaufmann, Max Planck 
Institute for Infection Biology, 
Berlin, Germany 
BCG:RDI 
BCG Pasteur with 
reintroduction of RD-1 
locus which contains 
protective Ags 
Ongoing pre-clinical studies S. Cole, Institute Pasteur, Paris, France 
Pro-
apoptotic 
BCG 
BCG Tice with 
diminished superoxide 
dismutase activity 
Ongoing pre-clinical studies D. Kernodle, Vanderbilt, US  Sponsor: NIH, VA, Aeras* 
 
*Supported by the Bill and Melinda Gates Foundation. Phase I clinical trial: trial that assesses the safety and 
immunogenicity of a drug or a vaccine in healthy volunteers. BCG, bacille Calmette–Guérin; GLP, good 
laboratory practice; GMP, good manufacturing practice; NIH, National Institutes of Health; SSI, Statens Serum 
Institute; TB, tuberculosis; VA, Medical Research Service, Department of Veterans Affairs. 
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Table 1.2. New generation of TB vaccines in live MTB, subunit antigens and DNA vaccines 
Live mycobacterial vaccines: modified Mycobacterium tuberculosis 
MTB PhoP 
Deletion of virulence 
associated gene phoP from 
MTB MT103 strain 
Ongoing pre-clinical studies 
and GLP production 
B. Martin, University of 
Zaragoza, Spain; B. 
Gicquel, Institute Pasteur, 
Paris, France 
MTB 
mc26030 
MTB H37Rv with deletion 
of panCD and RD-1 locus 
Ongoing pre-clinical studies 
and GMP production; Phase 
I clinical testing planned for 
2006 
W. Jacobs, Albert Einstein 
College of Medicine, New 
York  
Sponsor: NIH 
MTB 
mc26020 
MTB H37Rv with deletion 
of the lysA and the panCD 
locus 
Ongoing pre-clinical studies 
and GMP production; Phase 
I clinical testing planned for 
2006 
W. Jacobs, Albert Einstein 
College of Medicine  
Sponsor: NIH 
 
 
Subunit vaccines 
MTB72F 
Recombinant fusion protein 
(MTB39 and MTB32) in 
AS02A and AS01B 
adjuvants 
Phase I trials completed in 
US and Europe; no serious 
adverse events; additional 
trials ongoing in Europe 
Y. Skeiky, S. Reed, Corixa 
Corp. Seattle, US  
Sponsor: Glaxo Smith 
Kline, Aeras* 
Hybrid-1 
(85B–
ESAT6) 
Recombinant fusion of 
Ag85B–ESAT-6 in IC31 
adjuvant 
Phase I clinical trials 
commenced in 2005 
P. Andersen, SSI, Denmark 
Sponsor: SSI, TBVAC 
HyVac-4 
(Ag85B–
TB10.4) 
Recombinant fusion of 
Ag85B–TB10.4 in IC31 
adjuvant 
Ongoing pre-clinical studies 
and GLP production; Phase 
I clinical trial planned for 
2007 
P. Andersen, SSI, Denmark 
Sponsor: SSI, Aeras* 
Heatshock 
protein 
Nascent BCG proteins 
associated with purified 
heat-shock proteins 
Ongoing pre-clinical studies 
C. Colaco, 
ImmunoBiology,  UK  
Sponsor: ImmunoBiology, 
Aeras* 
 
 
Naked DNA and viral-vectored vaccines 
Hsp65 
(GroEL) 
DNA 
Conserved antigen from 
Mycobacterium leprae for 
immunotherapy 
Ongoing pre-clinical studies 
D. Lowrie, National Institute 
for Medical Research, 
London UK.  
Sponsor: Sequella Inc. 
MVA85A 
Attenuated strain of vaccinia 
(modified vaccinia virus) 
expressing Ag85A 
Completed and ongoing 
Phase I clinical trials; 
immunogenic, no serious 
adverse events reported 
A. Hill, H. McShane, Oxford 
University, UK  
Sponsor: Wellcome Trust 
Aeras 402 
(Ad35.TB-S) 
Non-replicating Ad35 
expressing multiple TB 
proteins including Ag85A, 
Ag85B and TB10.4 
Ongoing pre-clinical studies; 
GMP production for Phase I 
clinical trials planned for 
2006 
Aeras*, Crucell  
Sponsor: Bill and Melinda 
Gates Foundation 
  
2. Manufacture and screening of PLGA microparticle formulations containing rAg85B  
2.1 Introduction 
Manufacture of PLGA microparticles containing rAg85B, and screening formulations 
with regards to eliciting immunity, is required to develop particles suitable for aerosol 
vaccine deliveries. It is also necessary to validate the immunological advantages of these 
PLGA antigen formulations compared to simple solution formulations.  
Supplies of Ag85B were once quite limited since it was purified from MTB culture. 
MTB is both exceptionally slow growing and biohazardous. Therefore, the growing, 
separation and purification procedures make it difficult to obtain sufficient quantities of 
Ag85B antigens from the culture filtrate. E. coli systems have been reported to overexpress 
this antigen (Lakey, Voladri, Edwards et al., 2000). However, the inclusion bodies and 
aggregation influenced the antigen’s overall immunogenicity. In order to increase the ratio of 
soluble form of Ag85B, a couple of strategies were used in the E. coli expression system or 
procedure in this project. Firstly, the E. coli culture temperature was reduced to 22°C after 
isopropyl-β-thiogalactopyranoside (IPTG) induction; Secondly, E. coli stain Origami B was 
used. This strain has a chaperone vector and mutated reductases that are favorable for 
disulfide bond formation and appropriate conformation in expressed proteins. There is one 
disulfide bond in Ag85B. 
A number of microencapsulation techniques have been developed to date to make the 
microparticles of polymers. The choice of the technique depends on the nature of the 
polymer, the active ingredient and the intended use (Arshaday, 1991; Jalil and Nixon, 1990; 
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Wu, 1995). The microencapsulation method employed must include the following 
requirements: 1) Stability and biological activity of the active ingredients should not be 
adversely affected, during the encapsulation procedure, or in the final microparticle product. 
2) The yield of the microparticles having the required size range and encapsulation efficiency 
should be high. 3) The microparticles should be produced as a free flowing powder and 
should not exhibit aggregation or adherence. 
Three common methods are used to manufacture microparticles: solvent evaporation, 
phase separation and spray-drying.  
Solvent evaporation methods include single emulsion and double emulsion processes. 
Single emulsion process involves oil-in-water (o/w) and oil-in-oil (o/o). The polymer is first 
dissolved in a water immiscible, volatile organic solvent. The active ingredient is then added 
to the polymer solution and dissolves or disperses as particles (Wu, 1995). This polymer-
solvent-active ingredient solution/dispersion is then emulsified in a larger volume of water or 
oil (water for o/w, oil for o/o) in the presence of an emulsifier to yield an emulsion. The 
emulsion is then subjected to solvent removal by either evaporation or an extraction process 
to harden the oil droplets (Arshaday, 1991). In the former casem the emulsion is maintained 
at reduced or atmospheric pressure (where solvent vapor pressure is low) to enable the 
volatile solvent to evaporate. In the latter case, the emulsion is transferred to a large quantity 
of water into which the solvent associated with the oil droplets diffuses and evaporates. The 
solid microparticles are washed and collected by filtration, sieving or centrifugation. These 
are then dried under appropriate conditions or are lyophilized to give final product. The 
disadvantage of the single emulsion process is poor encapsulation efficiency of water-soluble 
active ingredient. The water-soluble ingredient will diffuse, or partition, from the dispersed 
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oil phase into the aqueous continuous phase and the hydrophilic ingredient is deposited on 
the microparticle surface (Wada, Hyon, Ike et al., 1988).  
The double emulsion process water-in-oil-in-water (w/o/w) is well suited to 
encapsulate water-soluble ingredients. An aqueous solution of the water-soluble ingredient is 
added to an organic phase containing PLGA with vigorous stirring to form the first microfine 
w/o emulsion. This emulsion is added gently with stirring into a large-volume of water 
containing an emulsifier to form w/o/w emulsion. The emulsion is then subjected to solvent 
removal by either evaporation or extraction process (Lewis, 1990). A number of hydrophilic 
drugs e.g. leuprolide acetate (Okada, Doken, Ogawa et al., 1994), a luteinizing hormone-
releasing hormone (LH-RH) agonist (Kamijo, Kamei, Saikawa et al., 1996) have been 
encapsulated into microparticles by this method. 
The phase separation process consists of decreasing the solubility of the 
encapsulating polymer by addition of a third component to the polymer solution in an organic 
solution. At a particular point, the process yields two liquid phases: the polymer containing 
coacervate phase and the supernatant phase depleted in polymer. The active ingredient, 
which is dispersed/dissolved in the polymer solution, is coated by the coacervate. Three steps 
are included: i) phase separation of the coating polymer solution, ii) adsorption of the 
coacervate around the drug particles, and iii) solidification of the microparticles. The 
polymer is first dissolved in an organic solution. Water-soluble drugs like peptides and 
proteins are dissolved in water and dispersed in the polymer solution (w/o emulsion). An 
organic nonsolvent is then added to the polymer–drug–solvent system, with stirring, which 
gradually extracts the solvent carrying the polymer. As a result the polymer is subjected to 
phase separation and it forms flexible “soft” coacervate droplets that entrap the drug. This 
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system is transferred to a large quantity of another organic nonsolvent to harden the 
microdroplets and form the final microparticles, which are collected by washing, sieving, 
filtration, or centrifugation, and are finally dried (Jain, 2000). In the phase separation method 
the phase equilibrium is not reached and hence the process involves a non-equilibrium 
system (Wu, 1995). Therefore, the formulation and process variables significantly affect the 
kinetics of the entire process and ultimately the characteristics of the final microparticles.  
Due to absence of any emulsion stabilizer in the coacervation process, agglomeration is a 
frequent problem. The coacervate droplets are extremely sticky and adhere to each other 
before the complete phase separation or the hardening stages of this method. Adjusting the 
stirring rate and temperature is known to rectify this problem (Wu, 1995).  
Biodegradable PLGA microparticles have been successfully prepared by double-
emulsion and phase-separation methods. The coacervation method tends to produce particles 
which are agglomerated, there is difficulty in production scale manufacturing, the method 
requires large quantities of organic solvent, and it is difficult to remove residual solvents 
from the final microparticle product (Takada, Uda, Toguchi et al., 1995). The double-
emulsion method on the other hand requires many steps, rigid control of the temperature and 
viscosity of the inner w/o emulsion, and difficulty in encapsulating higher concentrations of 
hydrophilic drugs (Jalil and Nixon, 1990; Takada, Uda, Toguchi et al., 1995). Contrary to 
these methods, the spray drying (SD) method is very rapid, convenient, easy to scale-up, 
involves mild conditions, and is less dependent on the solubility parameter of the drug and 
the polymer (Wagenaar and Muller, 1994). The spray-drying method can produce 
microparticles by dissolving the hydrophobic ingredient into organic solvent together with 
PLGA or from the w/o emulsion in which the hydrophilic ingredient in buffer solution 
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dispersed into PLGA organic solutions. Spray-drying can generate particles less than 5µm, 
which is the most promising alternative method to produce aerosol particles (Chan, 2006).  
PLGA microparticle manufacture by a spray-drying technique to produce respirable 
aerosols is the method of choice for the present studies. Compared with the solvent 
evaporation (SE) method of preparing microparticles, spray-drying (SD) has some 
advantages. Respirable particles can be separated in the manufacturing procedure by cyclone. 
Dispersion properties of particles from SD are better than those from SE since particles with 
irregular surface morphology and low bulk density, desirable physical properties, are usually 
obtained by SD; the manufacturing procedure is continuous and batch sizes are bigger; the 
loading efficiency is very good since losses into the continuous phase do not occur as in SE. 
However, the yield may be low, especially in small batch preparation. In SD, the feed rate, 
atomization pressure, inlet temperature, nitrogen flow rate, aspirator speed and polymer 
concentration are important factors controlling the product yield and particle sizes. Some 
other factors, such as nozzle size and water: organic solvent ratio in the emulsion systems, 
also play a role. Conditions can be optimized using a statistical method. Factorial 
experimental design may be used to determine important factors influencing particle 
properties.  
The ability of PLGA formulations to elicit an antigen specific immune response is an 
important property to evaluate. An in vitro assay was developed for screening antigenicity of 
different formulation. This T hybridoma cell recognition assay is specific for human immune 
response. THP-1 cells (human monocytes) are exposed to Ag85B or particles containing 
Ag85B. These cells then present the Ag85B epitopes on their surface to T hybridoma cells 
DB-1. The CD4 T hybridoma DB1 cells (kindly provided by Dr W. Henry Boom, Case 
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Western Reserve University) were derived from transgenic mice with human MHC genes for 
HLA-DR1. They are restricted to human HLA alleles and respond to human MHC 
molecules, which present Ag85B97-112 epitope (Canaday, Gehring, Leonard et al., 2003). 
After T cell recognition of Ag85B epitope 97-112, IL-2 will be secreted. IL-2 was monitored 
since it stimulates proliferation of T cells and plays a very important role in the consequential 
CMI. This assay provides the in vitro antigenicity screening which also has implications for 
use in humans. Different loadings of rAg85B, with or without the adjuvants MDP or TDB, of 
different concentrations in the PLGA formulations were screened by this assay. The 
advantages of microparticle delivery systems compared to solution formulations of antigen 
can be assessed by this in vitro assay. These studies provide important evidence of immune 
response required to justify in vivo animal challenge studies using optimized particle 
formulations to assess the protective effect of the vaccine.  
2.2. Materials and methods 
Recombinant Antigen 85B: rAg85B protein was produced from two E. coli strains. The first 
E. coli strain was JM109DE3, containing Ag85B gene with His tag (courtesy of Dr Douglas 
Kernodle, Vanderbilt University). 1L Luria-Bertani (LB) broth with 50µg/ml carbenicillin 
was inoculated with 20 ml of an overnight culture and grown at 37°C until the OD600 reading 
reached 0.4-0.5. The culture was induced by isopropyl-β-thiogalactopyranoside (IPTG) and 
grown at 22°C overnight.  The E. coli cells were pelleted and then probe-sonicated. The 
supernatant was passed through a nickel-affinity column (Ni SepharoseTM 6 Fast Flow, 
Amersham Biosciences, Piscataway, NJ).  The eluted fractions with His-tag proteins were 
further purified by Superdex 75 peptide column (Amersham Biosciences, Piscataway, NJ) 
with 20mM Tris, 1M sodium chloride, pH 7.5 as the eluting buffer. The rAg85B was 
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quantified at UV 280nm with extinction coefficient of UV280 of 1.0 for a 1.0mg/mL protein 
solution (Lakey, Voladri, Edwards et al., 2000). The rAg85B purified from JM109DE3 is 
referred to as rAg85B JM. 
The second E. coli strain was origami B strain carrying mutated thioredoxin reductase 
(trxB) and glutathione reductase (gor) genes and a chaperone GroEL /GroES vector pGro7. 
The plasmid vector pRSETB was introduced into origami B cells by a standard 
transformation protocol. Transformants were selected on agar plates with four antibiotics: 
carbenicillin, tetracycline, chloramphenicol and kanamycin. 1L LB broth and 50µg/mL 
carbenicillin, 12.5µg/mL tetracycline, 15 µg/mL kanamycin and 20µg/ml chloramphenicol 
were inoculated with 20mL of an overnight origami B strain and grown at 37°C to reach 
OD600 reading 0.4-0.5. The culture was induced by 1mg/mL L-arabinose and 0.2mM IPTG 
and shaken at 22°C for 20 hours. The remaining steps of the protein purification procedure 
were performed as described above. rAg85B purified from origami B is referred to as 
rAg85B Chap. 
Endotoxin in the protein preparations was removed with Detoxin-GelTM Endotoxin 
Removing Gel (Pierce, Rockford, IL). The endotoxin level was detected by QCL-
Chromogenic LAL (Cambrex Bio Science Walkersville, Inc., Walkersville, MD) and was < 
0.025ng/mg after purification. The proteins were dialyzed in 0.1M ammonium bicarbonate 
overnight and then lyophilized for 48h. 
SDS-PAGE: A precast 12% SDS-PAGE gel (Biorad, Hercules, CA) was used to determine 
the purity of the recombinant proteins. The gel was stained with Coomassie blue.  
Cells and media: THP-1 cells (American Type Culture Collection) were maintained in RPMI 
1640 (Invitrogen Corp., Grand Island, NY) supplemented with 10% fetal bovine serum (FBS) 
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(Hyclone, Logan, UT), 50 µM 2-mercaptoethanol, 1 mM sodium pyruvate, 10 mM HEPES 
buffer, nonessential amino acids, 1% of antibiotics/ antimycotics (Invitrogen Corp., Grand 
Island, NY) which contain 100U/ml of penicillin, 100µg/ml of streptomycin and 0.25 µg/mL 
of amphotericin B. The CD4 T- hybridoma DB1 cells (kindly provided by Dr W. Henry 
Boom, Case Western Reserve University) were derived from transgenic mice with human 
MHC genes for HLA-DR1. They are restricted to human HLA alleles and respond to human 
MHC molecules, which present Ag85B97-112 epitope (Canaday, Gehring, Leonard et al., 
2003). DB-1 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) 
(Invitrogen Corp., Grand Island, NY) supplemented as indicated above (complete DMEM). 
Infection medium was DMEM supplemented with 10% non-heat-inactivated FBS with 
antibiotics/antimycotics.  
T-hybridoma cell recognition assay: The anitigenicity of rAg85B was evaluated by a 
modified CD4 T cell hybridoma recognition assay (Gehring, Rojas, Canaday et al., 2003). 
THP-1 cells were incubated in 96-well flat-bottom plates (1.5 x 105 cells/well) with 10ng/ml 
of phorbol myristate acetate (PMA, Sigma, St Louis, MO) in infection medium for 24 h to 
promote adherence to plates. Cells were washed once with infection medium and incubated 
with 100U/ml of recombinant human IFN-γ (Endogen, Woburn, MA) for 24 h. The cells 
were washed twice with infection medium prior to Ag exposure and were exposed to 100µl 
of rAg85B at various concentrations or 100µL of microparticle suspension in infection 
medium at 250µg/ml. DB1 T-hybridoma cells (Gehring, Rojas, Canaday et al., 2003) (105 
cells/well, 100µL, specific for recognition of Ag85B 97-112) were added into wells at the same 
time as antigens. The cells were co-incubated at 37°C for 24h and supernatants were 
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harvested. ELISA was used to measure the amount of IL-2 produced by T-hybridoma cells. 
(Biosource, Camarillo, CA) (Fig 2.1). 
Microparticle manufacture: PLGA polymer (700mg)(MW 84.7kd, L:G 75:25, intrinsic 
viscosity 0.68 dL/g in chloroform, Durect Corp., Pelham, AL) was dissolved in 200ml 
methylene chloride. Either 1 or 2mg rAg85B were dissolved in 2.4ml of 20mM sodium 
phosphate buffer, pH 7.4 with or without the adjuvants muramyl dipeptide (MDP) or 
trehalose dibehenate (TDB, Sigma, St Louis, MO). The molecular structure and adjuvancy of 
these molecules are well documented (Powell, Foster, Becker et al., 1988; Ritzinger, 
Meredith, Takayama et al., 1981). The aqueous and organic phases were probe-sonicated for 
three 10s periods on an ice bath immediately prior to spray-drying. The microparticles were 
manufactured using a spray-dryer (Buchi Mini Spray-drier B-191, Buchi, Flawil, Switzerland) 
under an optimized condition.  
Encapsulation efficiency: The rAg85B amount was measured by DMSO-NaOH-SDS method. 
2mL DMSO were added to a vial containing 10-20mg of PLGA microparticles containing 
rAg85B and occasionally shaken for one hour. Then 10ml of 0.05N NaOH with 0.5% SDS 
were added and the mixture was gently mixed and allowed to stand for one hour. After 
centrifugation, the supernatant was subjected to Lowry’s method for protein quantification of 
rAg85B. A HPLC method was used for MDP quantification. The HPLC instrument 
employed was an Agilent 1100 series. HPLC conditions for MDP were: C18 reversed phase 
column (4.6 × 25mm), mobile phase 97% 25mM ammonium phosphate buffer, pH 7.0 and 
3% methanol at a flow rate 1ml/min and UV wavelength of 200nm.  
PLGA microparticle release profiles: Microparticles of 90mg PLGA-rAg85B (0.14% w/w)-
MDP (0.5% w/w) were put into 2ml of 67mM potassium phosphate buffer (pH 7.4) 
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containing 0.1% Tween 80 solution, and shaken in 37°C water bath. A volume of 1.5ml of 
suspension was centrifuged for 10min (Beckman GS-15R centrifuge, rotor F2402H at 
12000rpm, 4°C) and 1ml of supernatant was removed at intervals for measurement of 
rAg85B and MDP content. The rest of the sample and 1ml of fresh medium were added to 
the dissolution vial. Lowry’s method was used for protein analysis of rAg85B and HPLC 
method for MDP quantification.  
Phagocytosis of PLGA microparticles: PLGA-sodium fluorescein microparticles were 
prepared for phagocytosis assay. Following PMA treatment, the THP-1 cells were incubated, 
with 5 particles/cell, for 24 hours. Particles were visualized using a Zeiss LSM5 Pascal 
Confocal Laser Scanning Microscope at excitation and emission wavelengths 488 and 524nm, 
respectively. 
Determination of the role of surface-associated-rAg85B on PLGA microparticles: PLGA-
rAg85B JM (0.28% w/w)-MDP (0.5% w/w) microparticles were placed in 67mM potassium 
phosphate buffer, pH 7.4, and vortexed for 3 hours to remove the surface-associated antigen 
and then centrifuged. The supernatant solution was separated into two aliquots. One aliquot 
were mixed with PLGA control microparticles and the other aliquot were used directly in the 
assay. The residual PLGA-rAg85B-MDP microparticles, after the initial burst, were dried 
and reconstituted in the fresh medium into suspension at the microparticle concentration of 
250µg/ml. THP-1 cells were exposed to 100 µl of each sample, which were then subjected to 
the T cell hybridoma recognition assay. 
The surface-adsorbed-rAg85B PLGA microparticles were prepared. A certain amount 
of rAg85B JM in 20mM sodium phosphate buffer was placed into PLGA control 
microparticles. The mass ratio of rAg85B to microparticles was the same as that of spray-
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dried PLGA microparticles containing rAg85B (0.56% w/w). This formulation was used 
when the liquid completely evaporated. These dried microparticles were reconstituted in 
infection medium at 250µg/ml. 100µl of the suspension was used in T hybridoma recognition 
assay. 
Six-day antigen presentation assay: THP-1 cells were incubated in 96-well flat-bottom plates 
(1.5 x 105 cells/well) with 10ng/ml of PMA in infection medium for 24 h. Cells were washed 
once with infection medium and incubated with 100U/ml of recombinant human IFN-  for 24 
h. The cells were: rinsed twice with infection medium; pulsed with 200µl rAg85B Chap 
(25µg/ml) or 200µl 83µg/ml of microparticles encapsulating rAg85B Chap (0.14% w/w) and 
MDP (0.5% w/w) and further incubated for 6h; then cells were washed extensively with 
infection medium to remove the antigen solution and microparticles. 200µl DB-1 cells at 
density of 1×106 cells/ml were added at each time point (from day 1 to 6) to the wells. After 
24h co-incubation, the supernatant was harvested for IL-2 ELISA assay. 
Statistics: A one-way ANOVA was used to compare the multiple groups. The student’s t-test 
was used for analysis between any two individual groups. The statistical significance was set 
at p< 0.05. 
2.3 Results and discussions 
2.3.1 rAg85B expression in E. coli systems. 
To reduce the potential for protein misfolding and aggregation, IPTG induction and 
further fermentation were performed at 22°C. The preparation of rAg85B JM yielded 
16mg/L after purification and was the sole protein band visible in SDS-PAGE (Fig 2.2A). A 
second preparation of antigen, rAg85B Chap, was purified from the E. coli strain origami B. 
This origami B strain of E. coli carries mutated thioredoxin reductase (trxB) and glutathione 
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reducates (gor) genes and a chaperone GroEL /GroES vector which facilitate disulfide bond 
formation in the less reducing environment of the cytosol and could improve folding of 
Ag85B. The yield of rAg85B Chap was 4.5mg/L after purification. The mass of the purified 
rAg85B JM as determined by mass spectrometry (Nanospray-ESI-MS on the Applied 
Biosystems Q-star Pulsar mass spectrometer, Foster City, CA) was 34kD (Fig 2.2B).  
The antigenicity of soluble rAg85B was tested in the T-hybridoma cell recognition 
assay involving the human monocytic cell line THP-1 and DB-1 T-hybridoma cells which 
specifically recognize Ag85B97-112 epitope presented by MHC class II.  This assay system 
and DB-1 T hybridoma cells were developed by Gehring et al. (Gehring, Rojas, Canaday et 
al., 2003). Upon recognition of complex of MHC-II epitope, DB-1 cells produce IL-2, which 
can be measured by ELISA. Using this T-hybridoma cell recognition assay, presentation of 
the specific Ag85B peptide-MHC Class II complex by APC to T-hybridoma cells was 
measured. Both rAg85B preparations were taken up by THP-1 cells. Antigens were 
processed, and presented to DB-1 hybridoma cells as indicated by IL-2 production (Fig 2.2C). 
IL-2 production reached a plateau at a rAg85B concentration of 25-50µg/ml. rAg85B Chap 
induced higher IL-2 secretion from T-hybridoma cells DB-1 than the rAg85B JM, in the 
concentration range of 12.5-150µg/ml tested. The endotoxin level in the recombinant Ag85B 
was apparently lower than 0.025ng/mg after purification. 
Two soluble rAg85B protein preparations used in this study differed in antigenicity 
based on T-hybridoma cell recognition assay. The rAg85B Chap preparation, purified from 
an E. coli strain carrying the mutated thioredoxin reductase (trxB) and glutathione reductase 
(gor) genes and the chaperone GroEL /GroES vector elicited larger IL-2 production than 
rAg85B JM. Under physiological conditions, the E. coli cytoplasm is maintained in a reduced 
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state that does not favor the formation of stable disulfide bonds in proteins. The origami B 
mutations impair the reduction potential of both thioredoxins and glutathione (Bessette, 
Åslund, Beckwith et al., 1999). Furthermore, the chaperones provide a central compartment 
for a single protein chain to fold unimpaired by aggregation (Hartl and Hayer-Hartl, 2002). 
Ag85B has one disulfide bond and one free –SH group. The purified rAg85B Chap may be 
structurally different from the rAg85B JM preparation, explaining the difference in antigen 
processing. Further investigation is needed to define the difference between the different 
rAg85B proteins. 
2.3.2 Manufacture of PLGA microparticle 
2.3.2.1 Spray-drying condition optimization 
The Buchi B191 spray-dryer was used for microparticle manufacture. There are six 
parameters (nitrogen flow rate, aspiration pressure, atomization pressure, solution feed rate, 
inlet temperature and polymer concentration) affecting the outcome of the particle production. 
The preparation of particles in the size range 1-5 µm is most important since these particles 
can potentially deposit in the lungs. Yield is a secondary outcome that is not as important as 
particle size in the present study. The experiments were complicated by a feed tubing 
material incompatibility with the organic solvent methylene chloride. The tubing materials 
influenced the particle manufacture. Polytetrafluoroethylene (PTFE) was used in most of the 
feed tube part. However, the tubing portions under the pump and connections to the nozzles 
need to be resilient. Norprene was used in these connections but it was soluble to some extent 
in methylene chloride. In order to minimize the amount of oily material, extracted from 
tubing, and collected in the cyclone and jar, conditions were optimized by experimental 
design to nitrogen flow 600L/hr, atomization pressure 3.0 bar and aspiration rate 50%.  
-62- 
The other three parameters (polymer concentration, inlet temperature and feed rate) 
were optimized for PLGA microparticle manufacture. The particle size was the most 
important criteria for optimization. A factorial experimental design was used. Two-level, 
three factors, full fraction of experiment numbers were utilized (Table 2.1). Main effects of 
inlet temperature, feed rate and their interaction significantly affect the particle sizes. 
Polymer concentration at this range (0.35 to 0.5% w/w) did not play any role to change the 
particle size (Appendix 1A). The interaction between feed rate and inlet temperature is 
shown in Appendix 1B. It predicted that higher feed rate and lower inlet temperature in the 
tested range would produce the smallest positive particle size. The cuboidal plot indicated 
that the predicted smallest Dv50 3.62 µm likely be manufactured under condition of B- (lower 
inlet temperature) and C+ (higher feeding rate). The polymer concentration in the tested 
range did not affect the particle sizes (Appendix 1C). In order to obtain higher desirability in 
prediction, the optimized inlet temperature needed to be higher than 63°C at the feed rate of 
50% of the pump (Appendix 1D). 
From the results of factorial experimental design, the optimized condition for PLGA 
microparticles manufacture was: PLGA polymer concentration in methylene chloride 
(CH2Cl2) 3.5mg/ml, inlet temperature 65°C, atomization pressure 3.0 bar, aspirator rate 50%, 
feeding pump rate 50% (4.5ml/min), N2 flow control 600L/hr.  
Under this optimized condition, 24 batches of PLGA microparticle formulations with 
different source and loadings of rAg85B, different loadings of MDP, TDB, were generated 
(Table 2.2). The yield was in the range of 24-33%. The particle sizes and distributions are 
summarized in Chapter 3.  
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The spray-dried microparticles were observed as raisin like structures showing 
irregular surface under the scanning electron microscopy (SEM). (Fig 2.3A) The projected 
area equivalent diameter was in the range of 3-4µm. The particles morphology, shrunk and 
wrinkled, was due to the spray-drying conditions used. Rapid drying and evaporation leave a 
soft flexible shell that collapses at the end of spray-drying. The interior structure of the 
microparticles was hollow (Fig 2.3B). The polymers formed the shells of the microparticles. 
2.3.2.2 Release profile of rAg85B and MDP from PLGA microparticles 
PLGA microparticles exhibited a pulsatile release profile of rAg85B. This release 
profile corresponded with the microparticle structure. The PLGA-rAg85B (0.14% w/w)-
MDP (0.5% w/w) preparations provided a pulsatile release profile of rAg85B with high 
initial burst as demonstrated by in vitro dissolution  (Fig 2.4). In the first day 58% of the 
rAg85B was released from the microparticles. The cumulative quantity of rAg85B released 
reached a plateau of 66% on Day 3. Subsequently, a second period of release delivered an 
additional 14% (80% total release) by Day 20 and by Day 31, ~100% antigen was released. 
MDP was released from the microparticles in a large initial burst of 85% on day 1. The 
remaining 15% of MDP was continuously released over a period of 46 days. The initial burst 
most likely reflects release of surface associated protein and adjuvant.  
The release profile difference between rAg85B and MDP may be explained by their 
molecular size. rAg85B is a 34kD protein. The large molecular size of rAg85B (34kD) 
inhibits diffusion from the polymer shell, until erosion of the polymers. MDP is a small 
molecule with molecular weight of 492 Da. The small size of MDP made it easy to penetrate 
through the surface pores and dissoluted.  
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2.3.3 PLGA microparticle formulations can enhance the antigenicity of rAg85B. 
2.3.3.1 PLGA microparticle uptake by activated THP-1 cells.  
THP-1 cells are human monocytes from peripheral blood. They can be activated by 
some reagents, such as phorbol myristate acetate (PMA), and become macrophage-like cells. 
There are complement and Fc-mediated receptors expressed on THP-1 cell surfaces 
(Tsuchiya, Yamabe, Yamaguchi et al., 1980). HLA haplotypes of THP-1 were HLA-A2, -A9, 
-B5, -DRW1 and -DRW2 (Tsuchiya, Yamabe, Yamaguchi et al., 1980). The monocytic 
nature of the cell line demonstrates lysozyme production, the ability to phagocytose particles 
and restore T-lymphocyte response to Con A. During culture, THP-1 maintained these 
monocytic characteristics for over 14 months (Tsuchiya, Yamabe, Yamaguchi et al., 1980). 
Due to the macrophage-like and easy culturing properties, and as a human origin cell line 
required to interfere with humanized DB-1 cells, THP-1 cells are used as antigen presenting 
cells in the T cell recognition assay to help screening the PLGA microparticle formulations. 
In order to visually detect the phagocytosis of PLGA microparticles, sodium 
fluorescein (5% w/w) was encapsulated in PLGA under the same optimized spray-drying 
condition. Confocal microscopy was used to detect the location of PLGA-sodium fluorescein. 
Following PMA treatment, THP-1 cells were incubated with 5 particles/cell for 24 hours. 
The similar sized PLGA-fluorescein microparticles were taken up by THP-1 cells after 24 
hours incubation (Fig 2.5). This assay illustrated that these PLGA microparticles can be 
taken up by THP-1 cells. This phagocytosis can include these microparticles into the cells, 
and makes the antigens encapsulated in the particulate accessible to the APCs.  
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2.3.3.2 Presentation of PLGA microparticles containing rAg85 to DB-1 T hybridoma 
cells. 
In this project, muramyl dipeptide (MDP) and trehalose dibehenate (TDB) were used 
as adjuvants for encapsulation into the microparticles. MDP and trehalose dimycolate (TDM) 
are components of MTB cell wall. Trehalose dibehenate (TDB) is the synthetic analogue of 
TDM. The use of the cell wall components and their analogues as adjuvants to stimulate the 
immune response is well suited to vaccine optimization.  
PLGA microparticles containing adjuvants only, PLGA- MDP, PLGA- TDB and 
PLGA-TDB-MDP formulations at different loading of adjuvants (0.1, 0.5 and 1% w/w) were 
added to THP-1 cells and coincubated with DB-1 cells. Similar IL-2 production was elicited 
by each of the above PLGA formulations in the T-hybridoma cell recognition assay and all 
responses were of the same order of magnitude (50-90 pg/ml) (Fig 2.6). The addition of 
adjuvants alone to the PLGA microparticles did not produce large differences in IL-2 
secretion with respect to the PLGA control particles.  The PLGA particles themselves 
induced only a modest IL-2 response compared to the media only control, showing 80pg/ml 
versus 50pg/ml respectively.   
 PLGA particles encapsulating rAg85B (0.14% w/w) and MDP (0.5% w/w) (PLGA-
rAg85B-MDP) elicited significantly greater IL-2 secretion than soluble rAg85B or PLGA 
particle only controls.  Soluble rAg85B solution alone (36ng dose/well equivalent to 
microparticle dose) elicited a very weak IL-2 response of 79 pg/ml (± 2.1 SD).  In 
comparison, the IL-2 released after PLGA-rAg85B-MDP exposure was 2194pg/ml (± 211 
SD), which represented a 92-fold greater IL-2 response to PLGA-rAg85B-MDP 
microparticles than to the same amount of rAg85B in solution (after subtracting the medium 
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control). Notably, the effect of PLGA-rAg85B-MDP on IL-2 production was dependent on 
PLGA association or encapsulation. Mixing PLGA – MDP (0.5% w/w) microparticles with 
12.5 µg/ml soluble rAg85B (100µl mixture for assay), which represented a larger amount of 
rAg85B than present in the PLGA-rAg85B-MDP microparticles used above, was also 
compared in the T cell hybridoma recognition assay to the encapsulated Ag85B particles.  
IL-2 secretion was approximately 170 pg/ml (± 14 SD), significantly lower than that 
observed with the PLGA-rAg85B-MDP (Fig 2.8A). This demonstrated that mixing soluble 
rAg85B with PLGA-MDP elicited a significantly lower response (p=0.003). In conclusion, 
Fig 2.7A shows that encapsulation of rAg85B into PLGA-MDP microparticles significantly 
magnified the antigenicity of rAg85B.  
We also compared PLGA-MDP microparticle formulations encapsulating rAg85B JM 
and Chap in the hybridoma cell assay. IL-2 concentrations of 2194 pg/ml (± 211 SD) and 
2790 pg/ml (± 735 SD) were produced in response to PLGA-rAg85B JM-MDP and PLGA-
rAg85B Chap-MDP, respectively (Fig 2.7B). PLGA–microparticles containing rAg85B Chap 
gave a larger IL-2 response (360-fold after subtracting medium control) than the same 
amount of soluble rAg85B Chap that is consistent with observation of encapsulated rAg85B 
JM. There was no significant difference in IL-2 response between PLGA microparticle 
formulations encapsulating rAg85B JM or rAg85B Chap (p = 0.249), even though soluble 
rAg85B JM and Chap elicited statistically different IL-2 responses in the concentration range 
of 12.5-150 µg/ml (p <0.001). Therefore rAg85B JM was used for further study due to its 
high yield in E. coli expression. 
The loading of rAg85B was increased two-fold in PLGA-MDP (0.5% w/w) 
microparticles to 0.28% (w/w). The IL-2 response to rAg85B presented in these particles 
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increased in comparison to those loaded with 0.14% reported above (Fig 2.8A). PLGA-
rAg85B JM (0.28% w/w)-MDP microparticles resulted in secretion of 4532 pg/ml (± 216 SD) 
of IL-2, about a 1.24 fold increase in response to doubling rAg85B content. Testing an 
alternative adjuvant, PLGA-TDB (0.5%) microparticles containing rAg85B also elicited 
strong IL-2 secretion. PLGA- rAg85B (0.28% w/w)-MDP, PLGA-rAg85B (0.28% w/w)-
TDB and PLGA-rAg85B (0.28% w/w) induced IL-2 responses of 4532 (± 216 SD), 4211 (± 
146 SD) and 4282 (± 165 SD) pg/ml, respectively (Fig 2.8A). We also tested PLGA-
rAg85B-TDB (0.5%) microparticles with added MDP (0.5%), and these particles did not 
appear to increase the IL-2 responses in the T-hybridoma cell assay. However, the presence 
of rAg85B dramatically changed the response range of IL-2 secretion (Fig 2.8B). 
Interestingly, these results demonstrate that the presence of the adjuvants MDP or 
TDB at loading of 0.5% (w/w) in the microparticles in the concentration ranges tested did not 
influence the magnitude of response to rAg85B.   
PLGA microparticles exhibit a strong adjuvant effect as shown above. At 0.5% 
loading of MDP or TDB there was no significant improvement in rAg85B (0.14%) 
antigenicity. However, adjuvants at other concentration range or combination may have 
significant enhancement in immunity elicitation. Different loadings of MDP or TDB were 
included with rAg85B into PLGA microparticles. In the case of 0.1 and 1% loading of MDP, 
with rAg85B (0.14%), the existence of MDP could not enhance antigenicity of rAg85B, 
neither in the rAg85B loading of 0.28%. There were no significant difference between the 
PLGA-rAg85B and PLGA-MDP (0.1%)-rAg85B (0.28%)(Fig 2.9). For TDB, 0.1% loading 
in PLGA-rAg85B (0.28%) elicited significantly more IL-2 secretion in T cell recognition 
assay than that of PLGA-rAg85B (0.28%). While higher TDB content was not as good as 
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lower loading (0.1%). Therefore, TDB 0.1% enhanced antigenicity of rAg85B in PLGA 
formulations (Fig 2.10). 
The microparticle formulation of rAg85B has been shown to initiate higher levels of 
T cell recognition as indicated by IL-2 production than soluble rAg85B, which is important 
for Th1 CMI. There are two explanations for the PLGA-rAg85B formulation giving a greater 
response better than soluble rAg85B. The first possibility is that exogenous soluble proteins 
can be taken up by endocytosis or fluid-phase pinocytosis. However, the uptake of rAg85B 
from solution is not as efficient as that from microparticle formulations. Macrophages are 
particularly sensitive to particles ranging from 1-10µm. The phagocytosis of one 
microparticle with large quantities of rAg85B attached to the surface and within the polymer 
matrix, will result in higher levels of the protein in the phagosomal compartment than 
endocytosis of rAg85B soluble molecules. Secondly, it is also possible that particulate 
antigens are processed differently from soluble antigens. Rock et al. reported that distinct 
epitopes from Ovalbumin were generated with differing efficiencies, by macrophages and B 
cells, from particles compared to soluble antigens. This may be due to changes in the 
structure of the bound antigen, conformation or its accessibility to proteases (Vidard, 
Kovacsovics-Bankowski, Kraeft et al., 1996). The PLGA used in this study was a polymer of 
75:25 lactide to glycolide. The generally hydrophobic surface exhibits hydrophilic regions 
which favor hydrophobic as well as electrostatic interaction with antigen proteins. Further 
studies are required to elucidate the effect of particle-antigen interaction on the epitope 
presentation. 
Subunit vaccines have the advantage of reducing side effects of possible infection that 
whole organisms may generate from vaccination. However, they frequently have weak 
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antigenicity and immunogenicity and adjuvants are often needed for subunit antigen 
vaccination (Marciani, 2003). PLGA microparticles have the depot effect associated with 
encapsulation of the antigens; therefore, microparticles themselves are adjuvants 
(Raychaudhuri and Rock, 1998). Our data confirm this adjuvant effect compared to soluble 
antigen. Addition of other adjuvants may further improve the antigenicity. However, the 
incorporation of adjuvants may also limit their use in humans. Furthermore, the use of 
adjuvants may be complicated by cross interaction of other naturally occurring adjuvants. For 
example, lipopolysaccharides can sensitize an animal’s response to MDP (Takada and 
Galanos, 1987; Takada, Yokoyama and Yang, 2002). There was no statistically significant 
difference in IL-2 secretion between PLGA-rAg85B and PLGA-rAg85B-MDP at the 
concentrations (0.5% w/w). However, TDB 0.1% loading enhanced the rAg85B antigenicity 
in PLGA microparticles. Therefore, PLGA-rAg85B and PLGA-TDB (0.1%)-rAg85B are 
good formulations in terms of immunity elicitation. 
2.3.3.3 The influence of surface-associated-rAg85B on PLGA-microparticles. 
Surface-associated antigens and adjuvants were removed by washing and the residual 
microparticles were tested in the T-hybridoma cell recognition assay to determine whether 
the existence of surface-associated antigen was necessary for the antigen presentation activity 
of the formulation. The IL-2 response showed that neither initial-burst solution, initial-burst 
solution plus PLGA control microparticles, nor residual dried-microparticles after initial 
burst induced a similar level response as the PLGA-rAg85B-MDP microparticles (Fig 2.11A). 
Therefore, surface-association of rAg85B appeared to be important for the T-hybridoma cell 
response to PLGA-rAg85B-MDP. 
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The existence of surfactants in microparticles may reduce the nature and extent of 
phagocytosis by alveolar macrophages (Evora, Sorino, Rogers et al., 1998; Jones, 2002; 
Jones, Dickinson, Gumbleton et al., 2002). In our microparticle preparation, no surfactants or 
emulsifiers were used in the single emulsion before spray-drying. The large initial release of 
rAg85B indicated that the single emulsion was not sufficiently stable to hold the internal 
water droplets in water-in-oil emulsion. However, PLGA-subunit microparticle with this high 
initial burst of rAg85B was effective as vaccine formulations. The subunit proteins are most 
likely associated to the microparticle surfaces by means of physical chain entanglement via 
electrostatic and hydrophobic interaction (Sugiyama, Mitsuno and Shiraishi, 1996). Proteins / 
peptides may be embedded in the microparticle matrix but some portion of peptide chains 
extend from the particulate surface. The initial release may be explained by the extensive 
mixing, removing almost all of the rAg85B from the microparticle surface where diffusion 
from the microparticles would be the rate limiting phenomenon. A small quantity of protein 
would be left at the surface (Basinska, 2001) given the low concentrations (< 1µg/ml) and the 
high solubility of rAg85B. Following the initial release of rAg85B, the microparticles would 
behave as PLGA alone with respect to interaction with macrophages, until the remaining 
rAg85B was released from the microparticles by a mixture of diffusion and erosion 
mechanisms (Witt and Kissel, 2001). 
PLGA microparticles with surface-adsorbed rAg85B showed an adjuvant effect, as 
shown by IL-2 secretion of 721 ± 158 pg/ml, that was not as strong as that of spray-dried 
particles containing rAg85B, where IL-2 production of 3245 ± 77 pg/ml occurred (Fig 
2.11B). However, the surface-adsorbed-antigen PLGA formulations provided stronger 
antigenicity than the solution formulation, which stimulated IL-2 secretion at the level of 80 
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pg/ml. These data illustrated that the surface-associated antigen is important to enhance the 
antigenicity. However, its adjuvancy is much weaker than the spray-dried formulations 
containing rAg85B. The extent of the antigen detachment from the microparticles might be 
the reason for this difference. In spray-drying procedure, the antigens may be entangled and 
embedded in the microparticle shells which is a strong attachment to the particles. The 
physical adsorption force of antigens on particle surface may not be strong enough to hold 
the antigens to the particle surface during the reconstitution procedure. Large quantities of 
antigens may go into solution instantaneously.   
2.3.3.4 Epitope presentation by THP-1 cells exposed to PLGA microparticles 
encapsulating rAg85B.   
Prolonged epitope presentation by macrophages may be an advantageous property for 
a vaccine. The ability of PLGA microparticles containing rAg85B to present epitope over 
time was studied. Epitope presentation was compared over six days by THP-1 cells pulsed 
with soluble rAg85B Chap solution alone or the PLGA-rAg85B Chap (0.14% w/w) -MDP 
(0.5% w/w) (Fig 2.12). The absolute amount of IL-2 response differed for soluble antigen 
versus microparticles encapsulating antigen.  By assaying T cell recognition daily we were 
able to study the epitope presentation of a given formulation on the initial Day 1 (Set at 
100%) compared to subsequent Days 2 and 3, and the IL-2 response was unchanged.  
However, after Day three the level of IL-2 response fell. A more dramatic decrease in IL-2 
response was observed with soluble antigen than with the PLGA-rAg85B-MDP 
microparticles. On Day six, 16% of the IL-2 response that was elicited on Day one was 
observed for soluble rAg85B, while 54% of the response observed with the microparticle 
formulation of rAg85B remained. The THP-1 cells also showed different morphology after 
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exposure of rAg85B solution and microparticle formulations. Photomicrographs were taken 
on day 3 (Fig 2.13). rAg85B solution did not show significant difference in cell morphology 
from the control. Few cells exhibited pseudopodia (Fig 2.13B). While the THP-1 cells 
exposed to rAg85B microparticles (Fig 2.13C) seemed morphologically more activated and 
extended more pseudopodia compared to the control and rAg85B solutions. Thus, the 
microparticle formulation of rAg85B not only amplified the response, but also provided 
longer-lasting epitope presentation. This prolonged presentation favors T cell recognition and 
the subsequent cytokine secretion. 
In the first three days of the assay, the epitope presentation did not change compared 
to Day one. Antigen processing, forming complexes with MHC class II and sorting onto APC 
surface take some time, so there is concern over kinetic stability with respect to the complex 
of MHC class II: peptide epitopes. The kinetic stability of a MHC class II: peptide complex 
physiologically influences the recognition and expansion of specific T cells. Peptide epitopes 
must be loaded onto MHC class II in endocytic compartments and exported to the surface of 
APCs; this complex must be stable during the transit to the draining lymph node sustaining 
TCR signaling once contact between CD4+ T cells and the antigen-bearing APCs (Sant, 
Chaves, Jenks et al., 2005). If t 1/2 of the complex is less than 5 hours, T cell immunity will 
not be generated in vivo. Immunodominant peptide complexes with MHC class II could 
possess extremely long half-lives of more than 150 hours (Sant, Chaves, Jenks et al., 2005). 
Ag85B peptide 91-108 is a dominant CD4 T cell recognition-epitope and has been 
recognized by 85% of healthy donors (Valle, Megiovanni, Merlo et al., 2001). It is inferred 
that the epitope Ag85B 97-112: MHC II complex must be sufficiently stable, although kinetic 
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stability data is not available. On day six, the PLGA microparticle formulation of rAg85B 
still retained 54% of epitope presentation on APC surface, while soluble rAg85B had 16%.  
Another explanation for the extended production of IL-2 is that the replication of 
macrophages might prolong epitope presentation. The doubling time for THP-1 cells before 
differentiation is ~ 26 hours (ATCC, Information). However, macrophages which lose 
migration ability exhibit much slower replication, usually granulocyte-macrophage colony-
stimulating factor (GM-CSF) is needed to stimulate the growth (Nakata, Akagawa, 
Fukayama et al., 1991). The macrophage is one type of the cells can release GM-CSF 
(Bezdicek and Crystal, 1997) with the secretion level of 29-260 pg/ml / 5 ×105 cells / 24 
hours (Dakhama, Israël-Assayag and Cormier, 1996). It may be inferred that the estimated 
GM-CSF secretion would be 0.1-1 U/ml in the bioassay used in this study (108 Units/mg of 
GM-CSF (Komuro, Keicho, Iwamoto et al., 2001)). There was a 15-34% increase in 
macrophage numbers in the initial 7 days under the GM-CSF concentration of 0.2-2U/ml 
(Nakata, Akagawa, Fukayama et al., 1991). Therefore, the estimated increase in macrophage 
numbers is 7-17% at GM-CSF concentration of 0.1-1 U/ml. The newer cells may 
phagocytose the microparticles debris remaining and start to present the epitopes. Since the 
half life of epitope:MHC class II on THP-1 cell surface is the same to both of the formulation 
assay, if the macrophage replication is the major reason for the epitope presentation 
difference on day 6, then 7-17% of epitope presentation difference would be expected.  
About 38% epitope presentation difference was observed (Fig 2.13). The higher level of 
epitope presentation stimulated by microparticle formulation was most likely due to the 
encapsulated antigen in microparticles internalized into the THP-1 cells have depot effect and 
made the epitope presentation on cell surface longer. The release of antigens from 
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microparticles increases the density of epitopes in the phagosome (Torres, Ramachandra, 
Rojas et al., 2006) which favors the T cell recognition. However, the possibility that 
replicated macrophages phagocytose the microparticle debris after washing step could not be 
completely excluded.  
2.4 Summary 
PLGA microparticles encapsulating rAg85B were delivered to THP-1 cells for 
processing and presentation in the context of MHC class II to a CD4 T-hybridoma cell line 
DB-1. Microparticle formulations containing rAg85B were more effective in stimulating 
THP-1 cells to present antigen to the DB-1 T-hybridoma cells than rAg85B protein in 
solution. Submicrogram amounts of rAg85B in microparticles induced 92-360 fold larger IL-
2 production than the same amount of soluble rAg85B. This effect was enhanced when the 
quantity of rAg85B incorporated into the microparticles was doubled. 
rAg85B is one of the most promising vaccine candidates with both class I and II 
epitopes. The ability of rAg85B in the microparticle systems to elicit CD4 T-hybridoma cell 
activation has been demonstrated in an in vitro T cell recognition assay. In conclusion, two 
expression systems were used to produce rAg85B. These antigens were incorporated at 
different concentrations into PLGA microparticles by a spray drying process. Microparticles 
delivered rAg85B more efficiently to macrophages than soluble antigen delivery. In turn, 
rAg85B can be processed and presented well at the macrophage surface in the context of 
MHC class II. PLGA-rAg85B microparticles stimulate an antigen specific CD4 T cell 
hybridoma response that is two orders of magnitude greater than that observed for soluble 
rAg85B. The PLGA-rAg85B particle effect can’t be recapitulated by mixing of soluble or 
initial burst solution with control PLGA particles. This suggests that the strong adjuvant 
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effect of the particles requires surface absorption or encapsulation. These formulations 
provided extended epitope presentation on the APC surface for up to 6 days. This may mimic 
the boosting effects of independently administered vaccines but further studies are required 
to establish this proposition. Finally, the PLGA microparticles can be prepared in a particle 
size range suitable for pulmonary delivery as aerosols. 
Sufficient evidence was obtained from the in vitro assessment of microparticles 
containing rAg85B to justify their evaluation in protecting animals from infection with small 
aerosol inocula of MTB. 
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Fig 2.1 Principle of T hybridoma cell recognition assay. 
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Fig 2.2 The characterization of recombinant Ag85B. 
A) SDS-PAGE of two recombinant antigen 85B. Lane 1, rAg85B JM; Lane 2, rAg85B Chap; 
Lane 3, molecular weight marker.  
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B) Mass spectrometry of rAg85B JM. MW is 34412 Da 
 
x-axis is m/z, y-axis is relative abundance. 
 
 
 
 
B 
 
Calculations 
1564.7342 = (MW+n)/n                                      (1) 
1639.2236 = (MW+n+1)/ (n+1)                              (2) 
where n is the number of positive charges on one molecule,  
MW is the molecular weight of rAg85B  
 
MW = 34416 
n = 22 
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C) Antigenicity of two recombinant Ag85Bs in solution evaluated by T cell recognition 
assay. Blank square is rAg85B Chap, solid diamond is rAg85B JM. 
 
 
 
 
 
 
C 
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Fig 2.3 Morphology of PLGA microspheres. 
 
A) SEM of PLGA-MDP (0.5%)-rAg85B (0.14%) microspheres. The standard bar in the 
picture was 10µm. 
 
 
A 
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B) Interior morphology of PLGA microparticles. 
 
B 
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Fig 2.4 Release profile of rAg85B JM and MDP from PLGA- rAg85B JM-MDP. The 
dissolution was performed in 67mM sodium phosphate buffer, pH 7.4 at 37°C (shaken in 
waterbath). n=2 
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Fig 2.5 Confocal microscopy of phagocytosis of PLGA-sodium fluorescein particles by 
activated THP-1 cells. (1) Confocal image; (2) Normal image; (3) Overlap of the confocal 
and normal images. 
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Fig 2.6 T hybridoma cell responses to different loadings of PLGA-adjuvants microparticles, 
as measured by IL-2 ELISA. (n=3, bar is standard deviation.) 
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Fig 2.7 T hybridoma cell responses to different formulations, as measured by IL-2 ELISA. 
(n=3, bar is standard deviation in normal scale). All PLGA formulations contained MDP 
0.5% loading and Ag85B as of 0.14% loading.  
A) The adjuvant effect of PLGA microspheres; 
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B) The T hybridoma cell responses to Ag85B Chap and JM strains in different formulations. 
The p values were labeled in the figures. 
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Fig 2.8 T hybridoma cell responses elicited by different doses and formulations of rAg85B in 
PLGA microspheres, as measured by IL-2 ELISA. (n=3, bar is standard deviation). 
A) Different doses of Ag85B JM in PLGA microspheres at loading of 0.14 and 0.28% and 
with/without the adjuvant MDP or TDB; 
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B) Addition of MDP in the PLGA-TDB-Ag85B formulation did not improve the T 
hybridoma cell response. 
 
 
 
B 
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
PLGA-TDB (0.5%) PLGA-TDB(0.5%)-
Ag85B JM(0.28%)
PLGA-TDB(0.5%)-
MDP(0.5%)-Ag85B
JM(0.28%)
IL
-2
 p
ro
du
ct
io
n 
(p
g/
m
l)
p< 0.001 p =0.069
-89- 
 
Fig 2.9 MDP adjuvant effect on rAg85B-PLGA formulations. 
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Fig 2.10 TDB adjuvant effect on rAg85B-PLGA formulations. 
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Fig 2.11 The influence of surface-associated PLGA-rAg85B-MDP formulation on T 
hybridoma cell activation, measured by IL-2 ELISA. (n=3, bar is standard deviation). (*p< 
0.001) 
A) Spray-dried formulation with/without initial burst; 
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B) Particles with only surface-adsorbed Ag85B JM. 
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Fig 2.12 Kinetics of epitope presentation, as indicated by IL-2 release from T-Hybridoma 
cells exposed to macrophages pulsed with rAg85B Chap solution or PLGA-rAg85B (0.14% 
w/w)-MDP (0.5% w/w). (n=3, bar is standard deviation) 
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Fig 2.13 Morphology of THP-1 cells on day 3 (after 6 hour rAg85B exposure on day 0).  
(A) THP-1 control;  
(B) THP-1 after exposure of rAg85B Chap solution;  
(C) THP-1 after exposure of rAg85B-MDP-PLGA microparticles. 
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Table 2.1 Two-level, 3 factors experimental design for PLGA microparticle manufacture 
condition optimization. 
Std Run Block Polymer 
conc (% 
w/v) 
Inlet T 
(°C) 
Feed 
rate 
(%)* 
Yield 
(%) 
Dg50 
(µm) 
Dv50 
(µm) 
3 1 Block 1 0.35 80 30 23.22 3.0 77.68 
4 2 Block 1 0.50 80 30 16.99 2.1 79.37 
6 3 Block 1 0.50 65 50 38.32 4.2 10.70 
5 4 Block 1 0.35 65 50 29.00 2.6 11.6 
2 5 Block 1 0.50 65 30 18.06 2.8 29.24 
8 6 Block 1 0.50 80 50 12.61 2.8 28.72 
1 7 Block 1 0.35 65 30 49.22 2.7 13.30 
7 8 Block 1 0.35 80 50 20.68 2.4 16.17 
 
* 100% feed rate with the current tubing is 9ml/min; 50% of the pump is 4.5ml/min and 30% 
of the pump is 2.7ml/min.  
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Table 2.2 The PLGA microparticle formulations manufactured under the optimized 
conditions. 
 
 
 
                
Batch of PLGA 
microsphere 
MDP 
(w/w loading %) 
TDB 
(w/w loading %) 
rAg85B JM 
(w/w loading %) 
rAg85B Chap 
(w/w loading %) 
1  - - - - 
2 0.1  - - - 
3 0.5  - - - 
4 1.0  - - - 
5 - 0.1  - - 
6 - 0.5  - - 
7 - 1.0  - - 
8 - - 0.14 - 
9 0.1 - 0.14  - 
10 0.5 - 0.14 - 
11 1 - 0.14 - 
12 - 0.1 0.14 - 
13 - 1 0.14 - 
14 0.1 - 0.28 - 
15 0.5  - 0.28  - 
16 1 - 0.28 - 
17 - 0.1 0.28 - 
18 - 0.5  0.28  - 
19 - 1 0.28 - 
20 - - 0.28  - 
21 0.5  0.5  0.28  - 
22 0.5  - - 0.14  
23 - - 0.56 - 
24 - 0.1 0.56  
 
  
3 Physico-chemical property characterization of dry powder PLGA formulations as 
aerosols 
3.1 Introduction 
Respirable particles containing antigen were manufactured and they elicited an 
immune response in a complex cell culture model of marker immunity. However, their 
suitability for pulmonary delivery depends on their physico-chemical properties. In order to 
deliver PLGA-microparticles containing antigens to the lungs, aerodynamic particle size, 
distribution and general physico-chemical properties must be characterized to meet the 
criteria suitable for respirable aerosols. 
The target particle morphology, size and distribution for dry powders are important 
factors for aerosols. Scanning electric microscopy (SEM) is a technique capable of producing 
highly-resolution images of a sample (Martin and Bustamante, 1993). SEM images have a 
characteristic 3D appearance and are useful for judging the surface structure of particles. The 
equivalent diameter of a circular disc of the same projected area as the particle being studied, 
can be obtained through SEM 2D images (Martin and Bustamante, 1993). Laser diffraction is 
one of the most commonly used light scattering methods of particle sizing. Particles are 
passed through a laser (frequently Helium-Neon, λ= 682.3nm) creating a diffraction pattern 
on a detector array. An algorithm is used to calculate the particle size distribution from this 
diffraction pattern (Ranucci, 1992). Algorithms vary and are proprietary to specific 
instrument manufacturers. Diffraction patterns are correlated with the volume diameters of  
equivalent volume spheres to the particles being studied. The mass median aerodynamic 
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diameter (MMAD) and size distribution representing a population of particles, can be 
obtained by measurement of mass in different particle size ranges after aerosols are dispersed 
and deposited on different stages of an inertial sampler, e.g. the Andersen Cascade Impactor 
(ACI). Assuming a log-normal distribution, the median diameter is used to represent the 
fiftieth percentile of the distribution and geometric standard deviation (GSD) is used to 
represent the breadth of the particle size distribution. The aerodynamic diameter is that of an 
equivalent volume of sphere of unit density with the same terminal settling velocity as the 
particle being studied (Hickey, 2004a). The emitted dose from the device upon aerosolization 
can be measured using the USP sampling Apparatus B for delivered-dose uniformity. The 
typical operating conditions for sampling dry powder aerosols are under 60L/min flow rate. 
The emitted doses range from 75-125% of the nominal dose to meet the USP criteria 
(Pharmacopeia., 2005).  The fine particle fraction (FPF) is the portion of particles with sizes 
below than 5 µm. The fine particles are designated as those having the potential to be 
deposited in the lungs. 
Besides the particle size and distribution, a number of other physical properties of the 
particles may be characterized which influence the performance of dry powder aerosols. 
They includes: flow properties, specific surface area, powder moisture content; surface 
charge properties and crystallinity that relate to storage stability and aerosol dispersion 
efficiency and reproducibility.  
Bulk and tapped density are combined measures to assess powder flow properties. 
The bulk density is the mass of a powder divided by the volume prior to packing. Packing is 
usually achieved by tapping a volume of powder. The tapped density is the packed mass 
divided by the minimum volume of occupancy of the powder obtained after it has been 
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tapped until no further decrease in volume occurs (Carr, 1965). The Carr’s compressibility 
index (CCI) may be used to quantify the powder flow using the two density terms and is 
defined as: 
 
CCI = (Tapped density – bulk density) x 100% / Tapped density (Carr, 1965) 
 
As powder flow improves, the bulk density approaches the tapped density and any further 
tapping will not cause a decrease in volume. Therefore, as the CCI approaches 0, powder 
flow improves as particle interactions decrease (Carstensen, 1993). A free-flowing powder 
has a CCI less than ~20-21% (Carr, 1965). Hausner ratio is another term to indicate the flow 
properties of powders.  
 
Hausner ratio = tapped density / bulk density (Hausner, 1967) 
 
According to Wells (Wells, 1988), a Hausner ratio of <1.20 is indicative of good flowability 
of the material, whereas a value of >1.50 suggests poor flow. The Hausner ratio and the Carr 
index, which are measures of particle interaction, have been widely used to estimate the flow 
properties of powders. These terms were developed to assess compressibility for tabletting 
and have since been adopted for assessment of aerosol powders. 
When a powder is poured onto a surface from a fixed height, it forms a cone. The 
angle formed by the cone to the horizontal surface can be calculated and is known as the 
static angle of repose (Crowder, 2003). This angle is related to the potential flow properties 
of a powder. As the static angle of repose increases, powder flow decreases. A large static 
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angle of repose is indicative of large cohesive forces within the powder. Powders with static 
angle of repose < 40° are considered to be free-flowing powders; while angles >50°, indicate 
that the powders flow poorly or not at all (Carr, 1965). The static angle of repose has been 
defined as an indirect measure of particle size, shape, porosity, cohesion, fluidity, surface 
area and bulk (Carr, 1965).  
The surface area of a particle can be computed from measurement of the amount of a 
gas adsorbed onto a sample of powder to form a monolayer (Martin and Bustamante, 1993). 
This technique is accurate and relevant to further applications. When a mixture of nitrogen 
and helium are passed through a cell containing powder, adsorption and desorption of 
nitrogen gas can be measured with a thermal conductivity detector. Over a range of gas 
pressures, adsorption occurs non-linearly, in the simplest case asymptotically to monolayer 
surface coverage, but can be described by the Brunauer-Emmett-Teller (BET) equation. This 
equation allows the calculation of volume of gas adsorbed without specific assumptions 
regarding the nature of adsorption. The specific surface area is the surface area per unit mass 
of the sample (Martin and Bustamante, 1993).  
Moisture content measurement, by moisture balance determination, involves 
monitoring the weight change of a material after heating to vaporize associated water. It is 
useful in the measurement since any water present in the material may result in loss of 
activity of proteins or affect the physical stabilities (Chang, Reeder and Carpenter, 1996) 
(Dong, Korber, Lopez Esguerra et al., 2006) and influence dispersibility of dry powders. 
Water weight will be lost during heating allowing percent weight loss of the material to be 
calculated. Moisture content analysis and DSC allow determination of the stability of the 
materials in different temperature ranges (Brittain, 1995). 
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Differential scanning calorimetry (DSC) is a method of monitoring phase transitions 
that occur when the temperature of a material is increased. The glass transition temperature 
(Tg) of a material is the temperature at which a supercooled noncrystalline liquid existing 
below its crystallization temperature (amorphous state) converts to a glass. The amorphous 
state and its glass are metastable and kinetically-dependent transitions. Above Tg, the 
material becomes rubbery (amorphous), lacking long-range order and capable of elastic or 
plastic deformation without fracture. To assure long-term stability of the dry solid 
formulation, the solid-state material should exist in the glassy state rather than in the 
amorphous state in which it has a higher molecular mobility (Carpenter, Pikal, Chang et al., 
1997).  
Zeta potential is an important and useful indicator of electrical charge on particle 
surfaces. It can be used to predict and control the stability of suspensions (Martin and 
Bustamante, 1993). Zeta potential is the difference in electrical potential between a tightly 
bound layer of ions on particle surfaces and the bulk liquid in which the particles are 
suspended. It can be quantified by tracking the charged particles when they migrate in a 
voltage field, as performed by a zeta potential analyzer. The greater the zeta potential, the 
more likely the suspension is to be stable because the charged particles repel one another and, 
thus, overcome the natural tendency to aggregate. As a result, higher values of zeta potential 
imply more stable suspension, and lower values indicate colloid instability, which could lead 
to aggregation.  
Electrostatic charge can accumulate on aerosol powders. These surface charge 
properties can affect dry powder performance during mixing and device filling; passage of 
the drug through the device upon actuation and inhalation; solid-state adhesive and cohesive 
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interfacial interactions; and ultimately, lung deposition and therapeutic effect. Studies of 
medicinal aerosol electrostatics have been attempted previously. Electrostatic charge carried 
by a DPI aerosol cloud has been measured by Faraday cage (Adhiwidjaja, Matsusaka, Yabe 
et al., 2000), which precluded analysis of different size fractions and charge distribution. Use 
of the electrical low pressure impactor (ELPI™) for studying surface charge properties of dry 
powder particles allows a more comprehensive investigation of the phenomenon, with 
accurate determination of magnitude and polarity of charges on particles in the respirable 
size range over time. Furthermore, since each impactor stage is electrically isolated from the 
next, charges can be measured across individual stages, allowing size specificity of charging 
to be evaluated. ELPI was used to examine the surface electrostatic properties of PLGA 
microparticles that evolved as dry powders were generated as aerosols.  
The PLGA microparticles containing Ag85B intended for aerosol delivery were 
characterized in terms of physical stability and for their dispersion properties both for 
administration to animals and from inhaler to humans. 
3.2 Materials and methods  
Projected area equivalent diameter: Scanning Electron Microscopy (SEM, Model 6300, 
JEOL, Peabody, NY, USA) was used for projected area equivalent diameter measurement. 
The stubs were coated with gold-palladium alloy (150-250Å) using a sputter coater (Polaron 
5200, Structure Probe Incorporated Supplies, West Chester, PA, USA). The coater was 
operated at 2.2kV, 20mV, 0.1torr (argon) for 90 seconds. An accelerating voltage of 15kV 
was used. 
Volume median diameter (VMD): A small amount of each batch of PLGA formulations was 
suspended in 0.1% Tween 80 and sonicated for 1 min. The suspensions were placed in a 
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sample cell which had an integral stir bar and a volume of ~15ml for detection. The ideal 
suspension concentration was obtained at a laser obscuration of ~ 20-25%. Dv50 and span 
were measured using a laser diffraction particle sizer (Malvern 2600, Worcestershire, UK). 
Mass median aerodynamic diameter (MMAD): PLGA-disodium fluorecein (5% w/w) 
microparticle powders were dispersed from dry powder inhalation/dispersion devices 
(Inhalator® (Boehringer Ingelheim, Ingelheim, Germany) suitable for human use and DP-3 
insufflator (PennCentury, PA) for aerosol insufflation to animals). An eight-stage Andersen 
MKII nonviable cascade impactor (Graseby Andersen, Smyrna, GA) was used to collect the 
powders for characterization with respect to mass deposited on different stages. Dry powder 
aerosolization was performed under 60 and 28.3L/min flow rates (n=3). The plates of the 
impactors were coated with 1% silicon oil in hexane. glass-fiber filters (Pall Corp., Ann 
Arbor, MI) with a pore size of 0.22µm were used below the last stage of the impactor. 10mL 
of 20mM sodium phosphate buffer, pH 7.4 were placed in the preseparator. ~ 3mg of PLGA 
microparticle powders were filled in a gelatin capsule (#3) and inserted into Inhalator®.  
Following piercing of the capsule, sampling was continued for 10s. For the insufflator, ~3mg 
of powders were filled into the powder chamber. A 10mL syringe was used to push air 
through the chamber and puff the powder out. 10mL chloroform and 10mL 20mM sodium 
phosphate buffer, pH 7.4 were used to wash the plates, preseparator and USP induction port. 
After strong vortexing (Vortex-Genie 2, G-560, Scientific Industries, Inc., Bohemia, NY) and 
30min exposure to dissolution medium, the supernatant was decanted and assayed by UV 
spectrophotometry at 490nm. The supernatant in the filter stage was filtered through 0.2µm 
pore size PVDF filter (Whatman Inc., Clifton, NJ) to remove the debris of glass filters. 
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Bulk and Tapped density: Approximately 1g PLGA microparticle powders were placed in a 
graduated cylinder. The mass/volume before tapping was calculated as bulk density. The 
tapped density was obtained following about 100 taps which allowed the powder volume to 
plateau. 
Static angle of repose: PLGA microparticle powders were poured through a glass funnel onto 
a flat collection surface until the angle of repose did not change with addition of powder. The 
angle to the horizontal surface was measured. At least 1g of PLGA microparticle powders 
was needed for this purpose. 
Specific surface area: Single point surface area analysis was performed on PLGA 
microparticle powders using Quantasorb Jr (Quantachrome Instruments, Boynton Beach, FL). 
Accurately weighed PLGA microparticle powders were degassed at 25°C for 22hr, 40°C for 
3hr with nitrogen or no heating. The samples were subjected to repeated adsorption and 
desorption of the adsorbate, 30% nitrogen in helium gas.  
Moisture content:  Each sample was loaded onto an aluminum tray to achieve a coating with 
a thin layer of powder. The initial weight of the powder was recorded. The powder was 
heated to 105°C and held for 30min. The final weight of the powder was measured accurately 
using a moisture balance (Mettler LJ16 Moisture Analyzer, Mettler-Toledo, Columbus, OH). 
The difference between final and initial powder weight was calculated and attributed to the 
water content in the sample, recorded as a percent of the total weight. 
Thermal analysis: Differential scanning calorimetry (Perkin Elmer DSC 6, Wellesley, MA) 
was performed on powder samples. Known quantities of the powders were sealed in an 
aluminum pan and differences in heat flow were measured against an empty reference pan. 
Analysis was performed at a ramp rate of 10°C/min, unless otherwise mentioned. 
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Zeta potential: Zeta potential was measured for 0.2-0.3mg/mL PLGA microparticles  
suspended in 5mM sodium phosphate buffer, pH 7.4 (Zeta meter 3.0 Zeta meter, Inc, 
Staunton, VA and Zeta Plus, Brookhaven Instrument, Holtsville, NY). 
Kinetic surface charge properties: Upon aerosolization, real-time particle size measurements 
and surface electrostatics of dry powder aerosols dispersed from gelatin capsules were 
examined using an electrical low-pressure impactor (ELPI™, Dekati Ltd, Tampere, Finland). 
The DPI was connected to the mouthpiece and standard USP induction port, which was 
connected to the ACI pre-separator (loaded with 15 mL of 20mM sodium phosphate buffer, 
pH 7.4). A custom-manufactured aluminum connection to the pre-separator split the 
60 L/min stream in two; 40 cm Tygon™ tubing (R3603) was used to connect the two outlets 
with ELPI™ and ACI, each connected to a vacuum pump operating at 30 L/min. 
Microparticle powders ~ 3mg were aerosolized at 60 L/min using Inhalator® (Boehringer 
Ingelheim, Ingelheim, Germany) under ambient conditions of 23 -25°C and 34-35% relative 
humidity). The apparatus is shown in Fig 3.1.  
3.3 Results and discussions 
3.3.1 PLGA microparticles particle size and distribution 
In the 24 batches of PLGA microparticle formulations, most of the Dv50 were in the 
range of 3.6-6.0µm (Table 3.1). There was a tendency for formulations containing TDB to 
exhibit larger particle sizes, in some cases above 7µm (7.7µm, batch 14). However, the 
equivalent projected area diameter Dp50 was lower, in this example 3.6 µm. There was some 
aggregation of PLGA microparticles containing TDB in 0.1% Tween 80. PLGA 
microparticle formulations with TDB were more aggregated than other formulations, 
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probably because of the poor solubility of TDB in methylene chloride leading to bridges 
between the particles. Most of the particle distributions, expressed as Spans, were less than 2.  
The mass median aerodynamic diameter (MMAD) is known to influence lung 
deposition.  PLGA-sodium fluorecein (5% w/w) particles were sampled by Andersen non-
viable Cascade Impactor and chemical analyses were performed to generate stage mass data 
suitable for interpretation utilizing log probability mathematical fits. After the gelatin capsule 
was pierced, the microparticle formulation was dispersed from Inhalator®  at flow rate of 
60L/min. The powders deposited predominantly on stage 3 (cutoff 2.3µm), ~ 27% of the 
emitted dose. Approximately 17% and 8% of the emitted dose deposited on mouth-throat 
piece and preseparator, respectively. They were aggregates or particles larger than 8.6µm 
(Figure 3.2A). The MMAD was 2.5µm, which was much smaller than the projected area 
diameter 3.2µm and Dv50 of 4.6 µm, respectively (Fig 3.2B). 
The DP-3 dry powder insufflator is an easy-to-use, hand-operated pulmonary drug 
delivery device designed to produce an aerosol cloud of fine particles from the end of a 
small-diameter delivery tube (web). About 3mg of microparticle powders were loaded into 
the chamber of DP-3 insufflator. At a flow rate of 60L/min, the powders were dispersed in air 
from a syringe. Twenty-seven percent of the microparticles deposited on stage 3, the largest 
quantity among the stages. The preseparator and mouth-throat piece collected 17 and 7%, 
respectively. The size distribution was bimodal with MMAD 2.8 µm (Fig 3.3). The 
dispersion studies from DP-3 insufflator were also performed at 28.3L/min to assess whether 
a flow rate dependence of shear would influence particle size.  The microparticles deposited 
predominantly (25%) on stage 4 (cutoff size 2.1 µm) (Fig 3.4). In addition, 22% was 
collected on stage 3 (cutoff size 3.3µm). This bimodal distribution gave a MMAD of 3.0µm. 
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The MMAD, FPF and emitted dose in PLGA aerosol the dispersions under these two flow 
rates were similar. However, a difference was observed in the proportion collected in 
preseparator. A greater proportion was collected in the preseparator at 60 than 28.3L/min (17 
vs 10% of emitted dose). This demonstrated that, under relatively higher flow rate (60L/min), 
the powders might have more inertia and impact easily in the preseparator.  
Since the particles in the size range of micrometers are very sensitive to the humidity, 
the dispersion properties of the PLGA microparticle formulations were investigated after 28 
days storage under 85% RH environment (saturated KCl solution). The deposition pattern 
was similar to the dry powder from the desiccators with MMAD of 3.2µm (Fig 3.5). 
However, a difference in emitted dose between the dry and moisture-treated powders was 
observed at flow rate of 28.3 L/min (Table 3.2).  
The fine particle fractions (FPF, size < 4.7 µm) of dry powder and moisture-treated 
powders were similar, 71 (± 7.8) vs 78 (± 6.4)%. This indicated that the powder emitted from 
the insufflator behaved similarly at both humidities. The emitted dose of dry powder was 92 
(± 2.1)%. The humidified powder gave variable emitted dose from 16 to 92%. This 
variability was also observed when some powders were retained in the insufflator, which was 
rarely the case in the dry powders without moisture-treatment. The exposure to high humidity 
appeared to increase the moisture content of the microparticles.  
The DP-3 insufflator is suitable for the pulmonary delivery of PLGA aerosols to the 
animals. Even at slow flow rate, the deposition pattern and MMAD of this formulation were 
satisfactory.  
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3.3.2 Flow properties of PLGA microparticle powders 
Large angles of repose correlate with poor the powder flow. The results, of 39.1 ± 
1.9° were close to 40° (a transition angle of powder flow property, free flow powder < 40°). 
The Carr’s compressibility index (CCI) was 25.0 ± 1.0%, close to free flow powder of 20-21°. 
The Hausner ratio was 1.32 ± 0.23. Therefore, the PLGA microparticle powders have 
intermediate flow properties (between the extremes of easily or poorly flowing, Table 3.3). 
The irregular surfaces of microparticles made the air drag force possibly bigger (Chan, 2006) 
and reduced the contact area or points between particles, which can help to improve the 
aerosol dispersion (Telko and Hickey, 2005). The low powder density also influenced the 
powder performance. From the dispersion point of view, even without carriers the 
microparticles alone would be predicted to aerosolize well from devices.  
From the aerosol dispersion performance data under two humidity conditions, 
moisture treatment induced poor dispersion properties of PLGA powders which were 
observed as aggregated clumps. The interparticulate forces between small particles must be 
strong enough to withstand the external powder handling. The forces can be van der Waals, 
electrostatic, capillary and mechanical interlocking or solid bridging (Hickey, 2004a). 
Electrostatic interaction will be reduced under high humidity condition. However the 
presence of moisture leads to large capillary forces. Once the moisture content exceeds a 
certain limit, capillary forces will have a significant influence, as the presence of moisture in 
the interparticulate spaces would lead to the microparticle aggregation. Also the wetting of 
the particles may deform the morphology of the particles and increase the contact area 
between particles (Zeng, Martin and Marriott, 2000). Solid bridging may be induced by 
partial melting of the powders; solid diffusion; wetting agents may dry and harden; and 
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recrystallization of dissolved materials (Zeng, Martin and Marriott, 2000). Since the powders 
were all stored in a freezer, melting was excluded. Solid diffusion and recrystallization are 
the most likely explanation for solid bridging. In the presence of moisture, some components 
in microparticle powders may dissolve, diffuse to the surface or may form into new crystals 
during the treatment procedure. Solid bridges would be formed upon the material 
precipitation and crystallization, and further induce particle aggregations. Therefore, 
capillary forces and solid bridging may be two important factors in reduced flowability of the 
powders after moisture treatments. 
3.3.3 Specific surface area and moisture content 
Particle size is a primary determinant of surface area. As the number of irregularities 
increases, and the particle size decreases, the surface area increases (Lowell, 1979). The 
specific surface area was measured under 3 degassing conditions: room temperature degassed, 
no degassing and degassed at 40°C for 3 hr.  The specific surface area values of PLGA 
microparticles were: 15.7, 14.7 and 6.7m2/g. The degassing temperature, of 40°C, was close 
to the PLGA glass transition temperature. Freshly prepared microparticles were raisin like, 
collapsed hollow spheres. The heating procedure, which was held at 40°C, would increase 
the polymer mobility and potentially change the morphology of the microparticles.  
The larger surface area (Table 3.4) of microparticles may correlate with high surface 
energy that would be a factor affecting their stability, especially in the presence of adsorbed 
moisture. The moisture content in the PLGA powders at different time points under ambient 
conditions was analyzed. At time 0, there was 0.7% moisture content. At 4hr and 48 hr, the 
moisture content increased to 2.18 and 2.96%, respectively (Table 3.5). The moisture content 
plateaued after 4hr. This low moisture adsorption was consistent with the high 
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hydrophobicity of this PLGA polymer (75:25 L:G). However, the microparticle formulations 
with moisture contents above 2% were observed as clumps. The components in the PLGA 
microparticles were 0.8% of sodium phosphate (at pH 7.4 there are monobasic and dibasic 
sodium phosphate) and 0.14-0.56% of rAg85B. Monobasic and dibasic sodium phosphates 
are slightly and very hygroscopic, respectively. 1 mole of sodium phosphate dibasic can 
adsorb 2-7 moles of water depends on humidity and temperature (Windholz, Budavari, 
blumetti et al., 1983). Therefore, the PLGA microparticles with the sodium phosphate buffer 
components did not appear to resist the elevated humidity and became aggregated, which 
subsequently influenced dispersion. Whether Ag85B has strong hygroscopicity is not known, 
but as a protein it is likely to exhibit heterogeneous hydrophobic and hydrophilic regions. 
The moisture occupied on the PLGA surface and interparticulate spaces likely induced the 
capillary force and solid bridging between particles (see section 3.3.2). Consequently the 
powder dispersion was interfered. 
3.3.4 Thermal behavior of PLGA microparticles 
The DSC technique provides qualitative and quantitative information about the 
physicochemical status of formulations which was reported to be involved in the endothermic 
or exothermic process (Dubernet, 1995). DSC is useful for monitoring different samples of 
the same material to assess structural similarities or differences or the effects of additives on 
the thermal properties of a material. Using the DSC to evaluate the thermal properties of 
polymeric materials and microparticles allows the nature of the drug inside the polymer 
matrix to be assessed, which may emerge in solid solution, metastable molecular dispersion 
or crystallization (Dubernet, 1995) 
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In the PLGA microparticle formulations, the natural states of adjuvants MDP/ TDB, 
Ag85B and their interaction with PLGA polymers might be detected by analysis of the DSC 
thermagrams. The spray-dried PLGA (84.7kD, L:G=75:25) microparticles were scanned at 
10°C/min from 10°C to 300°C. The PLGA degraded at about 271°C. Therefore, the scanning 
range was set below 250°C. There was a glass transition with onset of 51.4°C in the initial 
scan of the PLGA control microparticles and there was no crystal transition peak in the tested 
temperature range. After cooling to 10°C, the 2nd and 3rd scans were performed. The Tg 
onsets for 2nd and 3rd scans were 46.1 and 46.4°C (Fig 3.6, Table 3.6). Thus, a maximum of 
two scans were conducted in each sample. Comparing the Tg of the PLGA microparticles in 
different scans, the initial scan gave much higher Tg onset. This may be explained by the 
rapid solidification of the polymer during the spray-drying process. The PLGA 
microparticles in all the scans were in the amorphous state.  
The existence of Ag85B decreased the Tg onset of PLGA control microparticles after 
encapsulation Ag85B. The reduction of Tg onset, with respect to PLGA control, in the initial 
scans was 1.3 and 3.2°C for 0.28 and 0.56% w/w loading of Ag85B in PLGA microparticles, 
respectively. The Tg onset in the 2nd repeated scan was reduced 0.5 and 0.4°C for these two 
Ag85B loadings, respectively (Fig 3.7, Table 3.7). The changes in the Tg onset temperatures 
demonstrated that there was interaction between Ag85B and PLGA microparticles. There 
was no melting peak for Ag85B at 180°C. This may indicate that, Ag85B is in the 
amorphous state and the Ag85B might disperse in the PLGA as the solid solute. The very 
low loading of Ag85B made it difficult to detect further in the solid-state. 
However, MDP or TDB alone in the PLGA microparticles significantly depressed the 
Tg.  1% w/w of loading, MDP and TDB reduced the Tg temperature by 4.08 and 4.21°C in 
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the initial scans, and 1.14, 4.00°C in the 2nd scan, respectively. TDB depressed the Tg to a 
greater extent than MDP. But this depression in Tg was minimized when co-encapsulated 
with Ag85B (Fig 3.8, Table 3.7). The typical transition peaks of TDB were absent in all the 
scans of polymeric particles containing TDB. This also indicated that most likely TDB 
dispersed in the polymer matrix. In order to investigate whether TDB is truly dispersed in 
polymers stably or in the metastable state, possibly due to the relative weak interaction 
between polymer and the adjuvants, an annealing step was employed at 40°C for overnight. 
The thermagram was the same as that of without annealing. This indicated that TDB was 
truly dispersed in the polymer microparticle matrix. 
The Tg of PLGA microparticles changed significantly upon the addition of the small 
molecules of adjuvants. The addition of small molecules into the polymer matrix increased 
the size of free volume cavities of the polymer. Increments in free volume induced by mixing 
plasticizers with amorphous polymers, represents one of the mechanisms that can explain the 
depression of polymer Tg (Sperling, 2001). MDP and TDB both have hydrophilic groups 
which interact with the polar chain groups, disrupt polymer chain–chain hydrogen bonding, 
removing further barriers to bond rotation and chain mobility. TDB has long fatty acid chains 
which would interact with high hydrophobic PLGA (75:25 L:G) to interfere with the polymer 
chain interactions. The small molecules and the polymer might develop strong interactions 
between each other, leading to plasticization of the polymer. The consequences in DSC are a 
lower Tg, and the absence of the fusion event of the small molecules (Dubernet, 1995).  
Ag85B, MDP and TDB all behave as plasticizers to PLGA microparticles. The 
addition of Ag85B into PLGA-Adjuvants actually reduced the Tg depression of PLGA. This 
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might be due to that, the interactions between Ag85B and adjuvants minimize the 
interactions between adjuvants and PLGA polar chains.  
Knowing Tg of polymer formulations has significant application in pharmaceutical 
field. It is known that the diffusion coefficients of small molecules through the polymer 
matrix increase several orders of magnitude when in the glass transition region (Karlsson, 
Stubbs, Karlsson et al., 2001; Sperling, 2001). Stability of the pharmaceutical formulations 
will be achieved by storing the products at a temperature of at least 40°C lower than Tg. 
3.3.5 Surface charge properties 
 The PLGA formulations containing different adjuvants and varied amounts of 
Ag85B showed negative zeta potential, implying negative charges on the microparticle 
surfaces (Table 3.8). This may be attributed to the presence of ionized carboxyl groups on the 
microparticles surface (Stolnik, Garnett, Davies et al., 1995). The zeta potential values were 
in the range of –38mV to –51mV. The colloid particles or suspensions with more positive or 
negative zeta potentials (instead of close to zero) are more stable in the suspension system by 
reducing the particle aggregations (Martin and Bustamante, 1993). Polymer microparticles 
with the large absolute charge values (either positive or negative) on their surfaces would be 
easily phagocytosed by macrophages (Tabata and Ikada, 1988). Therefore, macrophage-like, 
THP-1 cells would phagocytose PLGA microparticles easily. 
ELPI was used for evaluation of the surface charge properties after PLGA 
microparticles were aerosolized from the Inhalator. With the “charger off” condition, the 
powders deposited on different stages were bipolar (i.e. both positive and negatively charged) 
after PLGA control dry powder was aerosolized from Inhalator. Particles from 0.1 to 1.6µm 
in size had the most negative charges of –4000-5000fA. The particles from 1.6-10µm bore 
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positive charges with the maximum positive current of +13000fA.  This made the overall 
charge of the deposited powder positive. The ELPI charge property was different from the 
zeta potential measurement, which had negative values. Zeta potential measures the particles 
suspended in the buffer solution while the ELPI evaluates the true dry-state powder property 
which included all factors involved in the induction of charge in the DPI-PLGA 
microparticle system. It has been noted that a particular triboelectrification effect occurs 
between PLGA microparticles and DPI capsule material, inhaler materials (Peart, Orban, 
McGlynn et al., 2002). This contact can induce bipolarity of charge on the PLGA control 
microparticles. When the charger was on, all the particles were given positive charges and 
stage 9 (cutoff size 1.6µm) and 10 (cutoff size 2.5µm) collected most of the powder (+42000 
fA) (Figure 3.9). 
PLGA-Ag85B microparticles showed different surface properties upon aerosolization 
when charger was off. The powders were almost unipolar except the particle sizing from 4.0-
10.0µm with slight positive charge (+2000-3000fA). The particles on stage 9 deposited as 
negative charged particles with the value of –17000fA. The magnitude of negative charges 
made the overall surface charge negative after aerosolization. The only difference between 
PLGA control and PLGA-Ag85B formulations was the presence of Ag85B. The existence of 
Ag85B resisted the bipolar contact charge induction. There are positively and negatively 
charged amino acid residues in Ag85B protein. Ag85B may behave like an electron buffer 
when electrons move by the triboelectrification between particles and dry powder inhaler 
materials. It was estimated that ~53% of the microparticle surface area was covered by 
rAg85B (assuming that the particle size is 5µm, polymer density is 0.68g/ml, Ag85B loading 
is 0.56% and Ag85B exists as the nanosize particle (4.5nm diameter) on the microparticle 
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surface). The presence of Ag85B has the potential to change the surface properties of the 
microparticles.  
When the powder is bipolar, the collision between particles occurs more rapidly than 
uncharged particles. When the particles are unipolar, the collision rate is smaller than 
observed for uncharged particles. Thus, highly unipolar particles are less aggregated than 
particles that are not (Philip, Mehta, Mazumder et al., 1997).  This implies that PLGA –
Ag85B microparticles may be dispersed easily and that the potential for lung deposition may 
be improved. When the charger was on, all the particles were coated with positive particles 
and the largest quantity of positively charged particles were deposited on stage 9. 
3.4 Summary 
The PLGA microparticle formulations exhibited aerodynamic sizes (MMAD0 from 
2.5 to 3.0µm, which was suitable for pulmonary delivery to humans (Inhalator) and animals 
(insufflator). The thermal behavior of PLGA formulations containing Ag85B, and/or 
adjuvants, indicated an interaction between PLGA polymer and MDP, TDB and Ag85B as 
seen in the depression of the PLGA glass transition temperature. The Tg also indicated the 
storage temperatures for these PLGA formulations should be less than 10°C to reduce the 
possible mobility of the components in PLGA. The surface charge properties of PLGA 
control and PLGA-Ag85B were different after aerosolization from Inhalator. PLGA-Ag85B 
retained the unipolar property and this may be good for aerosol dispersion and lung 
deposition. Overall, the PLGA microparticle formulations were suitable for delivery as 
aerosols. For the purposes of the present work this observation supports the decision to 
continue into animal studies of protection from tuberculosis. However, in the event that 
protection is afforded to the animals, the Inhalator data demonstrates that the particles are 
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suitable for delivery to humans, which would be required in the clinical safety, tolerability 
and protection studies that are beyond the scope of the present work. 
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Fig 3.1 Experimental apparatus for ELPI measurement of kinetic surface charge properties of 
PLGA microparticles upon aerosolization. (Courtesy of M. Telko) 
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Fig 3.2 Deposition of PLGA-sodium fluorescein microspheres after dispersion from 
Inhalator at 60L/min for 10s. Powders were stored in desiccators at room temperature. 
A) Deposition pattern (n=3, mean ± SD) 
 
A 
 
 
0
5
10
15
20
25
30
35
-1 0 1 2 3 4 5 6
Fil
ter
mo
uth
 th
roa
t
pre
se
pe
rat
or
Plate #
%
 o
f e
m
itt
ed
 d
os
e 
-119- 
B) MMAD of this powder under the same conditions. (n=3, mean ± SD) 
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Fig 3.3 Deposition of PLGA microspheres after dispersion from Insufflator DP-3 sampled at 
60L/min airflow rate for 10s. Powder stored in desiccators at room temperature. 
A) Deposition pattern. (n=3, mean ± SD) 
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B) Aerodynamic size and distribution (n=3, mean ± SD) 
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Fig 3.4 Deposition of PLGA microspheres after dispersion from Insufflator DP-3 at 
28.3L/min for 10s. Powder stored in desiccators at room temperature. 
 A) Powder deposition on different stages (n=3, mean ± SD) 
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B) Aerodynamic size and distribution (n=3, mean ± SD) 
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Fig 3.5 Deposition of PLGA microspheres after dispersion from Insufflator DP-3 at 
28.3L/min for 10s. Powders were stored over saturated KCl solution for 28days at room 
temperature.  
A) Powder deposition on different stages (n=3, mean ± SD) 
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B) Aerodynamic size and distribution (n=3, mean ± SD) 
 
 
B 
Particle size (um)
0.1 1 10
%
 o
f c
um
ul
at
iv
e 
m
as
s
1
10
30
50
70
MMAD 3.2 um
-126- 
 
Fig 3.6 DSC thermagrams of spray-dried microparticle at repeated heat scanning at 10°C 
/min and speed of 20 and 30°C/min. 
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Fig 3.7 DSC thermagrams of spray-dried microparticle PLGA-Ag85B of different loadings 
(0.28 and 0.56% w/w) at scan rate of 10°C/min. 
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Fig 3.8 DSC thermagrams of PLGA microparticle containing adjuvants with/without Ag85B.  
Scan rate was 10°C/min. 
A) MDP as the adjuvant;  
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B) TDB as the adjuvant 
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Fig 3.9 The surface charge properties of PLGA microparticle formulations detected by ELPI 
upon aerosolization.  
A) Charger off;  
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B) Charger on 
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Fig 3.10 The surface charge properties of PLGA-Ag85B microparticle formulations detected 
by ELPI upon aerosolization.  
A) Charger off;  
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B) Charger on 
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Table 3.1 Median volume particle size and distribution of PLGA microparticle formulations. 
 
Batch of 
PLGA 
microparticle 
MDP 
(w/w loading 
%) 
TDB 
(w/w 
loading %) 
rAg85B JM 
(w/w 
loading %) 
rAg85B 
Chap 
(w/w loading 
%) 
Dv50 (µm) Span 
1  - - - - 4.61±1.00 
Dp50: 3.17 
1.16±0.16 
      1.32(GSD) 
2 0.1  - - - 5.93±0.07 1.42±0.04 
3 0.5  - - - 7.18 2.09 
4 1.0  - - - 5.59 1.40 
5 - 0.1  - - 5.84±0.13 2.14±0.30 
6 - 0.5  - - 6.36±1.19 1.98±0.54 
7 - 1.0  - - 8.98 2.35 
8 - - 0.14 - 4.30±0.13 1.38±0.34 
9 0.1 - 0.14  - 5.03±0.07 2.54±0.19 
10 0.5 - 0.14 - 5.78±0.04 
Dp50: 3.74 
0.29±0.04 
1.33(GSD) 
11 1 - 0.14 - 3.61±0.05 0.87±0.04 
12 - 0.1 0.14 - 3.73±0.24 1.47±0.55 
13 - 1 0.14 - 3.90±0.19 1.05±0.24 
14 0.1 - 0.28 - 3.97±0.48 1.14±0.51 
15 0.5  - 0.28  - 6.66±0.02 
Dp50: 4.40 
1.88±0.05 
      1.30(GSD) 
16 1 - 0.28 - 4.28±0.36 1.19±0.36 
17 - 0.1 0.28 - 3.55±0.01 0.78±0.01 
18 - 0.5  0.28  - 7.40±0.05 
Dp50:4.30 
      1.68±0.06 
      1.28(GSD) 
19 - 1 0.28 - 3.93±0.51 1.24±0.54 
20 - - 0.28  - 3.76±0.14 
Dp 4.25 
      1.88±1.05 
      1.25(GSD) 
21 0.5  0.5  0.28  - 7.71±0.05 
Dp50:3.60 
2.07±0.01 
1.26(GSD) 
22 0.5  - - 0.14  5.99±0.09 
Dp50:3.49 
0.27±0.03 
1.32(GSD) 
23 - - 0.56 - 5.14±0.11 1.34±0.14 
24 - 0.1 0.56  4.23±0.13 1.18±0.24 
Dv50: median volume diameter 
Dp50: median projected area diameter 
GSD: geometric standard deviation 
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Table 3.2 Mass median aerodynamic size (MMAD), fine particle fraction (FPF) and emitted 
dose of microparticle formulations under different conditions. 
 
 
a: aerodynamic size < 4µm 
b: aerodynamic size < 4.7µm  
 
 
 
 Inhalator DP-3 DP-3 DP-3 
Operating condition 60 lpm 60 lpm 28.3 lpm 28.3 lpm 
Powder condition desiccated desiccated desiccated 85% RH 
MMAD (µm) 2.5 ± 0.4 2.8 ± 0.3 3.0 ± 0.1 3.2 ± 0.2 
FPF of emitted dose (%) 68.8 ± 5.2 a 68.9 ± 8.4 a 71.1 ± 7.8 b 78.5 ± 6.4 b 
Emitted dose (%) 90.1 ± 2.7 92.9 ± 8.1 92.2 ± 2.1 57.8 ± 32.9 
FPF of total dose (%) 61.2 ± 3.7 a 64.0 ± 8.2 a 65.5 ± 4.0 b 45.4 ± 14.5 b 
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Table 3.3 Flow properties of PLGA microparticle formulations (n=3, mean ± SD) 
Bulk density (g/ml) 0.083 ± 0.02 
Tapped density (g/ml) 0.11 ± 0.09 
Static angle of repose (°) 39.10 ± 1.90 
Carr’s compressibility index (%)  25.00 ± 1.00 
Hausner ratio 1.32 ± 0.23 
-137- 
Table 3.4 Specific surface areas of PLGA microparticles under different degassing 
conditions. 
 Degassing condition Specific surface area (m2/g) 
1 No degassing, r.t 14.71 ± 0.46 
2 r.t       22hr 15.76 ± 0.12 
3 40°C 3hr 6.65 ± 0.14 
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Table 3.5 Moisture content of PLGA microparticles at room temperature and ambient 
humidity (34-35% RH) 
Time (hr) Moisture content (%) 
0 0.70 
4 2.18 
48 2.96 
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 Table 3.6 Glass transition onset temperature and heat capacity of spray-dried PLGA 
microparticles. 
 
 
Scanning rate (°C/min) No of run Tg onset (°C) ∆Cp (J/g*°C) 
1 51.38 0.272 
2 46.05 0.482 10  3 46.48 0.472 
20 2 47.42 0.413 
30 2 48.18 0.476 
 
 
-140- 
 
 
Table 3.7 Glass transition onset temperatures of different PLGA formulations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample  
initial run Tg onset 
(°C) 
2nd run Tg onset 
(°C) 
PLGA 51.38 46.05 
PLGA-Ag 0.28% 50.06 45.52 
PLGA-Ag 0.56% 48.17 45.67 
PLGA-MDP 1% 47.30 44.91 
PLGA-MDP 1%-Ag 0.28% 49.77 44.46 
PLGA-TDB 1% 47.17 42.05 
PLGA-TDB 1%-Ag85B 0.28% 49.98 46.10 
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Table 3.8 Zeta potentials of different PLGA formulations. 
 
 
 
 
 
 
 
 
 
 Zeta potential Zeta meter 3.0 
  counts Mean (mV) SD 
PLGA control 20 -50.9 6.5 
PLGA-MDP(0.5%)-Ag85B(0.28%) 20 -45.0 8.6 
PLGA-TDB(0.5%)-Ag85B (0.28%) 21 -56.6 4.6 
PLGA-MDP(0.5%)-TDB(0.5%)-Ag85B(0.28%) 25 -49.5 7.3 
9a PLGA-MDP(0.5%)-Ag JM(0.14%) 21 -41.6 6.2 
10a PLGA-MDP(0.5%)-Ag Chap(0.14%) 20 -42.0 9.1 
PLGA-MDP-(0.5%) 20 -49.9 7.4 
PLGA-TDB(0.5%) 21 -46.6 6.0 
PLGA-MDP(0.5%)-TDB(0.5%) 22 -45.7 8.6 
 ZetaPlus 
 Zeta potential (mV) SE 
PLGA control -49.7 0.9 
PLGA-Ag85B (0.14%)  -45.3 1.1 
PLGA-Ag85B (0.28%) -38.4 2.3 
Ag85B -37.6 1.2 
  
4 Study of Ag85B in microparticle systems delivered into the lungs for protection 
against tuberculosis in guinea pig model. 
4.1 Introduction 
The effectiveness of a vaccine is demonstrated by protection from microorganisms 
that induce diseases. Ultimately, the protective effect must be afforded to a human population. 
However, in the first instance, animal models of disease have proven helpful in assessing 
protection from virulent challenge. There is a substantial history of vaccine development for 
prevention of tuberculosis, in which protection has been evaluated in guinea pigs. 
In 1995, Horwitz et al. demonstrated that intradermal immunization 3-4 times with 
100µg Ag85B /time or a combination of Ag85B with four other culture filtrate proteins 
protected guinea pigs from weight loss (a weight gain of 15% was observed), death, lung 
destruction and bacterial burden in the lungs (reduced 0.8 log cfu (colony forming unit)) and 
spleens (reduced 0.8 log cfu) compared with control animals (Horwitz, 1995). Quantities of 
300-400µg of the subunit antigen Ag85B, and the same amount of four other antigens 
protected animals from infection to some extent. Delivery of a small amount of a vaccine 
composed of PLGA and Ag85B might be suitable for homologous immunization (using the 
same antigen for prime and boost vaccination) due to the efficiency of particle uptake by 
macrophages. 
Currently, BCG is the standard against which new vaccines are compared. rBCG30, a 
recombinant BCG expressing Ag85B (Horwitz, Harth, Dillon et al., 2000), and a BCG 
overexpressing ESAT-6 (Pym, Brodin, Majlessi et al., 2003) have been reported to afford 
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superior protection compared to BCG. Multiple BCG vaccination is not a good strategy as 
indicated by decreased survival in guinea pigs infected with MTB (Basaraba, Izzo, Brandt et 
al., 2006), the reduced protection level in neonatal calves after revaccination with BCG 
(Buddle, Wedlock, Palane et al., 2003) and little, or no, efficacy in clinical trials (Kubit, 
Czajka, Olakowski et al., 1983; Leung, Tam, Chan et al., 2001; Tala-Heikkila, Tuominen 
and Tala, 1998). 
For a subunit antigen against tuberculosis, another largely neglected approach to 
improve the immune resistance of the human population to tuberculosis is to enhance the 
immunity against MTB of persons previously vaccinated with BCG by heterologous boosting 
with subunit antigens.  
Only a few animal models have proven relevant to the pathogenesis of tuberculosis in 
humans (McMurray, 1994; Orme and McMurray, 1997). The guinea pig is sensitive to MTB 
infection, manifesting a pulmonary infection at low bacterial doses, while the alternative 
model, the mouse, is resistant to such exposure. The guinea pig reflects the natural history of 
the progressive infection of MTB and lung pathology seen in humans with active tuberculosis. 
Pulmonary infection induces “classical” granulomas replete with necrosis and cell 
breakdown, which has many similarities to human tuberculosis. The progress of the early 
infection is of importance because there is a silent tuberculosis bacillemia between initial 
implantation of the organism within the alveolus and the subsequent development of specific 
cell-mediated immunity. This results in seeding of other parts of the lungs and other organs 
(Smith, McMurray and Wiegeshaus, 1970). In humans, infection is nearly always contained 
and most organisms are killed once the cell-mediated response is mature. However, viable 
organisms persist in sites that were inoculated during the early bacillemic phase. The factors 
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responsible for the continued containment of MTB are poorly understood, but clearly include 
maintenance of an intact cell-mediated response. As a result, the guinea pig model is 
currently considered the “gold standard” for tuberculosis candidate vaccine testing (Orme, 
2005b). This model will be employed in the present studies for vaccination followed by a 
virulent low dose MTB (H37Rv) aerosol challenge. It is important to note that guinea pigs 
exhibit an excellent antigen specific DTH response in skin, which allows evaluation of 
systemic immunity following vaccination. Successful aerosol vaccination of guinea pigs with 
BCG has been demonstrated (Lagranderie, Frehel and de Chastellier, 1991). However, this 
observation was not pursued to a formulation strategy and the use of subunit proteins has not 
been evaluated. 
After the APCs phagocytose the pathogens or vaccines, the epitopes presented with 
MHC class I/II are recognized by naïve T cells. Naïve CD4 T cells can differentiate upon 
activation into either Th1 or Th2 cells, which differ in the type of cytokines they produce. 
The role of effector T helper cells is to control whole immune responses by secreting a 
multitude of cytokines and by expressing surface molecules. Th1 cells are associated with 
IFN-γ, IL-12 and TNF-α whereas Th2 cells typically produce IL-4, IL-5, IL-10 and IL-13. 
CD4 T cells polarization depends on the cytokine environment to which the cells are exposed 
(Langenkamp, Messi, Lanzavecchia et al., 2000). Naïve CD8 T cells are predestined to 
become cytotoxic. Proliferating CD8 T cells acquire effector function and migrate to the 
peripheral site of inflamed tissue to eliminate infected cells and release cytokines capable to 
slow down pathogen replication. Cytotoxic T-lymphocytes (CTL) responses against certain 
pathogens seem to require the presence of CD4 T cells during priming of naïve CD8 T cells. 
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Hence, a potent CTL vaccine should contain both CD4 and CD8 epitopes (Ridge, Di Rosa 
and Matzinger, 1998).  
Homologous and heterologous vaccination regimens will be used in this protection 
study. Single dose and multiple doses of PLGA-Ag85B and PLGA-TDB (0.1%) - Ag85B 
were used as the immunization formulations. In multiple dose studies, one group of animals 
were primed with BCG and then boosted by PLGA-Ag85B aerosol formulations. Guinea 
pigs challenged with low dose inocula of bacteria were used for anti-MTB immunization 
study. 
4.2 Materials and methods 
Animals: Dunkin-Hartley guinea pigs ~350g were obtained from established breeders 
(Charles River Breeding Laboratories, Portage, MI). The animals were housed in the 
university core facility and provided food, water and husbandry. 
Aerosol Vaccination: The vaccination regimen is shown in Fig 4.1. Five groups were 
employed in the single dose regimen. Six guinea pigs were assigned to each group. PLGA 
placebo as microparticle control, BCG as positive control and untreated animals as negative 
controls were included in this regimen. BCG (1× 103 cfu, Tice strain, Organon USA Inc, 
Roseland, NJ) was subcutaneously administered to guinea pigs.  PLGA-Ag85B (0.56% w/w), 
PLGA-TDB (0.1% w/w)-Ag85B (0.56% w/w) were the vaccination formulations containing 
subunit antigen. Animals were anesthetized with a mixture of ketamine (50mg/kg), xylazine 
(5mg/kg) prior to insufflation. ~10mg of PLGA microparticle formulations were insufflated 
(Model DP-3, Penncentury, PA) into the airways of guinea pigs. These two treatment groups 
were intradermally boosted 6 weeks later with Ag85B 100µg, TDB 200µg in 0.2% Pluronic 
L62 and 0.1% Tween 80 in 100µl PBS due to the absence of skin response to purified protein 
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derivative (PPD) and rAg85B. Half of the negative controls were administered with the same 
soluble antigen formulation mentioned above as the boosting control. In the multiple dose 
regimen, the animals were primed with PLGA-Ag85B (0.56% w/w, 10mg insufflation), 
PLGA-TDB (0.1% w/w)-Ag85B (0.56% w/w, 10mg insufflation) and BCG (s.c. 1×103 cfu). 
The animals were boosted 4 weeks later with ~10mg of PLGA-Ag85B (0.56% w/w)(for 
PLGA-Ag85B and BCG groups) and PLGA-TDB (0.1% w/w)-Ag85B (0.56% w/w)(for 
PLGA-TDB-Ag85B group) and 10 weeks after initial vaccination by insufflation of 
approximately ~3mg of PLGA-Ag85B (2.24% w/w)(for PLGA-Ag85B and BCG groups) 
and PLGA-TDB (0.1% w/w)-Ag85B (2.24% w/w)(for PLGA-TDB-Ag85B group). Animal 
weights were recorded twice a week. Six weeks after the last boost, the vaccinated animals 
were transferred to BL-3 lab.  
Cutaneous delayed type hypersensitivity (DTH): The skin test was performed one day before 
virulent strain challenge. Purified protein derivative (PPD) (100TU, Mycos Research, 
Loveland, CO) from MTB H37Rv and Ag85B (50µg in 100µl PBS) were injected 
intradermally (i.d.) on the two flanks of the animals. The injection sites were measured 24 
hours after i.d. injection for mean diameter of induration or erythema. 
Aerosol Exposure to MTB virulent strain H37Rv: A whole body exposure chamber was 
employed for quantitative experimental infection of animals by inhalation. A Collison 
nebulizer-Venturi unit (Waltham, MA) was employed to atomize the suspension of MTB, 
strain H37Rv (ATCC, Manassas, VA), at a concentration of 5 × 104 cfu in phosphate buffered 
saline (PBS), and mixed it with secondary air before it was drawn into the exposure chamber 
(University of Wisconsin, Mechanical Engineering Workshop, Madison, WI) by a vacuum 
pump. The droplet cloud was delivered to the exposure chamber, thereby exposing the 
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confined guinea pigs (Grover, Kim, Wiegeshaus et al., 1967; Wiegeshaus, McMurray and 
Grover, 1970). Five minutes after nebulization, the primary air supply was stopped and 
airflow through the chamber continued for 10 minutes.  A series of HEPA filters placed in 
the exhaust airline between the exposure chamber and vacuum pump removed 
microorganism before air discharge. Nebulization of this amount of MTB, H37Rv, has been 
shown to result in the inhalation and retention of 3-5 cfu in the periphery of the lungs (Smith, 
1991).  
After exposure to the virulent bacilli, guinea pigs developed primary pulmonary 
lesions that resemble typical human tubercles (McMurray, 1994). There is an exponential 
increase in viable mycobacteria recovered from lungs of guinea pigs between days 3 and 21 
post-infection. Between days 14 and 18, the first organisms appear in the trachebronchial 
lymph nodes draining the lung fields.  At approximately 18 to 21 days, mycobacteria are 
detected in the spleen (McMurray, 1994).  
Necropsy and Bacteriology: The necropsy and bacteriology studies were performed 4 weeks 
after virulent MTB challenge. Animals were anesthetized with pentobarbital (175mg/kg) and 
exsanguinated prior to necropsy. The peritoneal and chest cavities were exposed and the right 
lung lobe was inspected for grossly visible primary lesions prior to resection and 
homogenization. Lobes taken for histological evaluation were kept in 10% formalin until 
used. Guinea pig spleens were removed aseptically and weighed. The organ weights were 
recorded. Tissue samples were homogenized using Teflon-glass homogenizers, the 
homogenate was diluted with sterile saline and aliquots were inoculated onto duplicate 
Middlebrook 7H10 plates of oleic acid albumin agar. Plates were sealed with oxygen 
permeable tape and incubated at 37°C. Colonies were counted after 21 days. 
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4.3 Results and discussions 
4.3.1 Weight of animals after virulent strain challenge 
Sudden weight loss is one of the syndromes of active tuberculosis. Guinea pig models 
also demonstrate this symptom of infection (Baldwin, 1998). The weights of animals were 
measured twice a week until necropsy studies. The weight changes after virulent MTB 
challenge were recorded for single and multiple doses groups. In single dose groups, the 
mean values of total weight gain for groups of PLGA-Ag85B, PLGA-TDB-Ag85B 
formulations, BCG and untreated controls were 7.6, 2, 116.2 and 95.3g, respectively. BCG 
positive control groups showed consistent positive weight gain until 21 days post challenge 
and started to lose weight on day 26 before necropsy. Untreated controls and PLGA placebo 
groups gained weight slightly less than BCG and the weight loss began 18 days after 
challenge. The weight gains of PLGA-Ag85B and PLGA-TDB-Ag85B were much less than 
the untreated controls at almost each time point (Fig 4.2A). PLGA-TDB-Ag85B groups lost 
weight from day 14, much earlier than any other groups in single dose regimen. It should be 
noted that these groups were boosted i.d. with Ag85B (see methods section). This additional 
step was taken when there was no apparent immune response to the prime vaccine with this 
antigen as indicated by the absence of response to PPD and rAg85B. The weight change 
observed for the solution Ag85B boosted group requires further investigation. 
In the multiple-dose groups, there was a trend that all the animals gained weight until 
day 22 post-challenge. Untreated controls and PLGA-TDB-Ag85B treated groups began 
losing weight on day 26. While BCG prime: PLGA-Ag85B boosts and multiple doses of 
PLGA-Ag85B consistently gained weight to the conclusion of the study. The total weight 
gains for multiple doses of PLGA-Ag85B, PLGA-TDB-Ag85B, BCG prime:PLGA-Ag85B 
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boosts and untreated controls were 266 ± 6, 66 ± 19, 264 ± 15 and 122 ± 4g, respectively 
(Fig 4.2B). Treatments of homologous multiple doses of PLGA-Ag85B and BCG prime: 
PLGA-Ag85B aerosol boosts resulted in almost the same weight gain and the weight gains in 
these two groups were significantly higher than those of the untreated control group. 
4.3.2. DTH response in treated animals 
Six weeks after single dose vaccination, BCG groups had DTH induration responses 
to purified protein derivative (PPD) but no apparent responses to Ag85B except some 
erythema in the tested area. The animals vaccinated with PLGA formulations containing 
Ag85B showed erythema at the injection site in response to Ag85B but no response to PPD. 
Therefore, 100µg Ag85B, 200µg TDB in 0.2% Pluronic L62 and 0.1% Tween 80 in 100µl 
PBS was intradermally applied to boost the PLGA-Ag85B and PLGA-TDB-Ag85B groups. 
Six weeks following the boost, the control animals boosted with Ag85B solution showed 
responses to Ag85B. Both treatments of aerosol PLGA-Ag85B: i.d. solution Ag85B and 
aerosol PLGA-TDB-Ag85B: i.d. solution Ag85B showed strong DTH responses to Ag85B 
but only slight or no reactions to PPD. The diameters of induration for Ag85B responses 
were 13.8 mm ± 2.9 (SD), 14.2 mm ± 4.1 (SD) and 11.0 mm ± 1.4 (SD) for groups of PLGA-
Ag85B: solution Ag85B, PLGA-TDB-Ag85B: solution Ag85B and untreated control with 
Ag85B solution, respectively. There was no significant difference among these three groups 
in terms of induration diameters.  BCG groups responded strongly to the PPD test, but 
Ag85B skin test only induced redness in this group. 
In the multiple-dose groups, BCG prime: PLGA-Ag85B boost groups had responses 
to PPD but negligible DTH responses to Ag85B. PLGA-Ag85B and PLGA-TDB-Ag85B did 
not respond to PPD, only slight redness to Ag85B skin test. 
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Currently, PPD is the only reagent for diagnosis of infection with tuberculosis. Upon 
inoculation into the skin of sensitized individuals, a delayed-type hypersensitivity (DTH) 
response is evoked (Koch, 1897). This reagent allows the detection of individuals sensitized 
by mycobacteria (Hart, 1967). It is also used to assess the degree of immunity conferred by 
the only tuberculosis vaccine BCG (WHO, 1963). However DTH reaction does not correlate 
well with vaccine-derived protection from infection (Fine, Stern, Ponnighaus et al., 1994). 
The specific antigen can also be used in the skin test to detect the systemic cell-mediated 
immunity. In this study, PPD and Ag85B were used for detection of DTH responses prior to 
challenge. After i.d solution Ag85B boosting of the single dose groups, there were significant 
DTH responses to Ag85B rather than redness before id solution antigen boost. However, in 
these groups consistent protection was not observed in the lungs and spleens. However, there 
was slight protection effect in spleen for PLGA-TDB-Ag85B formulations. PPD did not 
elicit a DTH response in the groups of PLGA formulations containing Ag85B. In the 
multiple dose groups, BCG prime:PLGA-Ag85B boost responded to PPD to some extent. All 
the animals in this regimen did not respond to Ag85B. These results concurred with the lack 
of DTH induced by MTB culture filtrate protein (CFP) in guinea pigs despite protective 
effects in the lungs (Baldwin, 1998).  
The skin test results may help guide the development of a TB vaccine. The existence 
of strong adjuvant may help antigens to induce strong DTH reaction (Baldwin, 1998) but it 
cannot be inferred that this will result in protection. The solution Ag85B formulation 
consisted of 100µg Ag85B, 200µg TDB and 0.2% Pluronic L62. This formulation, 
containing a large quantity of TDB, is a very strong adjuvant. However, it’s relatively large 
induration readings did not correlate with a protective effect in guinea pigs (see section of 
-151- 
4.3.3). Pais et al. reported that the specificity of T cells involved in the classical tuberculin 
reaction to PPD were different from those involved in protective immunity (Pais, Silva, 
Smedegaard et al., 1998). Whether this is applicable to the skin response to Ag85B is 
unknown. However, the immunological specificity required to respond to a single antigen 
would suggest that this might be the case. 
4.3.3. Mycobacterial burden in organs 
The lungs and spleens were resected for determination of number of colony forming 
units of MTB, at necropsy. In single dose regimens, there was no difference between 
untreated control and control boosted with Ag85B solution. The formulations of PLGA 
placebo, PLGA-Ag85B and PLGA-TDB-Ag85B did not significantly reduce the MTB 
burden in the lungs compared with the untreated controls (Fig 4.3A). PLGA-TDB-Ag85B 
showed a drop (0.78 log cfu/g) in bacterial burden compared with the untreated control (p< 
0.05) in spleen (Fig 4.3B). PLGA-TDB-Ag85B most likely reduced systemic MTB 
disseminated from the lungs at some time during the development of infection in guinea pigs. 
However, this adjuvant antigen combination was not as good as BCG in reducing the 
bacterial burden in lungs and spleens. 
There were three vaccination strategies in the multiple-dose regimen. Neither of 
homologous multiple doses of PLGA formulations containing Ag85B effectively reduced the 
MTB burden in the lungs or spleens compared with untreated controls. The only effective 
vaccination regimen was the priming with BCG and then boosting twice with PLGA-Ag85B 
aerosols. This regimen significantly reduced the MTB burden in lungs and spleens compared 
with untreated controls (p<0.05) (Fig 4.4). Although in the multiple dose groups the MTB 
burden in the lungs of untreated controls seemed greater than that in single dose groups, BCG 
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prime: PLGA-Ag85B boost groups had lower MTB burden (0.3 Log cfu/g) compared with 
the BCG groups and the untreated controls (1.5 log cfu/g) in the raw data. This MTB 
reduction in the lungs by PLGA-Ag85B after BCG priming was substantial, considering the 
Ag85B mass of ~83µg in PLGA formulation. The data variation among the BCG 
prime:PLGA-Ag85B boost group was small (SD = 0.16) which indicated that the guinea pigs 
responded similarly among individuals within the group. Therefore, the boosted PLGA-
Ag85B enhanced the immunization of BCG. A logical control experiment for these studies 
would involve boosting a BCG vaccine with BCG alone. However, this is known to result in 
a serious life threatening immune repsonse that would be unacceptable (Basaraba, Izzo, 
Brandt et al., 2006).  
The raw data (Table 4.1) were analyzed by comparing the protective effect (log cfu/g 
untreated group – log cfu/g treatment group) to evaluate the multiple doses versus single dose 
regimens. Positive values indicate fewer bacteria in the organs and greater protection (Fig 
4.5). The lungs showed no significant difference between multiple dose and single dose 
regimens for PLGA-Ag85B and PLGA-TDB-Ag85B. However, statistically there was a 
significant difference between BCG and BCG prime:PLGA-Ag85B boost groups. Animals 
boosted twice with PLGA-Ag85B, by insufflation, exhibited enhanced lung protection (p = 
0.014).  
Comparison of the spleen data did not show any significant difference in the effect 
resulting from single dose and multiple doses of PLGA-Ag85B. However, PLGA-TDB-
Ag85B treatments showed different spleen protection pattern between single and multiple 
dose regimens (p < 0.05). The single dose reduced the bacterial burden (0.78 log cfu/g) 
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compared with untreated control but additional boosts obviously depleted the protective 
effect of the first dose.   
Neither single dose nor homologous multiple doses of PLGA formulations containing 
Ag85B appeared to protect the lungs from MTB infection as indicated by the similar bacterial 
burden in lungs compared with untreated controls. The memory CD4 T cells require 
restimulation before acting on target cells (Janeway, Travers, Walport et al., 2001). Single 
dose immunization with PLGA formulations is insufficient for this purpose. Multiple doses 
repeatedly stimulate CD4 T memory cells specific for Ag85B epitopes. However, in the 
present studies, no protection was observed in the lungs or spleens. The ability of the 
immune system – T cells to recognize antigens in in vitro bioassay, and the ability to induce 
protection following immunization in vivo do not necessarily correlate with each other. CD4 
Th1 immunity is an important factor in protection from tuberculosis and IFN-γ is a relevant 
cytokine marker to evaluate this response. However, high level of IFN-γ in the lung 
parenchyma does not imply protection. There is experimental evidence that despite large 
IFN-γ and IL-2 cytokine responses with respect to IL-4 and IL-5, no protective effects were 
seen in mice after virulent MTB challenge (Majlessi, Simsova, Jarvis et al., 2006).  
Although protection was not evident in animals treated with single dose and 
homologous multiple dose of PLGA formulations containing Ag85B, there were some 
differences between these two treatments. Firstly, the single dose of PLGA-TDB-Ag85B 
resulted in a statistical reduction of spleen MTB burden (p≤ 0.05) while the multiple doses of 
PLGA-TDB-Ag85B did not decrease bacterial burden in the spleen. Dendritic cells may be 
involved in the response to aerosol immunization. In the single dose, due to particle 
distribution, some of the aerosol powders deposited in the central airway where it is believed 
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that dendritic cells are located (Gong, McCarthy, Telford et al., 1992). After dendritic cells 
take up particles, they become mature and migrate to lymph nodes to present epitope to T 
cells. The T cells either come back to the infected area or permeate through the lymph nodes 
and serve in the systemic cell-mediated immunity. Repeated doses of aerosol particles 
possibly gained greater access to alveolar macrophages. Under these circumstances, the 
number of activated macrophages might exceed that of the dendritic cells. This could depress 
the function of dendritic cells. Macrophages can profoundly inhibit T cell responses to 
antigen presented by respiratory dendritic cells possibly by soluble inhibitors secreted by 
macrophages (Gong, McCarthy, Telford et al., 1992; von Garnier, Filgueira, Wilstrom et al., 
2005). Therefore, the immunity invoked by a large involvement of dendritic cells with 
respect to macrophages could diminish as more macrophages are activated. 
Secondly, a difference between single and multiple doses was observed with respect 
to the weight gain. In single dose, PLGA formulations containing Ag85B both lost weight 
significantly compared with untreated controls. In multiple doses, groups of heterologous 
BCG prime: PLGA-Ag85B boost and homologous PLGA-Ag85B both gained weight with 
respect to untreated controls. BCG prime: PLGA-Ag85B boost reduced MTB burden in lungs 
and spleens, which correlated with the weight-gain data. Histopathology data may explain the 
discrepancy of weight gain and non-protection in lungs and spleens for group of PLGA-
Ag85B. Lesion severity is, undoubtedly, a critical component of survival of infected animals. 
The degree of lymphocytic infiltration may have a better correlation with weight gain, 
survival and protection in guinea pig model (Baldwin, 1998). 
TB vaccine development should not ignore the identification of vaccines that can 
effectively boost preexisting immunity (McShane and Hill, 2005). There are several reasons 
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for this strategy. One is simplicity. A large proportion of the worldwide population has been 
immunized with BCG or exposed to infection with mycobacteria. Therefore, a more realistic 
use of subunit antigen vaccines would be to boost individuals previously vaccinated or those 
who may be at risk of reactivation disease due to latent tuberculosis. Another consideration is 
the ethical dilemma related to a first study in man. In order to conduct a Phase III trial on any 
TB vaccine in an endemic region, BCG would be given beforehand in all of the study groups, 
including the control group. These constraints would require any vaccine tested to build on, 
and be evaluated with respect to, BCG-initiated immunity (Xing, Santosuosso, McCormick et 
al., 2005). A heterologous regimen was used in the guinea pig study. The vaccination 
regimen of BCG prime: PLGA-Ag85B aerosol boosts significantly enhanced the protection 
efficacy of BCG alone in terms of MTB burden in lungs and spleens. In consideration of the 
amount of Ag85B used, only 83µg subunit antigen was used in these two boostings. The 
aerosol fine particle fraction  (<5µm) of this formulation was 65%, and in theory the fine 
particle dose would only be 54µg. The protective effect of this pulmonary boosting 
immunization in lungs was comparable to that performed by Horwitz et al. who 
intradermally boosted Ag85B 100µg after BCG priming (Horwitz, Harth, Dillon et al., 2005). 
Our data confirmed that Ag85B is capable of enhancing protective immunity upon boosting 
(Horwitz, Harth, Dillon et al., 2005) although different administration routes were used. It is 
critical that the primary immunization establishes a favorable immune response (balanced 
Th1 / Th2 immunity) (Sable, Goyal, Verma et al., 2007). Priming with BCG appears to allow 
a favorable immune response to Ag85B protein, which is also expressed and secreted by 
BCG. However, further studies are required to confirm the observed results before the 
evidence is considered conclusive.  
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4.4 Summary 
The pulmonary boost of PLGA-Ag85B appeared to enhance the protection afforded 
by BCG alone. This heterologous prime:boost immunization strategy was observed to reduce 
MTB burden in the lungs and spleens in guinea pigs compared with repeated single subunit 
antigen immunization strategy, which did not demonstrate protection within the limits of the 
experimental design. Although there was no influence in terms of MTB burden in lungs and 
spleens, the weight gain of guinea pigs in homologous multiple-dose group of PLGA-Ag85B 
was comparable to BCG prime:PLGA-Ag85B boost groups. This weight gain indicates that 
the guinea pig while apparently demonstrating the same degree of infection as some of the 
other groups (based on bacterial burden) may not exhibit the same severity of disease and 
degree of metabolic involvement. Histopathology and immunological (cytokine and 
chemokine profiles) data are needed for further interpretation of the data. There is the 
necessarity to repeat the protection study to confirm these results. 
The PLGA microparticle systems delivered as aerosols appear to be a good method of 
boosting to enhance the BCG-induced immunity. PLGA microparticles encapsulating Ag85B 
may be an effective delivery system for pulmonary administration of vaccine to prevent MTB 
infection. 
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Fig 4.1 Vaccination regimens for single dose and multiple dose groups. 
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Fig 4.2 Weight profiles of guinea pigs with respect to time following infection in different 
dose regimens after virulent MTB challenge.  
A) Single dose groups;  
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B) Multiple dose groups. 
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Fig 4.3 Bacterial burdens in different organs after single dose vaccination.  
A) In lungs; (n=6, mean ± SD)  
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B) In spleens (n=6, mean ± SD)   
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Fig 4.4 Bacterial burdens in different organs after multiple dose vaccination.  
A) In lungs; (n=6, mean ± SD) 
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B) In spleens (n=6, mean ± SD) 
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Fig 4.5 Protections in MTB burden in different organs between single and multiple doses 
vaccinations after standardization (Log (cfu of untreated)- Log (cfu of treatment)). In single 
dose BCG, in multiple doses group BCG prime and PLGA-Ag85B boost. 
A) In lungs.  
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B) In spleens.   
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Table 4.1 Protections from TB in the lungs for different vaccination regimens. 
Regimen Dose Organ 
Protections 
(Log  (cfu of untreated controls in each group) 
 –log (cfu of treatment)) 
PLGA-Ag85B single lung -0.17 
PLGA-Ag85B multiple lung -0.03 
PLGA-TDB-Ag85B single lung -0.24 
PLGA-TDB-Ag85B single spleen 0.78 
PLGA-TDB-Ag85B multiple lung -0.12 
BCG single lung 0.91 
BCG:PLGA-Ag85B multiple lung 1.52 
 
 
 
 
  
  
5. General Discussions 
Tuberculosis remains one of the leading causes of death from a single infectious 
agent. Due to problems with current the TB vaccine, BCG’s, including high variability in 
protection worldwide (Brewer, 2000; Fine, 1995) and diminishing immunity over 10-15 
years (Brewer, 2000), more than 200 TB vaccine candidates have been tested in different 
animal and primate models (Ginsberg, 2000; Izzo, Brandt, Lasco et al., 2005; Orme, 2005a) 
over the last ten years. However, research into alternative immunization routes has been rare. 
TB is primarily a respiratory mucosal infectious disease. Mucosal vaccination, especially 
pulmonary mucosal immunization, provides good protection against airborne infection (Lu 
and Hickey, 2007). Meanwhile, formulation of immunogens is one of the key factors 
influencing the final vaccination outcome. Microparticle formulation, which takes 
advantages of the macrophage sensitivity to particulates, is easily internalized by APCs to 
enhance immunity. Therefore, immunogens, formulations and immunization route are key 
factors that need to be considered in TB vaccine development. 
The research described in this dissertation, addresses inclusion of TB secreted Ag85B 
in a microparticle formulation (PLGA microparticles) for aerosol delivery by the pulmonary 
route, demonstrating strong antigenicity in an in vitro cell assay and sufficient 
inmunogenicity in an in vivo guinea pig model. The heterologous vaccination regimen of 
BCG prime: PLGA-Ag85B aerosol boost appeared to enhance the immunity elicited by BCG 
alone. PLGA microparticle dry powders are suitable for delivery as inhalation aerosols. The 
powder state potentially increases the stability of the immunogens encapsulated in this 
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formulation thereby reducing the cold chain requirement compared with the traditional BCG 
parenteral formulations. This is meaningful in developing countries where the cold chain 
requirement for protein/whole organism solutions/suspensions may not be possible. In 
addition, the risk of transmission of diseases, in general, from inadvertent or deliberate re-use 
of needles is avoided. Pulmonary vaccination, using microparticle systems encapsulating 
subunit antigens, is a novel strategy in TB vaccine development. The heterologous boost 
strategy is an alternative to homologous regimens. The latter may not provide significantly 
greater or even equivalent protection compared with BCG in experimental models. This 
needle-free vaccination will not only ease patient compliance, but also enhance the local 
immunization effect. For campaigns of mass immunization, needle-free immunization would 
reduce the cost and needle-related contamination considerations. 
There are three specific aims in this dissertation research. The achievements in each 
specific aim are outlined below (Table 5.1). 
5.1 Recombinant Ag85B expression and PLGA microparticle formulation manufacture  
The generation of recombinant Ag85B from E. coli systems with sufficient 
antigenicity and the manufacture of PLGA microparticle formulations encapsulating 
rAg85B/adjuvants were the main objectives in specific aim I.  The in vitro T hybridoma cell 
recognition assay was utilized for antigenicity screening. Two rAg85B were expressed from 
two systems with sufficient antigenicity. The rAg85B from Origami B strain carrying 
mutated reductases and chaperone vector had higher antigenicity than that from JM strain in 
the tested concentration range. These antigens were incorporated at different concentrations 
together with different loadings of adjuvants MDP or TDB into PLGA microparticles by a 
spray drying process under the optimized conditions discovered by factorial experimental 
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design. The microparticles are in the suitable size range as aerosols. The morphology of 
PLGA microparticles was irregular and raisin-like with hollow interior structure as 
demonstrate by scanning electron microscopy. The dissolution profile of rAg85B was 
different from adjuvant MDP from PLGA microparticle formulations. rAg85B exhibited a 
pulsatile release which peaked at days 1 and 20. Following an initial burst during the first day, 
MDP showed a continuous release up to 30 days. The objectives of production of 
recombinant Ag85B with sufficient antigenicity to elicit a marker of immune response in 
vitro and the manufacture of PLGA microparticles encapsulating rAg85B with/without 
adjuvants in respirable sizes were fulfilled. 
5.2 The immunological advantages of microparticle formulations over solution 
formulation of rAg85B and the physico-chemical suitability of PLGA microparticles as 
aerosols 
A successful pulmonary vaccine formulation must meet the physical property 
requirements for aerosol delivery. Their immunological effects are important factors in their 
use for vaccine development.  
The physico-chemical properties of microparticles provided more information on 
stability, flow property and hygroscopicity of formulations. The PLGA microparticle 
formulations exhibited an aerodynamic size (MMAD) range from 2.5 to 3.0µm, which was 
suitable for pulmonary delivery to humans (Inhalator) and animals (insufflator). Moisture 
influenced the fine particle dose by decreasing the emitted dose from the insufflator. This 
microparticle formulation had moderately good flow properties. The thermal behavior of 
PLGA formulations containing Ag85B and/or adjuvants illustrated that there was an 
interaction between PLGA polymer and MDP, TDB and Ag85B as seen in the depression of 
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the PLGA glass transition temperature (Tg). The Tg also indicated that the storage 
temperatures for the PLGA formulations should be less than 10°C, to reduce the possible 
mobility of the components in formulation. The surface charge properties of PLGA control 
and PLGA-Ag85B were different after aerosolization from Inhalator. PLGA-Ag85B 
retained the unipolar property and this may be good for aerosol dispersion and lung 
deposition. Overall, the PLGA microparticle formulations are suitable to be delivered as 
aerosols. 
The PLGA microparticle formulations could be internalized into the macrophage-like 
cells THP-1. PLGA microparticles encapsulating rAg85B delivered antigen to THP-1 cells 
for processing and presentation in the context of MHC class II to a CD4 T-hybridoma cell 
line DB-1. Microparticle formulations containing rAg85B were more effective in stimulating 
THP-1 cells to present antigen epitopes to the DB-1 T-hybridoma cells than rAg85B protein 
in solution. This demonstrated the strong adjuvant effect of PLGA microparticles. 
Submicrogram amounts of rAg85B in microparticles induced 92-360 fold greater release of 
IL-2 than the same amount of soluble rAg85B. The PLGA-rAg85B particle effect cannot be 
duplicated by mixing dissolved antigen, or initial burst solution, with control PLGA particles, 
or by utilizing antigen associated with the surface of PLGA particles (prepared by 
suspending the particles in solution of antigen and drying). This suggests that the strong 
adjuvant effect of the particles requires surface association or encapsulation of antigens. 
These formulations provided extended epitope presentation on the APC surface for up to 6 
days, which is favorable for T cell recognition. Therefore, these microparticle formulations 
offer the advantage of strong adjuvant effect and long epitope presentation on APC surfaces 
compared to the traditional solution formulations. 
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5.3 Protection effect of the aerosol vaccination in the guinea pig models after challenged 
with virulent strain H37Rv.  
The effect of vaccination with selected aerosol microparticle adjuvant/ antigen 
combinations was evaluated in guinea pig models of tuberculosis involving a low-dose 
virulent challenge. The pulmonary boost of PLGA-Ag85B appeared to enhance the 
protection efficacy of BCG alone. This prime:boost immunization strategy was observed to 
reduce MTB burden in the lungs and spleens of guinea pigs compared with repeated single 
subunit antigen immunization strategy, which had no protection within the tested period of 
time. Although there was no influence in terms of MTB burden in lungs and spleens, the 
weight gain of guinea pigs in homologous multiple-dose group of PLGA-Ag85B was 
comparable to BCG prime:PLGA-Ag85B boost groups. The bacteriology data of 
heterologous regimen of subunit antigen boost via pulmonary route after BCG prime, 
confirmed that the effective boost vaccine candidates might be non-whole organism based or 
heterologous to BCG (Xing and Caters, 2007). The DTH skin test results indicated the 
discoordination between response to PPD / specific antigen and the protection outcome as of 
reduction the bacterial burdens in the lungs and spleens.  
5.4 General conclusions 
The key points in this dissertation research are antigen selection, formulation 
screening, vaccination route and strategies. Ag85B was selected as the vaccine subunit 
protein due to its known antigenicity and immunogenicity (Horwitz, 1995; Kamath, Feng, 
Macdonald et al., 1999; Sable, Goyal, Verma et al., 2007). Biotechnologies for generation of 
this subunit antigen are available. The in vitro immunonological assay T hybridoma cell 
recognition assay was specifically modified for recognition of Ag85B epitope 97-112 
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(Gehring, Rojas, Canaday et al., 2003). This made the method of antigenicity screening 
accessible. Microparticle formulations of PLGA polymers encapsulating rAg85 with/without 
adjuvants MDP/TDB exhibited strong adjuvant effects compared with solution formulations 
of Ag85B. They enhanced rAg85B antigenicity by two orders of magnitude as measured by 
T hybridoma cell recognition assay. Only encapsulated Ag85B showed such strong 
antigenicity while soluble rAg85B with PLGA controls did not demonstrate enhanced 
antigenicity. Furthermore, the microparticle formulation stimulated the longer epitope 
presentation as observed in a 6-day bioassay. This may be explained by the depot effect 
provided by the microparticles containing rAg85B. Protein microparticles are effective 
delivery systems capable of eliciting strong cell-mediated response (Evans, Ward, Kern et al., 
2004), which is recognized as the essential element required for tuberculosis immunization. 
Pulmonary mucosal vaccination mimics the natural route of airborne infection with MTB.  
Homologous and heterologous vaccination regimens were used to assess the extent of 
protection from challenge with virulent MTB in the guinea pigs. Homologous immunization 
included administration of three aerosols  (prime and two boosts), a regimen which is 
commonly followed for protein-based vaccination (Agger and Andersen, 2001). However, 
this strategy did not provide evidence of protection in the time frame of the study. 
Heterologous regimen with BCG prime: PLGA-rAg85B boosts appeared to depress the 
bacterial growth in the lungs and spleens. The lungs had significantly lower bacterial burden 
compared with that of BCG alone. Overall, the results illustrated that aerosols of PLGA 
microparticles were effective in boosting the BCG-induced immunity.  
These results support the initial hypotheses. Ag85B/adjuvants in microparticle 
formulations intended for pulmonary delivery: (a) target macrophages; (b) elicit related cell-
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mediated immune response in vitro and (c) gave preliminary indication of protection against 
challenge with virulent MTB H37Rv in guinea pig models. THP-1 phagocytic cells were 
shown to engulf microparticles. The in vitro T hybridoma cell recognition assay 
demonstrated the microparticle formulations containing rAg85B enhanced the antigenicity by 
two-order of magnitude as measured of IL-2 cytokine marker. Aerosol vaccination of the 
selected microparticle formulations encapsulating Ag85B demonstrated modest protection of 
guinea pigs against challenge with virulent MTB H37Rv. The BCG prime: PLGA-rAg85B 
aerosol boost appeared to protect the lungs and spleens from infection, as indicated by the 
estimates of bacterial burden in the organs. However, these initial studies require repetition 
before definitive conclusions can be drawn.  
Due to safety concerns, in particular in immunocompromised persons, and to 
technical challenges regarding manufacture and reproducibility, live mycobacteria vaccines 
are not the product of choice of most vaccine manufacturers. The live attenuated 
microorganism vaccines elicit immunity based on their ability to replicate in the host. 
However, serious side effect may be observed in persons with severe immunosuppression 
and acute leukemia (Mitus, Holloway, Evans et al., 1962). There was a risk of an increase in 
HIV viral load following measles-mumps-rubella (MMR) vaccination (Stanley, Ostrowski 
and Justement, 1996). One case of death was reported due to the measles pneumonitis 
following MMR vaccination of a patient with HIV infection (CDC, 1996). Subunit antigens 
have a record of relative safety since no microorganism replication is involved. An influenza 
vaccine: a trivalent influenza subunit vaccine provided clinically effective protection against 
influenza illness in HIV-1-infected patients (Yamanaka, Teruya, Tanaka et al., 2005). 
Conventional influenza subunit vaccine Agrippal (Chiron, Siena, Italy) and adjuvanted 
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subunit vaccine Fluad (Chiron, Siena, Italy) both elicited seroconversion rate of 53-68% and 
44-72% in HIV-1 patients (Gabutti, Guido, Durando et al., 2005). Therefore, TB subunit 
antigen might offer a good safety profile to HIV patients. Since HIV patients are susceptible 
to co-infection with TB, there is urgency to elucidate the extent of protection offered by 
vaccines in these high-risk patients. Levels of serum antibodies to five MTB antigens 
increased before microbiological and clinical symptoms of active TB in HIV patients were 
identified (Gennaro, Affouf, Kanaujia et al., 2007). Partial reconstitution of the CD4+-T-cell 
in CD4 gene knockout mice restored responses to tuberculosis DNA vaccines (D'Souza, 
Romano, Korf et al., 2006). These reports indicated that TB non-bacterial vaccines possibly 
protect the host from MTB infection when HIV-infected patients have concurrent highly 
active antiretroviral therapy under which the CD4+-T-cell counts are known to increase 
(Autran, 1999). Since the immunological responses to antigen vaccines may decrease 
(Arpadi, Markowitz and Baughman, 1996; CDC, 1993) as HIV disease progresses, 
vaccination early in the course of infection may be more likely to induce an immune 
response. Microparticles containing Ag85B might be used in HIV-positive individuals. Most 
HIV-positive people are immunized with BCG routinely in childhood, especially in 
developing countries; hence, most were “primed” with BCG well before being infected with 
HIV. If a booster vaccine administered to HIV-positive individuals before their immune 
system deteriorates is able to augment their immunoprotective capacity against tuberculosis, 
this may help protect these high-risk persons from one of the most common and devastating 
opportunistic infections in acquired immune deficiency syndrome (AIDS).  
Microparticle formulations containing subunit antigen delivered via pulmonary route 
are a new development in vaccines for tuberculosis. These studies offer the first evidence for 
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the effect of a protein subunit vaccine delivered to the lungs, as a booster of BCG, for 
protection against tuberculosis, which has significant implication for worldwide disease 
control. 
5.5. Future studies 
Some questions emerge from the present studies that need to be addressed to fully 
interpret the outcome of the in vitro and in vivo studies. 
A). Conformation of subunit antigen proteins. 
The influence of the structural conformation of subunit antigens on epitope 
presentation and antigenicity in the cell-mediated immunity is not clear. The soluble forms of 
rAg85B from JM and Origami B E. coli strains appeared to result in different antigenicity in 
the T hybridoma cell recognition assay. The rAg85B from Origami B strain showed higher 
antigenicity in the concentration range tested than the JM strain (Fig. 1). The Origami B 
strain, rAg85B, is a mutant with respect to glutathione and thioredoxin reductases, which is 
favorable for the disulfide bond formation, and facilitates the antigen folding, assisted by 
concurrently co-expressed chaperones. Thus, a more appropriate conformation may be 
obtained in Origami B strain rAg85B. In order to answer this question, techniques of CD, 
FTIR, NMR may be used to access the 2D and 3D structure of antigens. This question is 
relevant to future vaccine development. If the conformation is unnecessary, then fusion of 
different epitopes may be a strategy to elicit stronger immunity. The literature contains some 
evidence that the conformational stability of the antigens may not be a concern and 
maintenance of the necessary primary and/or partial secondary structures might be sufficient 
to elicit effective antigenicity and immunogenicity. The fusion vaccine candidates, Ag85B-
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ESAT-6 (Langermans, Doherty, Vervenne et al., 2005), Mtb32F-Mtb39F (Mtb72F) (Skeiky, 
Alderson, Ovendale et al., 2004) both showed stronger immunity than the single antigens.  
B). The efficiency of epitope presentation for antigens associated with microparticles 
requires more detailed investigation.  
PLGA microparticles appeared to act as adjuvants improving antigenicity. However, 
the explanation is not clear. There are three possibilities. Firstly, phagocytosis of 
microparticles by macrophages is much more efficient than pinocytosis of soluble antigens, 
in terms of the number of antigen molecules internalized. Secondly, differences in the 
mechanism of epitope presentation may occur between solution formulation and 
microparticle formulation. Vidard et al.’s research showed that the efficiency of presentation 
between solution and particle forms resulted in differences in response to ovalbumin. 
Macrophages generated distinct epitopes with different efficiencies from particles and 
solution formulations (Vidard, Kovacsovics-Bankowski, Kraeft et al., 1996). Therefore, the 
clarification of the epitope presentation efficiency in two formulations for Ag85B may 
explain the adjuvant effect and provide meaningful base foundation for the future vaccine 
development.   
A third explanation, that microparticles elicit immunity independently of the antigen 
was not supported by the T-cell recognition assay in which IL-2 production was not elevated 
for particles alone. However, in general particles are known to activate macrophages as part 
of the general housekeeping response (Bezdicek and Crystal, 1997). 
C)  Formulations 
(1) The PLGA polymer was of L:G 75:25 and molecular weight of 84.7 Kd. The glass 
transition temperature of ~50°C suggested that the storage temperature may need to 
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be under 10°C. Since tuberculosis predominantly occurs in developing countries, 
where the cold-chain conditions are required, this may not be a suitable polymer. 
However, PLGAs with different molecular weight having higher glass transition 
temperatures are available and should be assessed for this application. 
(2)  Surfactants, such as Pluronic F68 and F127, which are considered safe (Kibbe, 2000) 
for human administration and do not reduce phagocytosis of particulates (Jones, 
2002), may be added into emulsion in spray-drying to manipulate the release profile 
of Ag85B. The controlled continuous release or pulsatile release may be suitable for a 
CMI response, mimicking a boost. A single administration would result in the release 
of two or more distinct doses of drug at time intervals relevant to induction of the 
response. 
D).  Animal study  
(1) In single dose vaccination regimens, it is not clear that the weight changes in groups 
of PLGA-Ag85B and PLGA-TDB-Ag85B were due to the soluble rAg85B boosting. 
Since only the groups boosted with soluble rAg85B reduced the weights significantly 
compared with untreated controls and PLGA controls. Therefore, the weight changes 
of the single dose groups PLGA-rAg85B and PLGA-TDB-rAg85B after virulent 
MTB challenge should be monitored independently, in the absence of a soluble 
rAg85B boost. 
(2) Draining lymph nodes may be sampled for MTB burden and histopathology since the 
infection spreads initially to the lymph nodes. Lymph node lesions become severe 
and progress more rapidly than pulmonary lesions (Basaraba, Dailey, McFarland et 
al., 2006). It was recognized that a rapid and progressive enlargement of intra-
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thoracic hilar lymph nodes was due to rapidly progressing granulomatous 
lymphadenitis (Kraft, Dailey, Kovach et al., 2004). The involvement of hilar lymph 
nodes following low-dose aerosol challenge in the guinea pig resembled the early, 
extra-pulmonary manifestation of tuberculosis.  The granulomatous inflammation and 
necrosis of intra-thoracic hilar lymph nodes is an early and significant manifestation 
of low dose aerosol infection of guinea pigs with MTB (Basaraba, Dailey, McFarland 
et al., 2006). The size, bacteriology and histopathology of lymph nodes may allow 
more detailed interpretation of the progress of the disease and host immunity after 
challenge.  
(3) The IFN-γ, IL-10, IL-4 and antibodies to Ag85B may be evaluated. The subunit 
antigens occasionally exhibit weak in vivo immunogenicity compared to in vitro 
studies (Sable, Kalra, Verma et al., 2007). This may, in part be a reflection of the 
narrow range of responses that are examined in vitro. For example, in the present 
studies only one cytokine, IL-2, was selected as the marker for immunogenicity (Lu, 
Garcia-Contreras, Xu et al., 2007). Therefore, the immunogenicity of inducing CD4 
Th1 cell-mediated immunity may be monitored. Recently, it has been postulated that 
the vaccines inducing balanced Th1 and Th2 response following immunization are 
most effective in protection from tuberculosis (Giri, Verma and Khuller, 2006; Sable, 
Verma and Khuller, 2005). The requirement of Th1 and Th2 cytokine balance is 
governed by IFN-γ, IL-10, IL-4 (Wigginton and Kirschner, 2001). Due to the limited 
availability of commercially available ELISA, or relevant reagents, for guinea pig 
proteins and the relatively short-half life of these cytokines, cytokine mRNA methods 
could be used for this purpose (Carding, Lu and Bottomly, 1992). 
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(4) Dendritic cells play an important and unique role in priming Th1 and Th2 CMI 
cytokine polarization, which has lead to the development of dendritic cell-based 
vaccine for TB (McShane, Behboudi, Goonetilleke et al., 2002). Whether it also 
involves microparticle phagocytosis and stimulates the recognition of T cells is 
unknown. Identification of functions of lung dendritic cells and macrophages in 
processing, migration and presentation to T cells is important. This will improve the 
understanding of the reduction of MTB burden in lungs and other organs such as 
spleens.  
 
In addition to the questions remaining from the completion of the dissertation 
research, new approaches may be taken to the future study of TB vaccines and their 
development. These approaches would be the subject of independent projects and would 
involve the elucidation of different mechanisms than those addressed in the present research. 
(1) The heterologous regimen of subunit antigen Ag85B and subunit antigen DNA may 
be used as pulmonary prime and boost strategy. One of the advantages of DNA 
vaccines is that their translated antigen proteins have access to cytosol to elicit CD8 
Th1 immunity which is recognized as an important component of immunity involved 
in the prevention of TB (Raychaudhuri and Rock, 1998). Therefore, a combined 
approach may provide better protection than the homologous vaccination. 
(2) Pulmonary homologous of DNA vaccines, including Ag85B DNA, fusion antigen 
Ag85B-ESAT-6 DNA, Ag85B-MTB72F DNA may be a valuable alternative because 
of the multiple epitope presentation and the broader immunity that might be 
anticipated. 
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(3) A heterologous regimen of BCG parenteral prime: aerosol DNA boost; BCG 
parenteral prime: aerosol virus boost immunization regimen might have an 
application in protection from TB. Viral vectors have the ability to induce high levels 
of transgene product in a wide range of cell types, an advantage over plasmid DNA 
vectors or protein-based vaccines. Viral vectors have been used parenterally or 
mucosally to activate antigen-specific immune responses. These features make them 
attractive candidates boost vaccines for enhancing BCG prime immunization (Xing, 
Santosuosso, McCormick et al., 2005). The limitation to viral-vector vaccines is that 
a strong antibody response may be engendered against the virus which would hinder 
repeated administration of the same virus to a previously exposed host. 
(4) Regimens of BCG aerosol prime: aerosol subunit antigen/ aerosol DNA/ aerosol virus 
vector, have not been investigated. Both prime and boost via pulmonary mucosal 
immunization may provide better protections from TB. 
(5) The morphology of BCG is a rod-like structure with length of 2-5µm and cross-
section diameter of 0.2-0.3 µm. The BCG particles can deposit into the lungs easily 
due to their elongated shape and sensitively recognized by macrophages in the lungs. 
The generation of stable dry powder aerosols of BCG, which can maintain the 
individual shape of BCG while retaining sufficient immunogenicity, is a challenging 
task for TB vaccine formulations. This is approach is currently under investigation. 
(Wong, Sampson, Germishuizen et al., 2007).  
(6) Research into the influence of TB vaccines on HIV patients is rare. The BCG vaccine 
is not recommended for immunocompromised individuals, since it has been shown to 
be deleterious in some cases (D'Souza, Romano, Korf et al., 2006). HIV patients are 
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immunocompromised of CD4 T cell, which is a very important immunocomponent to 
protect the hosts from TB. Whether the promising TB non-bacterial vaccines to 
normal populations are also functional to HIV-infected patients requires investigation. 
(7) The use of pulmonary delivery of microparticles for vaccination to protect from 
diseases other than TB should also be investigated. It is anticipated that the lung 
would be an excellent site of vaccination to elicit mucosal humoral immunity that 
would be important in the treatment of a variety of diseases acquired by the 
pulmonary route, such as respiratory syncytial virus, influenza, bacillus anthracis, 
streptococcus pneumoniae and Francisella tularensis (Lu and Hickey, 2007). 
5.6 Concluding marks 
The current study of aerosol delivery of microparticle formulation of TB antigens 
illustrated that the pulmonary route is a promising route of delivery and means of vaccinating 
susceptible populations. Microparticle delivery systems may act as adjuvants and enhance the 
antigenicity. The observed protection from the BCG prime: aerosol PLGA-Ag85B boost is 
relevant to TB vaccine development and the approach to immunization in the field. The 
combination of suitable antigens, appropriate formulations, a novel delivery route, advanced 
technologies and appropriate vaccination regimens would facilitate a new vaccination 
strategy for protection against the insidious disease of tuberculosis.  
-182- 
Table 5.1 Overview of the activity, procedure and brief results in each specific aim. 
Specific aim Activity Procedure Results 
1 
(rAg85B generation 
and PLGA 
microparticle 
manufacture) 
Ag85B vector 
expression in two 
strains of E.coli 
 
 
Evaluation of 
antigenicity of rAG85B  
 
Optimization of spray-
drying condition for 
PLGA microparticles  
 
Manufacture of PLGA 
microparticles 
1. plasmid 
transformation 
2. antigen expression 
3. purification  
4.   MS of rAg85B 
5.   T hybridoma cell   
recognition assay to 
assess antigenicity 
6. Fractional design to 
optimize spray-
drying conditions 
7. manufacture of 
formulations 
8.   morphology and 
release profile 
rAg85B was obtained 
with sufficient 
antigenicity 
 
The optimized 
conditions were found 
and 24 batches of 
microparticle 
formulations were 
produced. 
 
 
Pulsatile release of 
rAg85B from 
formulation 
 
 
2 
(In vitro screening of 
microparticle 
formulations and 
physical property 
characterization of 
these formulations as 
aerosols) 
Macrophage cell 
recognition of particles 
 
Immunological 
characterization of 
microparticles 
 
 
Physical property 
characterization of 
microparticles as 
aerosols 
9.   Phagocytosis of 
particles by THP-1 
cells 
10. microparticle 
adjuvant effect 
11. epitope 
presentation 
elicited by 
microparticles 
12. MMAD, emitted 
dose, FPF 
13. flow property 
14. Specific surface 
area, moisture 
adsorption 
15. Thermal behavior 
 
Microparticles can be 
taken up by 
macrophage-like cells. 
 
In vitro cell assay 
indicated the strong 
adjuvant effect of 
particles; prolonged 
epitope presentation 
was elicited by 
microparticle 
formulations. 
 
The physical 
properties showed 
that PLGA 
microparticle 
formulations are 
suitable to be 
delivered as aerosols 
4 
(Protection study after 
aerosol delivery of 
microparticle 
formulations) 
Aerosol delivery of 
microparticles 
containing rAg85B 
 
Aerosol challenge with 
virulent MTB  
16. pulmonary delivery 
of formulations to 
guinea pigs (single 
or multiple dose, 
homologous or 
heterologous 
regimen) 
17. Challenge guinea 
pigs with virulent 
MTB 
18. Necropsy and 
assessment of 
protection 
 
Heterologous regimen 
BCG prime: PLGA-
Ag85B aerosol boost 
appeared to improve 
the immunity elicited 
by BCG alone. 
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APPENDIX 
Appendix I. Factorial design experiment analysis to optimize the best spray-drying 
conditions. 
A) Main effects of different factors affected the particle sizes in Design experiment;   
A 
 
 
 
DESIGN-EXPERT Plot
Dv50
A: polymer conc
B: inlet
C: feed
N
or
m
al
 %
 p
ro
ba
bi
lit
y
Normal plot
Effect
-66.20 -32.51 1.18 34.86 68.55
1
5
10
20
30
50
70
80
90
95
99
B
C
BC
A: polymer conc 
 
B: Inlet temperature 
 
C: Feed rate 
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B) Interaction between inlet temperature and feed rate which affects particle sizes. [B]: 
inlet temperature; [C]: feed rate; 
 
B 
 
 
 
 
 
DESIGN-EXPERT Plot
Predicted Dv50
Interaction Graph
Interaction of B:inlet and C:feed
P
re
di
ct
ed
 D
v5
0
-16.9
-0.855
15.19
31.235
47.28
63.325
79.37
C-
C-
C+
C+
B- B+
B: Inlet temperature 
 
C: Feed rate 
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C) Prediction of particle sizes Dv50 of PLGA microspheres influenced by three factors 
(polymer concentration, inlet temperature and feed rate) in spray-drying. 
 
C 
DESIGN-EXPERT Plot
Predicted Dv50
inlet
fe
ed
polymer conc
B- B+
C-
C+
A-
A+
 -16.9
 -16.9
 3.62
 3.62
 40.355
 40.355
 14.915
 14.915
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D) Prediction of the optimized conditions for spray-drying to produce PLGA 
microsphere formulations. Desirability reflects the most desirable value for each 
response variable (range from 0-1. The higher the value, the more ideal condition is to 
generate desirable value for response). 
 
DESIGN-EXPERT Plot
Actual Factors:
X = polymer conc
Y = inlet
Actual Constants:
feed = 50.35
0.421  
0.566  
0.711  
0.855  
1.000  
  D
es
ira
bi
lit
y 
 
  0.20
  0.27
  0.35
  0.42
  0.50
55.00  
58.75  
62.50  
66.25  
70.00  
  polymer conc  
  inlet  
X=polymer conc 
Y= Inlet 
 
Actual constants: 
Feed = 50.35 
D 
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Appendix II. The calibrated cutoff aerodynamic diameters in Andersen Cascade 
Impactor at the flow rates of 60 and 28.3L/min. 
 MMAD (µm)  
at the flow rate of  
Stage 28.3 LPM 60 LPM 
-1 - 8.6 
0 8.7 6.5 
1 6.1 4.5 
2 5.0 3.2 
3 2.8 1.9 
4 1.8 1.1 
5 1.0 0.5 
6 0.5 0.2 
7 0.3 - 
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Appendix III. The cutoff aerodynamic diameters on each stage in electrical low 
pressure impactor (ELPI) at flow rate of 30L/min. 
 
Stage Cutoff diameter (µm) 
1 0.0290 
2 0.0575 
3 0.0966 
4 0.161 
5 0.269 
6 0.392 
7 0.628 
8 0.970 
9 1.630 
10 2.440 
11 4.080 
12 6.730 
13 10.16 
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